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TUMOR NECROSIS FACTOR-a 
Since the purification of Tumor Necrosis Factor-a (TNF-a) in the mid 1980's 
the anti-tumor capacity of TNF-a has received considerable attention. Acute 
softening of the tumor, hemorrhagic necrosis and occlusion of the neo-
o vasculature led to tumor necrosis. The mechanism behind this process was not 
well understood, until recently. The initial enthusiasm of the anti-tumor 
capacity of TNF-a in rodent tumor models was tempered by the severe toxicity 
encountered in clinical phase IIII trials. Only 1/50 to 1120 of the dose required 
for anti-tumor effect in human xenograft tumor models in mice, can be 
administered in man. In 1992 Lejeune et al combined TNF-a, melphalan and 
Interferon y (IFN-y) to achieve impressive results in anticancer therapy. The 
combination proved to be very successfill in the isolated perfusion setting in the 
treatment of extensively metastasized melanoma patients. Complete response 
(CR) rates of 80-90 % were achieved. In isolated limb perfusion (ILP) the 
concentration gap between animal studies and clinical trials could be 
overcome. Investigations were expanded to other forms of cancer, and 
Eggennont et al proved the same regimen to be as successful in locally 
advanced extremity soft tissue sarcomas, with a limb salvage percentage of 
over 80 %, followed by a much easier and less mutilating resection of the 
tumor remnants. Currently, TNF-a based isolated limb perfusion has become 
the standard of treatment for patients with multiple in transit melanoma 
metastases or non-resectable extremity sarcomas. This led to the approval and 
registration of TNF-a in Europe for clinical use in patients with locally 
advanced extremity soft tissue sarcomas treated by ILP with TNF-a and 
melphalan (Beromun®). 
Angiographic studies revealed that the main target of TNF-a was the tumor 
associated vasculature (TA V). The immediate reaction and softening of the 
tumor in ILP treated patients were associated with selective occlusion of the 
TAV. Blood flow decreased and metabolic activity in tumors was arrested. 
Morphological and immunohistochemical studies of tumor biopsies from 
patients after TNF -a based ILP showed early damage to the T A V, as shown by 
perivascular release of von Willebrand Factor (vWF). Whether damage to the 
vascular endothelium equally plays a pivotal role is a matter of debate. 
Previous findings in our laboratory with TNF-a based isolated limb 
perfusion. 
After the initial success of isolated limb perfusion in patients with advanced 
disease a preclinical program was started to unravel the mechanism behind the 
observed impressive results obtained with TNF-a and melphalan. 
A rat model for isolated limb perfusion was developed. In this model perfusion 
of a soft tissue sarcoma with TNF -a alone did not result in a measurable tumor 
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response, nor did perfusion with melphalan as the sole agent. The combination 
of TNF-a and melphalan however, resulted in a synergistic anti-tumor 
response. Surprisingly, in vitro no synergism between the two agents could be 
demonstrated. It was postulated that the main target of TNF-a-based isolated 
perfusion was the tumor associated vasculature. Non tumor vessels were 
relatively spared. The explanation for the susceptibility of the newly formed 
tumor blood vessels for TNF-a may be found in the vascular endothelium. 
Human endothelial cells in vitro showed growth arrest and cell death after 
treatment with TNF-a and IFN-y (as shown by others). The endothelial cell 
lining was harmed after TNF-a-based ILP, with massive permeability changes. 
Platelet aggregation followed these initial changes. Two types of reaction of the 
TA V can be discerned: 1) the immediate-type and 2) the delayed-type. The 
immediate-type may result from upregulation of endothelial adhesion 
molecules, followed by influx of ploymorphonuclear cells (PMN's), another 
explanation being found in acute and marked hyperpermeability, followed by 
platelet aggregation, congestion of blood, edema and tumor necrosis. In 
contrast, the delayed-type is associated with mild hyperpermeability, interstitial 
edema, scattered tumor necrosis, possibly leading to increased concentration of 
melphalan in the tumor or prolongation of its effect. Tumor cells will thus be 
exposed to the direct toxicity of melphalan. 
Previous findings with Iiposomes. 
In contrast to isolated perfusion, systemic treatment with TNF-a either alone or 
in combination with melphalan does not result in a measurable response. The 
severe toxicity of TNF-a allows only low dosages and disseminated disease 
cannot be controlled. Furthermore, TNF-a is cleared rapidly from the 
circulation and demonstrates poor tumor localization. 
Encapsulation ofTNF-a in liposomes would not only lower the toxicity of the 
cytokine, but could also increase localization in tumor tissue and reduce 
clearance. 
In studies with liposomal encapsulation of other cytokines and 
immunomodulators an enhancement of activity was demonstrated. A major 
drawback however remained the fairly rapid clearance of the first generation 
conventional liposomes. The incorporation of hydrophilic chains, like 
polyethylene-glycol (PEG) coupled to the phospholipid 
phosphatidylethanolamine, resulted in increased blood residence times with a 
concurrent enhancement of the percentage of injected dose at the tumor site. 
Another cytokine, Interleukin 2 (IL-2); was extensively studied after 
encapsulation in these so called long-circulating or sterically stabilized 
liposomes. Encapsulation resulted in enhancement of the immunomodulatory 
activity of IL-2 such as generation of leukocytes and anti-tumor activity in 
metastasized carcinoma. 
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TNF-a has been encapsulated in conventional liposomes. Improved 
pharmacokinetics and biological activity in vivo as compared to TNF-a in the 
free form has been demonstrated, as well as reduced toxicity. In anti-tumor 
therapy the encapsulation of TNF-a in long circulating liposomes seemed 
pal1icularly attractive in the combination with liposome encapsulated 
doxorubicin (DOXIL ®). 
Aim of the stndy: 
The aim ofthis thesis was to study the applicability of the combination ofTNF-
a and cytostatics in isolated organ perfusion. Furthermore, encapsulation of 
TNF-a in liposomes was studied to achieve a mean to revive the systemic 
application of the cytokine. To this end several experimental set-ups were 
designed and elaborated. 
I. A model for isolated organ perfusion was designed in which the 
combination of TNF-a and melphalan could be tested. Various 
combinations were tested to achieve a maximal anti-tumor effect, in 
vitro as well as in vivo. 
2. Melphalan is the agent of choice in isolated limb perfusion, pre-
clinically as well as in patients. Doxorubicin however, is a drug with 
well known anti-tumor effects on sarcomas. Therefore, doxorubicin in 
combination with TNF-a was used in ILP, to study the putative 
mechanism of synergy between TNF-a and doxorubicin. 
3. It was shown by others that TNF-a could lead to cell cycle disturbance, 
resulting in a decrease of anti-tumor effects of doxorubicin. The effect 
ofTNF-a on cell cycle events was studied. 
4. To minimize the toxicity of TNF-a when administered systemically, 
the possibility to encapsulate TNF-a in sterically stabilized liposomes 
was studied. The distribution of liposome encapsulated TNF-a and 
change ofpharmacokinetic profile ofTNF-a was investigated. 
5. From the above experimental set up the interest in systemic 
administration ofTNF-a was renewed. In TNF-a-based ILP high dose 
TNF-a is used to achieve the well known fine results. Others proved 
that also low dose TNF-a could lead to anti-tumor activity in 
combination with chemotherapy. The administration and subsequent 
efficacy of low dose TNF-a in combination with Ii po some 
encapsulated doxorubicin (DOXIL ®) was therefore studied. 
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ABSTRACT 
Isolated perjilsion of the extremities with high dose Tumor Necrosis 
Factor-a (TNF-a,! plus melphalan leads to dramatic tumor response in patients 
with irresectable soft tissue sarcoma or multiple melanoma in transit metastases. 
We developed in vivo isolated organ perjilsion models to determine whether 
similar /umor responses in solid organ tumors can be obtained with this 
regimen. Here, we describe the technique of isolated kidney perjilsion. We 
s/udied the feasibility of a perfusion with TNF-a and assessed its antitumor 
effects in tumor models differing in tumor vasculature. The maximal tolerated 
dose (MTD) proved /0 be only 1 I'g TNF-a Higher doses appeared to induce 
renal jailure and a secondary cy/okine release with fatal respiratory and septic 
shock like symptoms. 
In vitro the combina/ion of TNF-a and melphalan did not result in a synergis/ic 
growth inhibi/ing effect on CC531 colon adenocarcinoma celis, while an 
additive ejjix/ was observed on os/eosarcoma ROS-1 celis. In vivo isolated 
kidney perjilsion, with TNF-a alone or in combination with melphalan, did not 
result in a significant antitumor re.5ponse in either tumor model in a subrenal 
capsule assay. We conclude that, due to the susceptibility of the kidney to 
perjilsion with TNF-a, the minimal threshold concentration ofTNF-a to exert its 
ontitumor effects was not reached The applicability ofTNF-a in isolated kidney 
peljilsiol1 for human tumors seems, therefore, questionable. 
INTRODUCTION 
Tumor Necrosis Factor-a (TNF-a) in combination with melphalan with 
or without the addition of interferon, is presently used in the treatment of 
patients with 'in transit' metastases of malignant melanoma and patients with 
locally advanced soft tissue sarcoma (STS). In both groups of patients the 
cytokine TNF-a and the cytotoxic agent melphalan are used in isolated perfusion 
of the limb (ILP). The efficacy in the treatment of locally advanced soft tissue 
sarcomas, characterised by high response rates (>80%) resulting in limb salvage 
in about 80% of the patients, has now been well established by published reports 
of multicentre experiences in up to 200 perfusions (Eggermont et aI, 1993; 
Eggermont et ai, 1996a; Eggermont et aI, 1996b). Initially the procedure was 
developed in the more traditional field of applying ILP, e.g. in the treatment of in 
transit melanoma metastases, and high complete remission rates in melanoma 
patients have been reported (Lienard et ai, 1992, 1994). 
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The exact mechanism of TNF-a anti-tumor activity has not yet been 
fully elucidated, but a number of theories exist (Sidhu and Bollon, 1993). TNF-a 
has direct and indirect effects. It can induce tumor specific immunity (Spriggs 
and Yales, 1992) and is cytotoxic/cytostatic for some tumor cell lines in vilro 
(Dealtry el ai, 1987). Its direct effect on tumor cells was proven shortly after the 
discovery of the cytokine (Watanabe el ai, 1988), but the indirect effects 
probably play a more important role. The detrimental effects on the tumor-
associated vasculature is mediated by endothelial cells (Shimomura, 1988), 
however, the effect on the microvasculature seems to be dose dependent 
(Fajardo et ai, 1992). 
In contrast, high dosages of TNF-a exert a number of undesirable 
effects. The maximum tolerated dose (MTD) in humans is 350 J.lg/m' 
(Brouckaert et ai, 1986; Asher el ai, 1987) which is 10-50 times lower than the 
desired anti-tumor dose when given intravenously. Because of severe toxicity, 
observed already at relatively low doses of TNF-a after systemic administration, 
in phase lJlI clinical trials virtually no tumor responses were observed (Spriggs el 
ai, 1988; Feinberg et ai, 1988). This is not surprising as TNF-a was never 
administered systemically at doses that might have anti-tumor activity. This led 
Lejeune et al (1993) to the development of the isolated perfusion with TNF-a 
together with melphalan and y-interferon. The successful application of TNF-a 
in this setting warrants that the applicability of TNF-a in isolated organ 
perfusion setting is investigated. Isolated single lung perfusion with TNF-a 
proved to be safe (Weksler et ai, 1994; Pogrebniak el ai, 1994; Pass el ai, 1996). 
Reports on the use of TNF-a in isolated liver perfusion at the National Cancer 
Institute in the USA (Fraker et ai, 1994) as well as by our group (Borel Rinkes el 
ai, 1997) have appeared very recently. 
Here, we report on the development of in vivo isolated kidney perfusion 
and its anti-tumor effects in two tumor models. 
MATERIALS AND METHODS 
Animals 
Male rats of the inbred W AG-Rij strain (Harlan CPB, Austerlitz, the 
Netherlands), weighing 250-300 grams were used. Rats were kept under standard 
laboratory conditions. All rats were fed a standard laboratory diet (Hope Farms, 
Woerden, the Netherlands). The experimental protocols adhered to the rules laid 
down in the "Dutch Animal Experimentation Act" (1977) and the published 
"Guidelines on the protection of Experimental Animals" by the council ofthe EC 
(1986). The specific protocol was approved by the "Committee on Animal 
Research" of the Erasmus University Rotterdam, the Netherlands. 
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Tumor Necrosis Faclor-a 
Recombinant human TNF-a (rhTNF-a) was kindly provided by 
Boehringer Ingelheim GmbH, Ingelheim/Rhein, Germany. RhTNF-a had a 
specific activity of 5.8 x 10 Ulmg as determined in the murine L-M cell assay 
(Kramer and Carver, 1986). Endotoxin levels were less than 1.25 endotoxin 
units/mg protein. TNF-a was delivered in 0.5 ml vials in a concentration of 2.4 
mglml. 
Melphalan 
Melphalan (Alkeran, 50 mg per vial, Wellcome, Beckenham, UK) was 
diluted in 10 ml diluent solvent. Futther dilutions were made in 0.9 % NaCI to 
give a volume of 0.5 ml in the perfusion circnit. 
Unilateral nephrectomy 
It is probable that when two kidneys are perfused in vivo, kidney 
function as measured by blood urea nitrogen (BUN), creatinine and electrolytes 
remains stable after isolation and perfusion of one kidney. To analyse to what 
extent renal function is compromised by unilateral nephrectomy five rats 
underwent a unilateral nephrectomy and at regular intervals BUN, creatinine and 
electrolytes were recorded. The right kidney was chosen for anatomic reasons. 
The left kidney shows compensatory hypertrophy: the size of the kidney is larger, 
there is a gain in cell volume and diameter of the glomerulus as well as a larger 
volume of the tubule (Fine 1986). 
Operative procedures were carried out under clean conditions. 
Anaesthesia was induced with ether (Diethylether p.a. Merck, Darmstadt, 
Germany). The abdomen was shaved and prepped with Ethanol 70 %. Through a 
lumbotomy the right kidney was exposed and freed from its surrounding fat. 
Ureter, renal artelY and vein were dissected and tied with 4-0 silk sutures (B 
Braun Melsungen AG, Germany). The right kidney was removed and the 
lumbotol11Y closed with 2-0 silk in a running way. After three weeks the animals 
were sacrificed. 
Perfusion fluid 
In our experiments a modified Krebs-Henseleit solution (NaCI 118.00 
I11mol/l, CaC!, 2.52 mmolll, MgS04 1.66 mmolll, NaHC03 24.88 mmolll, 
KH,PO, 1,18 mmolll, +D-glucose 5.55 mmolll, Na-pyruvaat 2.00 mmolll, 
Mannitol 33.00 mmolll) was used as perfusate. 
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Operative techniqne: Isolated Kidney Perfnsion (IKP) 
Anaesthesia was induced with ether. A Zeiss operative microscope (Carl 
Zeiss, Germany) was used. The abdomen was shaved and prepped with Ethanol 
70 %. Through a median laparotomy the left kidney and vessels were exposed in 
the retroperitoneum by sharp and blunt dissection. Branches of the renal artery 
and vein (adrenal and spermatic) were dissected when needed and temporarily 
occluded with ligatures. A tobacco-pouch ligature was placed in the vein with 
Nylon 9-0 (SSC, B Braun, Melsungen AG, Germany). A bolus of 50 IE Heparin 
(Heparin Leo, Weesp, the Netherlands) was injected intravenously. Isolation of 
the renal artery and vein was carried out by means of micro vessel clamps. Via a 
venotomy and arteriotomy the vessels were cannulated with Silastic tubing (.025 
in. lD, .047 in. OD and .012 in. lD, .025 in OD respectively, Dow Corning, 
Michigan, U.S.A.). Another bolus of 50 IE Heparin was added to the perfusion 
circuit. 
Isolated kidney perfusion 
caval vein aolle 
renal vein 
Perfusion model 
( 01 
~-~ 
Figure 1. Schematic 
representation of isolated 
kidney periusion 
Isolated kidney perfusion was performed to design a model resembling 
isolated limb perfilsion where TNF-a is administered to the oxygenated 
extracorporeal perfusion circuit. In this model I, 2 or 5 J.1g TNF-a was added to 
the perfusion circuit. Perfusion with TNF-a was carried out for 15 minutes. Thus 
TNF-a was allowed to pass the kidney multiple times. 
Flow through the kidney was regulated by a non-pulsatile roller pump 
(Watson-Marlow 505U, Falmouth, UK). Perfusion pressure was recorded on a 
Datex AS/3 monitor and kept between 100 and 120 mmHg, adjusting the flow 
generated by the roller pump accordingly. 
Perfusion fluid was warmed to approximately 37' C by counterculTent 
(Polyscience 210, Merck, Amsterdam, the Netherlands). Temperature was 
recorded (Thermodig KJ-Il, Mera, Benelux). 
Flow through the kidney was approximately 1 m1/min. The reservoir was 
gassed with Cm'bogen (95% 0" 5% CO, gas mixture), to keep the oxygen 
pressure of the perfusate at 350-400 mmHg and the saturation at 99.5%. 
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When TNF-a andlor melphalan was added to the perfusion circuit a 
washout is carried out with 6 ml perfusion fluid (about 4 times the intravascular 
kidney volume). 
At the end of the perfusion period the venotomy was closed by 
tightening the tobacco-pouch ligature. Arteriotomy was closed with Nylon 10-0 
(SSC, B Braun, Melsungen AG, Germany). The laparotomy was closed with silk 
2-0 (B Braun) in one layer in a running way. Total operation time varied between 
90 and 120 min. Blood loss was kept to a minimum. 
During the recovery period the animal was kept warm with a 200 W 
lamp and then returned to his cage. 
Parameters and Histology 
Weight loss was recorded after operation. In the post operative period, 
the animals were observed at regular intervals for signs of toxicity, and deaths 
were recorded. Clinical condition (skin, eyes, stools and behaviour) was judged. 
Renal function was assessed through blood urea nitrogen and creatinine levels as 
well as electrolytes in plasma. 
For histopathological analysis 2 rats for each TNF-a concentration were 
sacrificed 24 hours after treatment. Kidneys were fixed (emersion method) in 4% 
formaldehyde solution and embedded in paraffin. Care was taken to keep the 
time of perfusion fixed, the warm ischaemia period as short as possible and time 
between nephrectomy and fixation constant. Sections of the kidneys were stained 
with haematoxylin and eosin. 
For analysis of the vasculature of the tumors, the same procedure was 
followed. 
Tumor models 
Colon carcinoma CC531 
The 1,2 dimethylhydrazine-induced, moderately differentiated colon 
adenocarcinoma CC531 (Marquel el ai, 1984), transplantable in syngeneic Wag-
Rij rats, was used. The tumor is weakly immunogenic as determined by the 
immunization-challenge method of Prehn and Main (1957). The tumor was 
maintained in vitro in RPM] 1640 medium supplemented with 5% fetal calf 
serum (virus and mycoplasma screened), I % penicillin (5000 U/ml), 1% 
streptomycin (5000 U/ml) and 1% L-glutamine (200mM). All supplementaries 
were obtained from Gibco (UK). Before usage the cells were trypsinized (5 min, 
37 0 C), centrifuged (5 min, 700g), resuspended in RPM! 1640 and counted. 
Viability was measured with trypan blue (0.3% in a 0.9% NaCl solution). 
Viability always exceeded 95%. 
For in vivo studies the tumor was inoculated in the flank of syngeneic 
Wag-Rij rats, where it was allowed to grow until the time of the experiment. 
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Osteosarcoma ROS-J 
The ROS-I osteosarcoma (transplantable to Wag-Rij rats) was used in 
the second series of experiments. This tumor originated spontaneously in the 
tibia of a rat. The ROS-I cells grow as a monolayer in Dulbecco's modified 
Eagle's medium. To this medium 5% foetal calf serum and glutamic acid (Gibco, 
Paisley, UK) was added. Cells were maintained in a humidified atmosphere of 
CO,lair (5/95) at 37°. From the tissue cultures new solid tumors were produced 
by serial inoculation in the flank where it was allowed to grow until the time of 
the experiment. 
Experimental design 
In vitro testing of tumor cell lines for susceptibility to TNF-a and 
melphalan: tumor cells were seeded at IxlO4 cells per well in a flat bottomed 96-
well microtiter plates (Costar, USA) in a final volume of 0.2 ml medium per 
well, and incubated at 37°C in 5% CO2 for 48 h in the presence of different 
concentrations of rl-luTNF-a and melphalan. Concentrations of TNF-a used 
were 0.00 I, 0.0 I, 0.1, I, 10 and 100 ~ol/ml. Concentrations of melphalan used 
were 0.04, 0.1, 0.9, 5 and 8 ~tInollml. 
Growth of tumor cells was measured using the Sulphorhodamine-B 
assay according to the method of Skehan et af (J 990). Eight replicate 
experiments were performed. Tumor growth was calculated using the formula: 
tumor growth = (test well/control) x lOa percent. The drug concentration 
reducing the absorbance to 50 percent of control (ICso) was determined from the 
growth curves. 
In vivo tumor model: for the in vivo isolated kidney perfusion the Sub-
Renal Capsule Assay (SRCA) was used. Recipient animals were anaesthetised 
with ether, a midline incision was made and two small tumor fragments of 6-7 
mg were placed under the renal capsule of either kidney, one in the upper pole 
and one in the lower pole of the kidney. To exclude perfusion defects of the 
kidneys the location of inoculation of CC531 and ROS-l was varied between the 
upper or lower pole of the kidney. After seven days the animals were used for the 
experiments. At 14 days after inoculation the animals were sacrificed, the tumors 
were enucleated and weighed. The tumors in the right kidney were used as an 
internal control. Nine replicate experiments were performed. 
Statistical significance was assessed using the Mann Whitney U test. 
RESULTS 
Unilateral nephrectomy 
Unilateral nephrectomy was very well sustained. There was a mmor 
increase in creatinine shortly after operation, but all animals showed a quick 
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recovery. Kidney functions fluctuated within a normal range. 
Sham perfusion 
In five animals isolated kidney perfusion with perfusate only was 
performed (figure 2). BUN and creatinine levels were elevated for 3 days, but 
returned to normal withiu 1 week. Blood levels were followed for three weeks, 
but showed only fluctuation. After perfusion kidneys showed slight oedema, 
depending on perfilsion pressure. Perfusion pressure greater than 120 mm Hg 
resulted in some oedema, kidneys perfused with less than 120 mm Hg showed no 
oedema; thus all perfusions with TNF-a were performed with a pressure less 
than 120 mm Hg. At sacrifice no macroscopic abnormalities were seen. All rats 
survived the procedure. 
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Figure 2. Course of kidney function parameters as a function of time (days) following 
Isolated kidney perfusion with 1 ~g TNF-a in a roller-pump regulated perfusion setting. 
After 15 minutes perfusion urea and creatinine levels returned to normal in sham (II) and 
1 ~g TNF-u groups (J.), after 2 ~g TNF-a (V) rats were sacrificed after 2-3 days in bad 
clinical condition (values depicted are a mean of 6 rats ± SO). 
TNF -a perfusion 
After perfusion with 1 flg TNF-a a rise in blood urea nitrogen (BUN) 
and creatinine levels were observed during the first four days after operation 
(figure 2). In spite of this initial toxicity all rats survived the procedure and 
kidney functions returned to normal after 6 days and remained within normal 
range. Animals recovered their preoperative weight after a median of 25 days 
after isolated kidney perfusion. Perfusion with 2 flg TNF-a resulted in a 
continuous rise of BUN and creatinine (figure 2), and rats were sacrificed in bad 
clinical condition. After two days rats were lethargic and had bloody diarrhoea. 
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After isolated kidney perfusions with 5 Ilg added to the perfusion circu it, rats 
died very quickly due to shock and respiratory failure within 24 hours (data not 
shown). 
Histology 
Kidneys perfused with perfusate only did not show any major changes in 
histology (figure 3a). 
In kidneys perfused with 1 flg TNF-a no severe abnormalities could be 
seen, but signs of focal tubular necrosis and bleeding were seen in the 2 Ilg 
(figure 3b) and 5 Ilg groups. Scattered mononuclear inflammatory cells are 
present in the interstitium. The glomeruli appeared to be relatively unaffected. 
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Figure 3. A: HE stained section (250 x) of a kidney 24 hours after perfusion with perfusate 
only. See text for explanation. B. HE stained section of a kidney 24 hours after 15 minute 
perfusion with 2 ~g TNF-a. Focal tubular necrosis is indicated (arrow). 
Animal weight 
All animals showed a decrease in weight after the perfusion. The first 
week weight gain was minimal, but 21 days after isolated kidney perfusion the 
animals recovered thei r preoperative weight. 
In vitro sensitivity of the colon adenocarcinoma CC531 to TNF-a and 
Melphalan 
Cells of the CC531 tumor showed on ly a minor response to increasing 
dosages of rHuTNF-a as determined by the Sulphorodamine-B assay. The [C50 
of cells treated with more than 10 Ilglml TNF-a was just reached, which means a 
significant reduction in the number of tumor cells after 48 hours of incubation (p 
< 0.05). 
The dose/response curve of CC53 I cells to melphalan alone (0 Ilglml 
TNF-a) showed sensitivi ty in vitro at dosages higher as I Ilglml (figure 4a). The 
IC,o of melphalan is reached with a concentration of> I 0 Ilglml. The cell line 
proved to be relatively resistant to the cytotoxic effects of melphalan. 
The IC50 of the adenocarcinoma ce lls to treatment with melphalan was 
on ly slightly reduced in the presence of incrementing dosages of TNF-a (figure 
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4a, for clarity only 0.5 and 10 Jlg TNF-a is shown). The maximal growth of 
CC531 is reduced in the presence of TNF-a. Because the dose/response curves 
all bend towards total growth inhibition, irrespective of the concentration of 
TNF-a, a synergy between the cytokine and the cytotoxic drug in this tumor 
system in vitro could not be demonstrated. 
In vitro sensitivity of the osteosarcoma ROS-l to TNF -a and Melphalan 
The dose-response curves of the ROS-l osteosarcoma cell line to TNF-a 
and melphalan are depicted in figure 4b. The osteosarcoma cell line shows 
relative minor sensitivity to TNF-a alone (Manusama et ai, J996b). The IC50 for 
melphalan is reached at 6 Jlg/ml. 
Maximum growth of the osteosarcoma in vitro at lower dosages of melphalan is 
reduced in the presence ofTNF-a at the various concentrations used (for clarity 
only 0.5 and 10 Jlg/ml TNF-a curves are shown). Total growth inhibition is 
reached with increasing dosages of melphalan, almost independent of TNF -a. 
These experiments therefore could not reveal synergism of TNF-a and 
melphalan in the tumor cytotoxic effects, but an additive effect at best. 
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Figure 4. A: Dose/response curve of CC531 colon adenocarcinoma to melphalan in the 
absence or presence of various concentrations TNF-u, as determined in the 
Sulphorhodamine B assay (III = 0 ~Ig/ml TNF-a , A. = 0.5 ~g/ml TNF-a , 0= 1 0 ~g/ml TNF-
a; for clarity concentrations between 0.5 and 1 0 ~g/ml TNF have been omitted). 
B: Dose/response curve of ROS-1 osteosarcoma to melphalan in the absence or 
presence of various concentrations TNF-u, determined in the Sulphorhodamine B assay 
(l1li = 0 ~Ig/ml TNF-a, A = 0.5 ~Ig/ml TNF-a, 0= 10 ~g/ml TNF-a). 
Tumor response of CC531 
In the SRCA the relative low concentration of 0.2 flg/ml TNF-a had to 
be used. Kidney functions were severely disturbed at higher dosages. Sham 
perfusion and isolated kidney perfusion with 0.2 flg/ml TNF-a under oxygenated 
conditions showed no significant inhibition of tumor growth (data not shown). 
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There was minor growth inhibition of the solid tumor in this location, but none of 
the tumors showed regression. 
A combination of the MTD of TNF-a (1 ~g) and the dose used in isolated limb 
perfilsions of 40 ~g melphalan was chosen at first to investigate whether there 
were any synergistic or additive effects in vivo. We could not prove significant 
growth inhibition with this combination. 
In subsequent experiments we tested the combination of a high dose 
melphalan (500 ~g) with the MTD of TNF-a (I ~g). These experiments showed 
growth inhibition, but no significance was reached (figure 5, n~9; treated versus 
control; mean 57 mg versus 81.llmg, s.d. 12.59 versus 13.22, p~O.l999). 
Tumor response of osteosarcoma 
In this tumor model only minor sensitivity was shown to the maximally 
tolerated dosages of TNF-a and melphalan. Mean tumor weight (n~9; treated 
76.0±11.91 mg versus control 105.8±12.76 mg; p~0.157) was only slightly 
reduced, again without significance (figure 5). 
CC531- CC531+ ROS-l - ROS-l+ 
Figure 5. Growth inhibition of CC 531 adenocarcinoma and ROS~1 osteosarcoma in 
the Subrenal Capsule Assay after isolated kidney perfusion with 1 ~g TNF-a combined 
with 500 ~g melphalan (CC531- = sham, CC531+ = treated, ROS-1- = sham, ROS-1+ = 
treated; data shown are mean values of 9 rats ± SO, p=n.s.) 
DISCUSSION 
Isolated perfusion with Tumor Necrosis Factor-a in combination with 
ischaemia (Jvfanusama ef ai, 1994) or with melphalan (Jvfanusama ef ai, 1996a,b) 
has been reported to result in complete tumor regression in preclinical tumor 
models. Isolated limb perfusion in patients with in-transit melanoma with TNF-a 
21 
Chapter 2 
in combination with melphalan and y-interferon resnlted in high complete 
remission rates (Lienard ef ai, 1992; 1994). Also high limb salvage rates have 
been reported with the same treatment protocol in patients with non resectable 
soft tissue sarcomas (Eggermont et ai, 1993; 1996a,b). 
Isolated organ perfusion with TNF-a is clearly a more complicated 
matter than isolated limb perfusion. Different models have been developed to 
evaluate the efficacy of TNF-a in organ perfusion, such as in lung (Weksler et 
ai, 1993; 1994; Pogrebniak ef ai, 1994), and in liver (Fraker et ai, 1994; Borel 
Rinke,I' ef ai, 1997). TNF-a in isolated lung perfusion has been shown to be safe 
and in a phase I study tumor responses have been observed in patients with lung 
metastases (Pass ef ai, 1996). 
The isolated perfused kidney model has been used to study the effects of 
cytotoxic agents (Asbach and Bersch, 1980). Here we demonstrate that 
analogous to the isolated limb perfusion (ILP) isolated perfusion of the kidney 
(IKP) is technically feasible. 
In the current model the MTD was reached at I Ilg TNF-a, showing only 
a transient renal toxicity. At 2 Ilg TNF-a fatal renal toxicity was seen. This 
involved acute renal failure leading to death by day 4, An acute fatal shock 
syndrome was noted at 5 Ilg. 
It is known that TNF-a may have direct toxic effects to the kidney 
(Kahky ef ai, 1990; Gaskill, 1988; Tracey ef ai, 1986). Acute tubular necrosis 
was seen with portal infusion of sublethal doses of TNF-a with relative sparing 
of the glomeruli. In surviving animals a decrease in kidney function was noted. 
The serious toxicity seen in our experiments with higher dosages of TNF-a may 
be pa.tially explained by the production of TNF-a by glomerular macrophages, 
mesangial cells and renal tubular cells upon stimulation (Affres ef ai, 1991; 
Tipping ef ai, 1991; Baud and Ardaillou 1995). Analogous to the production of 
TNF-a and interleukin-l by Kupffer cells (Kahky ef ai, 1990), we hypothesise 
that a potent second cytokine release is responsible for the increased toxicity. In 
rats perfused with 5 Ilg the secondary cytokine response was so extreme that the 
rats died of acute respiratory distress. Similar observations have been reported by 
Fraker ef ai (1994) in pigs, shown to be due to a secondalY cytokine response 
that could not be prevented by anti-TNF-a antibody treatment. Toxicity to the 
lung is manifested by pulmonary oedema and adult respiratory distress syndrome 
(Pogrebniak ef ai, 1994). Thus, in contrast to the very high concentration of 
TNF-a that can be applied in the ILP setting, the kidney proves to be a very 
susceptible organ which only tolerates 1/50lh of the TNF-a dose used in ILP. 
In vitro synergy between TNF-a and melphalan for the rat colon 
adenocarcinoma cell line CC531 was not observed. Also, synergy could not be 
proven for the osteosarcoma cell line ROS-I. Here an additive effect at best is 
reached. 
For in vivo studies two solid tumor systems were chosen with a different 
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vascularization pattern. The rational for this choice is based on our previous 
work with the highly vascularized soft tissue sarcoma BN175 where the 
synergistic anti-tumor effects with the combination of TNF-a with melphalan 
results were shown to induce vascular changes accompanied by increased 
vascular permeability and platelet aggregation (Manusama et ai, 1996b; Nooijen 
et ai, 1996). 
The observations in our in vivo experiments made clear, however, that 
no strong synergistic antitumor effects existed in either tumor. Instead ofthe high 
concentration of 10 flglml TNF-a as used in isolated limb perfusion with ROS-I, 
the relatively low dose of 0.2 flglml had to be used because of dose limiting 
toxicity. Thus, the minimal threshold concentration of TNF-a was not reached 
and therefore the crucial vascular effects in vivo described previously 
(Manusama et ai, 1996b; Nooijen et ai, 1996) are not observed. 
Since isolated kidney perfusion in the rat allowed only low dosages of 
TNF-a, the dual role of TNF-a on the tumor vasculature may be an explanation 
for the discrepancies between in vitro and in vivo results. It has been 
demonstrated that low TNF-a concentrations are promoting angiogenesis while 
high concentrations ofTNF-a are toxic to the vessels (Fajardo et ai, 1992). The 
concentration of TNF-a used in isolated kidney perfusion is only 0.2 flglml. At 
this concentration a promotion of angiogenesis might even be more plausible 
than the vascular destruction seen with higher dosages. Thus, the typical effects 
of TNF-a are not seen which is an explanation for the absence of growth 
retardation in the tumor models used in our experiments. 
While the model of isolated kidney perfusion was developed to evaluate 
the effect ofTNF-a in isolated organ perfusion, it is also possible to treat kidney 
tumors with this regimen. Because the main target of TNF-a is the vascular 
endothelium, well vascularized renal tumors could potentially be responsive. In a 
recently published study isolated perfusion of the kidney in a miniature swine it 
appeared possible to perfuse the kidney with 1 mglml (Walther et ai, 1996). 
We conclude from our studies with the isolated kidney perfusion model 
that since only 1/50'h of the TNF-a concentration was tolerated the advantage of 
regional application is lost and perspectives for efficacy in tumor bearing species 
is much reduced. Ifthe dose needed for anti-tumor effect is 50 times higher than 
the maximal tolerated dose in isolated kidney perfusion (Asher et ai, 1987; 
Lienard el ai, 1992, 1994; Eggermont et ai, 1996a,b) the outlook for clinical 
applicability seems to be poor. 
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ABSTRACT 
We have shown previously that isolated limb perJusion (ILP) in sarcoma-
bearing rats results in high response rates when melphalan is used in combination 
with TNF-a. This is in line with observations in patients. Here we show that ILP 
with doxorubicin in combination with TNF-a has comparable effects in two 
different rat sarcoma tumor models. The addition oJTNF-a exhibits a synergistic 
anti-tumor effect, resulting in regression oj the tumor in 54% and 100% oj the 
casesJor the BN175jibrosarcoma and the ROS-1 osteosarcoma respectively. The 
combination is shown to be mandatory Jor optimal tumor response. The effect of 
high dose TNF-a on the activity oj cytotoxic agents in ILP is still unclear. We 
investigated possible modes by which TNF-a could modulate the activity oj 
doxorubicin. In both tumor models increased accumulation of doxorl.lbicin in 
tumor tissue was Jound: 3. 11iJld in the BN175 and l.8-/0Id in the ROS-1 sarcoma 
after ILP with doxorubicin combined with TNF-a in comparison with an 1LP with 
doxorubicin alone. This increase in local drug concentration may explain the 
synergistic anti-tumor responses after ILP with the combination. In vitro TNF-a 
Jails to augment drug uptake in tumor cells or to increase cytotoxicity oj the drug. 
These findings make it unlikely that TNF-a directly modulates the activity oj 
doxorubicin in vivo. As TNF-a by itself has no or only minimal effect on tumor 
growth, an increase in local concentrations oj chemotherapeutic drugs might well 
be the main mechanism Jar the synergistic antitumor effects_ 
INTRODUCTION 
Low concentrations at the tumor site and dose limiting systemic toxicity 
are common causes for failure of solid tumor treatment with anti-tumor agents. As 
cytotoxic drugs typically exhibit a steep dose response-curve, increasing local 
concentration should favour tumor response. In isolated limb perfusions local drug 
concentrations are increased while systemic exposure to the drugs is minimal. In 
isolated limb periiJsions (lLP) melphalan is used most commonly, but also other 
agents (e.g doxorubicin and cisplatin) are applied with varying success in perfusion 
of limb or organ (e.g lung) (Abolhoda et ai, 1997; Klaase et 01, 1989; Rossi et 01, 
1992; Tonak et ai, 1979; Weksler et ai, 1994). Tumor Necrosis Factor alpha (TNF-
ex), a cytokine with known anti-tumor activity, can not be used systemically in 
dosages high enough to obtain a tumor response (Asher et 01, 1987; Fajardo et 01, 
1992). However, in ILP with TNF-ex tumors are exposed to concentrations of up 
to 50 times higher than those reached after systemic administration of the 
maximum tolerated dose (MTD), without major side effects (Benckhuijsen et ai, 
1988). Previously it was demonstrated that the addition ofTNF-ex to melphalan in 
ILP could improve response rates in patients with multiple melanoma in transit 
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metastases or irresectable soft tissue extremity sarcomas (Eggermonl el ai, 1993; 
Eggermonl el ai, 1996a; Eggermont et ai, 1996b; Lejeune el ai, 1993; Lienard el 
ai, 1994; Lienard et ai, 1992). Tn both patient groups very high response rates of 
above 85% have been reported, with a limb salvage rate of more than 85%. Tn 
Europe TNF-a was recently approved and registered for clinical use in patients for 
the treatment of locally advanced extremity soft tissue sarcomas by ILP with TNF-
a and melphalan. Comparable results have been reported by us for ILP with the 
combination of TNF-a and melphalan in soft tissue sarcoma and osteosarcoma-
bearing rats (Manusama et ai, 1996a; Manusama el ai, 1996b)(de Will el ai, 
2000). TLP with TNF-a alone or melphalan alone at concentrations used in the 
clinical setting had negligible antitumor effects, whereas the combination showed 
strong synergistic anti-tumor efficacy. 
TNF-a may potentiate the effects of chemotherapy in ILP in various 
ways. TNF-a has a broad spectrum of activities, which range from enhancement 
of proliferation to direct cytotoxicity on tumor cells, activation of inflammation and 
effects on endothelium (Fajardo el ai, 1992; Walanabe et ai, 1988). The tumor 
associated vasculature (TA V) responds to TNF-a with rounding ofthe endothelial 
cells resulting in increased gaps, allowing easy passage of soluble materials and 
even cells (Folli et ai, 1993; Renard et ai, 1995; Smylh el ai, 1988). Moreover, 
intravenous injection of TNF-a in human melanoma xenograft-bearing mice 
resulted in significant reduction of the interstitial fluid pressure (lFP) ofthe tumors 
(Kristensen el ai, 1996). This phenomenon could increase localization of cytotoxic 
drugs in the tumor interstitium and explain improved tumor response. Secondly, 
clinical and experimental results demonstrating massive destruction of the 
endothelial cells, which has also been shown in vitro and on angiograms in patients 
after TLP, suggest that the TAVis the primary target for TNF-a and therefore that 
destruction of the endothelial lining might be responsible for the anti tumor 
response (Olieman el ai, 1997; Salo et ai, 1986; Watanabe el ai, 1988). This 
process is accompanied by inflammatory responses and seemed to be dependent on 
infiltrating leukocytes (Manusama et ai, 1998). Coagulative and haemorrhagic 
necrosis and destruction of the endothelial lining was also seen when TNF-a was 
used as a single agent in ILP, however without significant effect on tumor growth 
in rats. This indicates that the direct TNF-a effect is most likely playing a minor 
role in the anti-tumor capacity (Manusama et ai, 1996a; Nooijen el ai, 1996a). 
Although in the majority of the perfusions, especially for the treatment of 
melanoma, melphalan is used, also other agents might be successful. 
Anthracyclines are among the most active agents against solid tumors and 
doxorubicin is the most widely used agent of this class (Bielack el ai, 1996; Budd, 
1995). Moreover, doxorubicin is the agent of choice for the treatment of sarcoma, 
and has shown good anti-tumor activity in clinical and experimental perfusion 
settings for the treatment of lung metastasises (Abolhoda el ai, 1997; Weksler et 
ai, 1994), and could therefore be a suitable cytotoxic agent for TLP in sarcoma-
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bearing patients. 
In this study we undeltook isolated limb perfusions with doxorubicin and 
TNF-a in soft tissue sarcoma- and osteosarcoma-bearing rats to examine the effect 
ofTNF-a on the anti tumor activity of doxorubicin and secondly an attempt was 
made to unravel possible mechanisms by which TNF-a potentiates the anti-tumor 
activity of doxorubicin. 
MATERIALS AND METHODS 
Chemicals 
Human recombinant Tumor Necrosis Factor-a (specific activity 5x 107 
IU/mg) was kindly provided by Dr G. Adolf (Bender Wien GmbH, Wien, Austria) 
and stored at a concentration of 2 mg/mL. Endotoxin levels (LAL) were below 
0.624 EUlmg. Doxorubicin (Adriablastina®) was purchased from Farmitalia Carlo 
Erba (Brussels, Belgium). 
Animals and tnmor model 
Male inbred BN rats were used for the soft tissue sarcoma model (BNI75) 
and W AG/RIJ rats for the osteosarcoma model (ROS-I). Rats were obtained from 
Harlan-CPB (Austerlitz, the Netherlands) and weighing 250 - 300 g. Small 
fragments (3 mm) of the syngeneic BNl75 or ROS-I sarcoma were implanted 
subcutaneously in the right hindleg as previously described (Manusama et ai, 
1996a, b). Tumor growth was recorded by calliper measurements and tnmor volume 
calculated using the formula 0.4(A2xB) (where B represents the largest diameter 
and A the diameter perpendicular to B). All animal stndies were done in 
accordance with protocols approved by the Animal Care Conunittee of the Erasmus 
University Rotterdam, the Netherlands. 
The classification of tnmor response was: progressive disease (PD): 
increase of tumor volume (> 25 %) within 5 days; no change (NC): tnmor volume 
equal to volume dnring perfusion in a range of -25 % and + 25 %; partial remission 
(PR): decrease of tumor volume between -25% and -90 %; complete remission 
(CR): tumor volume less than 10% of initial volume. 
Isolated limb perfusion protocol 
Rats were perfused according to the isolated limb perfusion technique 
originally described by Benckhuijsen et ai, and adapted for the rat by Manusama 
et aI, (Benckhuijsen et ai, 1982a; Manusama et ai, 1996a). Briefly, the femoral 
altery and vein of anaesthetized rats were cannulated with silastic tubing. 
Collaterals were occluded by a groin tourniquet and perfusion started when the 
tourniquet was tightened. The extracorporeal circuit included an oxygenation 
reservoir and a roller pump (Watson Marlow, Falmouth, UK). The perfusion was 
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performed with 5 mL Haemaccel (Behring Pharma, Amsterdam, Netherlands) and 
TNF-a (50 ~g) and/or doxorubicin (400 ~g BN175, and 200 ~g ROS-I) were 
added as boluses to the oxygenation reservoir. Control rats (sham) were perfused 
with Haemaccel alone. The concentration ofTNF-a was adapted from previous 
animal studies and doxorubicin concentrations were chosen which had no local 
toxicity and induced maximally stable disease after single perfusion (Manusama 
et ai, 1996a). Perfusion was maintained for 30 min at a flow rate of2.4 mLimin. 
During the perfusion the hindleg of the rat was kept at a temperature of 38-39°C 
with a warm water mattress. A washout with 2 mL oxygenated Haemaccel was 
performed at the end of the perfusion. Perfusion was performed at a tumor diameter 
of 12-15 mm, which is arowld 7 or 10 days after implantation for BNl75 and ROS-
I respectively. 
'C) 
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In vitro assessment of anti-tumor activity 
Figure 1. Schematic 
representation of isolated 
limb perfusion 
BNI75 soft tissue sarcoma cells or ROS-I osteosarcoma cells were added 
in 1 00 ~I aliquots to 96-well plates at a final concentration of 105 cells per well and 
allowed to grow as a monolayer in DMEM supplemented with 10% FCS. 
Doxorubicin and/or TNF-a were diluted in DMEM supplemented with 10% FCS, 
added to the wells and allowed for three days to incubate. The range of fmal drugs 
in the wells was 0.0005 - I 00 ~g/mL for doxorubicin and 0 - I 0 ~g/mL for TNF-a. 
A total of 5 to 6 separate assays were performed in triple and the percentage of 
growth inhibition calculated according to the formula: percentage of tumor cell 
growth = (test well/control well)xIOO%. Percentage oftumor cell cytotoxicity was 
measured using the sulphorhodamine B assay (Keepers et ai, 1991). 
In vitro assessment of doxorubicin uptake in tumor cells 
To determine if the observed anti-tumor response after ILP and 
cytotoxicity in vitro correlated with cellular uptake of doxorubicin, cells were 
exposed to doxorubicin with and without TNF-a and intracellular doxorubicin 
levels determined by flowcytometry as previously described (Luk and Tannock, 
1989). Briefly, BN175 soft tissue sarcoma cells or ROS-l osteosarcoma cells were 
added in 500 ~I aliquots to 24-well plates at a final concentration of 5xl 04 cells per 
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well and allowed to grow as a monolayer in DMEM supplemented with 10% FCS. 
Doxorubicin and TNF-a were diluted in DMEM supplemented with 10% FCS and 
added to the wells, after which cells were incubated for 0, 10,30,60, and 120 min. 
The final drug concentration in the wells was 0, 0.1, 1.0 and 10 flg/mL for both 
doxorubicin and TNF-a. Thereafter monolayers were treated with trypsin-EDTA 
for 2 min and the cell suspensions were washed two times in complete medium and 
resuspended in PBS. Cellular uptake was measured on a Becton Dickinson 
FACScan using Cell Quest software on Apple Macintosh computer. Excitation was 
set at 488 nm and emission at 530 nm. Fluorescence was corrected for cell size 
using the fOlward scatter (FSC) with the formula corrected fluorescence (FLcor) 
= fluorescence at 530 nm (FL530) I FSC - FL530, I FSC (FL530, and FSC, are 
fluorescence and forward scatter with no drug added to the cells). 
Assessment of doxorubicin accumulation in solid tnmor and concentration in 
perfusate dnring ILP 
To determine the influence of TNF-a on doxorubicin accumulation in 
tumors during ILP, tumors (and muscle) were surgically removed after ILP and 
total doxorubicin content determined as previously described (Mayer et ai, 1989). 
As the ILP included a thorough washout there is no intravascular doxorubicin 
present. Briefly, after incubation in acidified isopropanol (0.075 N HCl in 90% 
isopropanol) for 24 h at 4°C, the tumors were homogenized (pR0200 homogenizer 
with 10 mm generator, Pro Scientific, CT, USA), centrifuged for 30 min at 2500 
rpm and supernatants harvested. Samples were measured in a Hitachi F4500 
fluorescence spectrometer (excitation 472 nm and emission 590 nm) and compared 
with a standard curve prepared with known concentrations of doxorubicin diluted 
in acidified isopropanol. Measurements were repeated after addition of an internal 
doxorubicin standard. Detection limit for doxorubicin in tissue was 0.1 flg per 
gram tissue. 
For perfusate measurements samples were drawn from the perfusion vial 
at 0.5, 5, 15 and 30 min after ILP was started. Samples were centrifuged for 30 min 
at 2500 rpm and supernatant measured for doxorubicin content as described above. 
Cell pellets were incubated in acidified isopropanol and doxorubicin content 
determined as described above. 
Statistical analysis 
The in vivo and in vitro results were evaluated for statistical significance 
using the Mann Whitney U test with SPSS for windows. In vitro data was analysed 
by curve fitting using GraphPad Prism. P values below 0.05 where considered 
statistically significant. 
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RESULTS 
In vivo tumor response to doxorubicin and TNF-a 
To evaluate the anti-tumor activity of doxorubicin when combined with 
TNF-a in an isolated limb perfusion setting, soft tissue sarcoma and osteosarcoma-
bearing rats were per/hsed with the agents combined or alone. Figure 2 shows the 
tumor responses of soft tissue sarcoma (BNI75) in rats after ILP. Perfusion with 
buffer or TNF-a alone resulted in progressive disease in all animals. Although lLP 
with doxorubicin (400 JJ.g) alone resulted in a slight inhibition of the BNI75 tumor 
growth when compared with the sham control, none of the rats showed a tumor 
response (Table I). ILP with 400 JJ.g doxorubicin combined with 50 JJ.g TNF-a 
resulted in increased anti tumor activity with a response rate of 54% (PR and CR 
combined)(p< 0.01 compared with doxorubicin alone). 
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Figure 2. Growth curves of subcutaneous implanted soft tissue sarcoma BN175 after 
isolated limb perfusion with medium alone (III), 50 I1g TNF-a (Jo.), 400 I1g doxorubicin ('f), 
or combination of TNF-a and doxorubicin (e). Mean tumor volumes are shown ± SEM. 
Number of rats per group is shown in table 1. 
In osteosarcoma (ROSl)-bearing rats ILP with buffer or doxorubicin (200 JJ.g) 
alone had no significant effect on tumor growth (Figure 2). ILP with TNF-a 
alone resulted in significant inhibition oftumor growth as compared with the 
sham perfusion and a response rate of33% was observed (Table 2). ILP with 
200 JJ.g doxorubicin combined with 50 JJ.g TNF-a further increased the anti 
tumor response with a response rate of I 00% (PR and CR combined) (p <0.05 
compared with TNF-a alone). 
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Table 1. Tumor response of BN-175 after Isolated Limb Perfusion with doxorubicin and 
Tumor Necrosis Factor-a (TNF-a) five days after treatment. 
Tumor responseu 
PD' 
NC 
PR 
CR 
Response rate(%) 
Sham 
n~12 
12 
TNF-a 
n~10 
10 
Doxorubicin TNF+Doxorubicinb 
n~10 n~13 
6 2 
4 4 
6 
54 
a responses were scored as described in Materials and Methods 
b TNF-a and doxorubicin. 50 and 400 Ilg respectively, were added to the 
perfusate (5 mL) as boluses. 
c PD: progressive disease, NC: no change, PR: partial remission, CR: complete 
remission. 
Table 2. Tumor response of ROS-1 after Isolated Limb Perfusion with doxorubicin and 
Tumor Necrosis Factor-a(TNF-a) during five days after treatment. 
Tumor responsea Sham TNF-a Doxorubicin TNF+Doxorubicinb 
n~8 n~ll n~8 n~IO 
PD' 8 3 2 
NC 3 6 
PR 6 
CR 2 
Response rate(%) 33 100 
a responses were scored as described in Materials and Methods 
b TNF-a and doxorubicin, 50 and 400 Ilg respectively, were added to the 
perfusate (5 mL) as boluses. 
c PD: progressive disease, NC: no change, PR: partial remission, CR: complete 
remiSSIon. 
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Figure 3. Growth curves of subcutaneous implanted osteosarcoma ROS-1 after isolated 
limb perfusion with medium alone (III), 50 ~g TNF-ex (A), 200 ~g doxorubicin ("'1'), or 
combination of TNF-a and doxorubicin (e). Mean tumor volumes are shown ± SEM. 
Number of rats per group is shown in table 2. 
In vitro assessment of anti-tumor activity of doxornbicin and TNF-ex 
The in vivo experiments clearly demonstrate pronounced improvement of 
tumor response when doxorubicin was used in combination with TNF-a. In vitro 
experiments were performed to further study the nature of this interaction. 
Exposure of soft tissue sarcoma BNl75 or osteosarcoma ROS-l tumor cells to 
doxorubicin resulted in a response curve with an IC50 of 0.1 and 2.0 Ilg/mL 
respectively (figure 4). No significant cellular toxicity could be observed when 
BN 175 cells were exposed to TNF-a alone, however a dose depended growth 
reduction was observed when ROS-l cell were exposed to TNF-a with a maximum 
reduction of 38% at 10 Ilg/mL. Addition of TNF-a to doxorubicin did not 
significantly alter the IC50 of doxorubicin in the BN-175 cell cultures, indicating 
that addition of TNF-a in vitro did not influence the sensitivity of the cells to 
doxorubicin significantly. On ROS-l cells only an additive effect ofTNF-a and 
doxorubicin was observed. The curve only shifted downwards and not to a lower 
doxorubicin concentration, which indicates that the drugs do not influence each 
other but have separate effects. 
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Figure 4, In vitro growth of (a) the BN175 and (b) ROS-1 tumor cells as function of the 
doxorubicin concentration in combination with 0 ~g (0), 0,1 ~g (A.), 1,0 ~g (V) or 10 ~g 
TNF-a per mL (l1li), The mean of 5 to 6 individual experiments performed in triple is shown 
±SEM. 
In vitro uptake of doxorubicin in tumor cells 
Figure 5 shows that increased intracellular concentrations of doxorubicin 
are observed in both cell types when cells were incubated with increasing 
concentrations of doxorubicin, A 10-fold higher doxorubicin concentration in 
culture supematant (ranging from LO to 10 f-Lg/mL) resulted in 4,5-fold and 3,9-
fold augmented cellular uptake for BN175 and ROS-l respectively (p < 0,01 and 
p < 0.05), Addition however of TNF-a to the culture medium did not influence 
intracellular doxorubicin content significantly for all the TNF-a concentrations 
tested, or even a slight but not significant reduction in uptake was noticed with 
increasing concentrations ofTNF-a (figure 6), 
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Figure 5. Uptake of doxorubicin by (a and c) BN175 tumor cells, or (b and d) ROS-1 tumor 
cells in vitro as determined by fiowcytometry after exposure of the cells to 0, 0.1, 1.0 or 10 
~g per ml doxorubicin for 2 hrs (a and b) or for various durations of time at a fixed 
doxorubicin concentration of 10 ~g per ml c and d). The graphs are good representatives 
of the experiments performed. 
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Figure 6. Uptake of doxorubicin in (a) BN175 or (b) ROS-1 tumor cells in vitro at 
respectively 120 and 60 min of exposure to the agent in the presence of 0, 0.1, 1.0 or 10 
~g TNF-a per mL. The mean of 5 experiments is shown ± SO. 
Doxorubicin accumulation in solid tumor after ILP 
Possibly the observed beneficial effect of TNF-a in vivo could be 
explained by an increased extravasation of doxorubicin into the tumor interstitium, 
resulting in a higher local concentration and accordingly in an improved anti tumor 
activity. Therefore, concentrations of doxorubicin in tumor and surrounded tissue 
after ILP were determined. Figure 7 shows that measurable amounts of doxorubicin 
localized both in BNI7S and ROS-I tumors after ILP, which correlates with an 
observed decline of the drug concentration in the perfusate (data not shown). 
Moreover, addition ofTNF-a to the perfusate resulted in significantly enhanced 
accumulation of doxorubicin in both these tumors, 3 . I-fold in the BNl7S and 1.8-
fold in the ROS-I sarcoma, when compared with ILP with doxorubicin alone. 
Addition of TNF-a had no significant effect on doxorubicin accumulation in 
muscle of the leg (p > OA). Strikingly a significant discrepancy in drug levels was 
observed between BNI7S and ROS-I tumors. 
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Figure 7. Accumulation of doxorubicin in (a) soft tissue sarcoma BN175 or (b) 
osteosarcoma ROS-1 in vivo during isolated perfusion. Rats were perfused with 
doxorubicin (400 1'9 BN175 and 200 1'9 ROS-1) with 50 1'9 TNF-a or without TNF-a, after 
which tumors and muscle were excised and total doxorubicin content determined as 
described in materials and methods. The mean of 6 rats are shown ± SO 
DISCUSSION 
In the present study we demonstrate that isolated limb perfusion in 
sarcoma-bearing rats with doxorubicin in combination with TNF-a results in high 
response rates in two different tumor models. These findings are in close agreement 
with our previoU$ work using melphalau (Manusama ef ai, 1996a; Manusama ef 
ai, 1996b). Secondly, it is demonstrated for the first time that TNF-a enhances 
intratumoral accumulation of doxorubicin, which is an attractive explanation for 
the augmented tumor response in TNF-a-based ILP. We speculate that TNF-a 
increases interstitial drug levels in the tumor as intravascular doxorubicin is washed 
out at the end of the ILP procedure and intracellular uptake of doxorubicin is not 
affected by TNF-a as was shown in vitro. 
Doxorubicin has been shown to be the most effective drug in treatroent of 
sarcomas aud therefore put forward as the drug of choice in the treatment of these 
malignancies (Bielack ef ai, 1996; Budd, 1995). Here we demonstrate that 
perfusion with doxorubicin alone is not or only par1ial effective, which however 
is also observed when melphalan is used as a single agent in the perfusion setting. 
A striking observation is the augmentation of the doxorubicin-induced 
anti-tumor response by TNF -a in vivo, which has also been shown for melphalau 
and TNF-a in these tumor models (Manusama ef ai, 1996a; Manusama ef ai, 
1996b). Strong tumor responses were observed in both models after ILP with the 
combination therapy, which cannot be explained by just adding up the responses 
after ILP with the single agents. An important observation is that cbemotherapy by 
itself is not or partially effective as shown here aud by others (Klaase ef ai, 1989). 
Secondly, it was previously shown in our rat tumor model as well as in the clinic 
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that lLP with TNF-a alone had no effect on tumor growth although massive 
haemorrhagic necrosis and pathology was observed (Manusama et ai, 1996a; 
Nooijen et ai, 1996: Posner et ai, 1994). These observations indicate that other 
mechanisms have to be identified to explain the interaction between TNF-a and 
chemotherapy. 
Several specific activities of TNF-a could potentiate the anti tumor 
activity of chemotherapy. It has been postulated that the increased tumor response 
observed after lLP with melphalan and TNF-a is due to destruction of the TAV, 
resulting in haemorrhagic necrosis, platelet aggregation and erythrostasis (Nooijen 
et ai, 1996: Watanabe et ai, 1988). Moreover, recently is has been shown that 
perfusion with melphalan in combination with TNF-a and IFN-y resulted in 
apoptosis of endothelial cells of the TAV (Ruegg et ai, 1998). Also inflammatory 
events such as granulocyte infiltration were suggested to playa role (Manusama 
et ai, 1998; Nooijen et ai, 1996). These findings led to the speculation that 
destruction of the TAV is the mechanism by which TNF-a potentiates cytotoxic 
agents. Watanabe et al demonstrated toxic effects of TNF-a on newly formed 
tumor vasculature in mice resulting in haemorrhage, congestion and blood 
circulation blockage (Watanabe et ai, 1988). Others suggested that TNF-a-induced 
thrombus formation played an important role (Shimomura et ai, 1988). However, 
these effects are also observed after perfilsion with TNF-a alone (Nooijen et ai, 
1996). 
Recent studies show that perfusion of melanoma-bearing patients with 
melphalan in combination with TNF-a and IFN-y results in detachment and 
apoptosis of endothelial cells of the tumor (Ruegg et aI, 1998). Moreover, the vitro 
experiments demonstrated an important role for TNF-a and IFN-y mediated down 
modulation of the aV~3 function, which is speculated to play an prominent role 
ill the in vivo observations. TI,ese finding would argue in favour for a TNF-a 
mediated destruction of the vasculature. The in vitro observations also 
demonstrated the necessity ofIFN-y for the induction of endothelial apoptosis. In 
our model, as well as in various clinical trails, on the other hand it has been shown 
that tumor responses are only slightly improved by the addition of IFN-y 
(Eggermont et ai, 1996b; Lienard et ai, 1992b). This would argue against an 
impOltal1t role for TNF-a-mediated destruction ofthe TAV in the tumor response, 
or 011 the other hand it indicates that endogenous produced IFN-y is of major 
importance. 
A consistent finding in our two models is the augmented accumulation of 
doxorubicin in tumor tissue when TNF-a is added to the perfusate. In both models 
this increase could very well explain the improved efficacy. On the other hand, 
TNF-a may increase the uptake of doxorubicin by the tumor cells. However, 
intracellular concentration of doxorubicin in vitro was not enhanced when TNF-a 
was added in vitro. Moreover, TNF-a did not seem to affect the in vitro cytotoxic 
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activity of doxorubicin significantly. In contradiction to these findings, synergy 
between TNF-a and doxorubicin in vitro has been shown in previous studies 
depending on sensitivity ofthe cells to TNF-a, presence of multi-drug resistance 
or order of exposure (Alexander et ai, 1987; Bonavida et al. 1990; Fruehauf ef ai, 
1991; Soranzo et ai, 1990). This effect has also been shown without an increased 
intracellular accumulation of doxorubicin (Safrit et ai, 1993). Others demonstrated 
that exposure of tumor cells to TNF-a resulted in a reduced sensitivity of these 
cells to doxorubicin (Prewitt et ai, 1994). It is suggested that arrest of the cells in 
the 0110 phase by TNF-a turns them insensitive to doxorubicin, which is a cell 
cycle dependent cytotoxic agent. In our study we did not observe such phenomenon 
when the tumor cells were exposed to doxorubicin and TNF-a. These observations 
suggest that in vivo TNF-a has an indirect effect on the anti-tumor activity of 
doxorubicin. Therefore, we postulate that TNF-a augments the accumulation of 
doxorubicin in the tumor by increasing the leakiness of the tumor associated 
vasculature (TA V), and by doing so increases the local drug level. Previously an 
increased leakiness of the TA V as well as a reduction of the interstitial fluid 
pressure in tumor has been shown by others after systemic administration ofTNF-a 
(Folli ef al. 1993, Kristensen et ai, 1996; Renard et ai, 1995; Smyth et ai, 1988). 
Moreover, increased drug accumulation in tumor has previously been shown after 
systemic treatment with TNF-a when a liposomal doxorubicin preparation was 
injected (Suzuki et ai, 1990). Preliminary results from a clinical phase I-II trail with 
doxorubicin and TNF-a in hyperthermic ILP demonstrated comparable favourable 
outcome as is obtained with Melphalan and TNF-a (Di Filippo ef ai, 1998). 
From our study we propose that the observed augmentation of the anti-
tumor activity of doxorubicin by TNF-a is mainly due to an increased 
accumulation of doxorubicin in the tumor during ILP as is shown in both models. 
A direct effect ofTNF-a on the sensitivity of the tumor cells to doxorubicin was 
ruled out by in vitro examinations. 
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ABSTRACT 
Addition of Tumor Necrosis Factor-a (TNF-a) to chemotherapy 
enhances tumor response in several treatment modalities. However, it has been 
shown that TNF -a, and several other cytokines, exert inhibitory effects on cell 
cycle progression and by doing so may attenuate sensitivity of these cells to 
cell cycle dependent cytotoxic drugs (e.g. doxorubicin). Here we determined 
the cytotoxic effect of TNF -a on several tumor cell lines in vitro in 
combination with doxorubicin (cell cycle dependent) or melphalan (cell cycle 
independent), and its effect on cell cycle progression. The rat cell lines were 
prepared from tumors which were used previously in animals studies, in which 
synergy was shown between TNF -a and the cytotoxic drugs. 
Here we demonstrate that addition of TNF -a to doxorubicin or 
melphalan in vitro had no attenuating effect on the cytotoxic drugs. Depending 
on the cell type used, addition of TNF -a induced no or only an additive 
cytotoxic effect. Moreover, also pre-incubation of the cells, prior to 
doxorubicin or melphalan, induced no or only an additive cytotoxic effect. Also 
in the TNF -a sensitive WEHI-164 cell line, which was used as a positive 
control, addition resulted in enhanced cytotoxic effect which was of an additive 
kind. Examination of the effect of TNF -a on cell cycle progression revealed 
that exposure of BN-175 or CC531 rat tumor cells or WEHI-164 tumor cells 
was without effect, independent of sensitivity of the cells to TNF -ex Only ROS-
I tumor cells demonstrated a cell arrest in the G2 phase, which did not result 
in attenuation of the cytotoxicity of doxorubicin towards these cells. 
TNF -a has recently been registered in Europe for combination 
therapy of sofi tissue sarcoma with melphalan by isolated perfusion. The 
presented findings warrant further exploration of the usefulness of TNF -a in 
combination with cytotoxic drugs for the treatment of solid tumors. 
INTRODUCTION 
Tumor Necrosis Factor-ex (TNF-ex) has impressive anti-tumor activity 
in clinical and preclinical setting. Especially isolated limb perfusion (ILP) with 
high dose TNF-ex and melphalan (with or without interferon-y (IFN-y)) proved 
to be very successful in patients with large irresectable soft tissue sarcomas 
achieving limb salvage in over 80% of patients (Eggermont et ai., 1996b; 
Eggermont et al., 1996a). The same regimen was also highly effective as 
induction biochemotherapy in ILP for in transit melanoma metastases (Lienard 
et aI., 1992). We have previously shown in various tumor models in vivo that 
synergism between TNF-ex and melphalan is responsible for the anti-tumor 
effect (Manusama et al., 1996a; Manusama et al., 1996b; de Wilt et ai., 1999). 
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From these studies it becomes clear that TNF-a enhances the anti-tumor 
activity of melphalan in lLP. Moreover, we demonstrated recently that TNF-a 
could also enhance the activity of doxorubicin, an anthracycline, in an lLP 
setting (van del' Veen, 2000). Anthracyclines are among the most active agents 
against solid tumors and doxorubicin is the most widely used agent ofthis class 
(Bielack et aI., 1996; Bramwell, 1988; Budd, 1995). Moreover, doxorubicin is 
the agent of choice for the treatment of sarcoma, and has shown good anti-
tumor activity in clinical and experimental perfusions settings (Weksler el al., 
1994; Abolhoda et al., 1997; Wang el al., 1995). Clinically however, ILP with 
doxorubicin was reported to cause considerable regional toxicity and 
conflicting reports with regard to efficacy have been published (Klaase el al., 
1989, Rossi el aI., 1994). Addition ofTNF-a in such a setting could facilitate 
lower dosages of doxorubicin with concomitant diminished side-effects. 
The success of application of TNF-a in an ILP setting has resulted in 
registration of TNF-a for the treatment of soft tissue sarcoma confined to the 
limb in combination with melphalan in an ILP setting. Extension of the modes 
of application of TNF-a was hereby initiated, including organ perfusion and 
systemic application of low dose TNF-a in combination with formulated drugs 
(such as liposomal doxorubicin). TNF-a is speculated to have a destructive 
effect on the tumor associated vasculature at high dosages, but on the other 
hand, TNF-a has growth promoting activities when only low levels are 
present, which could negatively influence tumor therapy (Fajardo, et al. 1992). 
However, at relatively low dosages TNF-a was also found to increase the 
permeability of the vasculature for cytotoxic drugs which benefits local drug 
levels and therefore treatment outcome (Brett el ai., 1989; Folli el ai., 1993). 
Impotiant however are the observations that TNF-a causes resistance 
in vitro to cell cycle specific agents (Prewitt el ai., 1994). It is shown that 
cytokines, like TNF-a, IL-IJ3 and IL-6 cause cell cycle arrest acting at major 
control points in GOIGI (Prewitt el ai., 1994; Sgagias et ai., 1991; Belizario 
and Dinarello, 1991; Vieira et al., 1996). This may lead to a decreased effect 
of certain cell cycle specific chemotherapeutic drugs such as doxorubicin, an 
antibiotic that targets DNA topoisomerase II. Melphalan on the other hand 
exerts its effects throughout the cell cycle. It may therefore well be that pre-
treatment with TNF-a attenuates the growth inhibiting effects of doxorubicin, 
but has no effect on melphalan activity. On the other hand, synergistic activity 
of doxorubicin and TNF-a has been shown in vitro, although the synergistic 
interaction between cytokines and cytotoxic agents seems to be sequence 
dependent (Ehrke et ai., 1998; Kreuser et aI., 1995; Watanabe et al., 1995; 
D'Alessandro and Borsellino, 1996). We demonstrated, next to enhancement of 
the anti-tumor activity of doxorubicin by high dose TNF-a in ILP, that low 
dose TNF-a acts synergistically on solid tumors when combined with a long 
circulating liposomal formulation of doxorubicin (DOXIL) (len Hagen el ai., 
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1999)(ten Hagen et aI., in pre,,). Preliminary clinical studies demonstrated 
beneficial effect of TNF-a when combined with doxorubicin in ILP (Di 
Filippo et ai., 1998). 
The recent registration of TNF-a for high dose anti-tumor therapy in 
ILP, and the demonstrated positive effects of TNF-a in other treatment 
modalities when combined with doxorubicin formnlations, warrant further 
expansion of the application of this cytokine for the treatment of solid tumors. 
In this study we examined whether TNF-a is capable of inducing cell arrest in 
tumor cells and by doing so negatively influence the anti-tumor activity of 
doxorubicin. The tumor cells were extracted from experimental tumors which 
were shown to be sensitive to the combination treatment of TNF-a with 
melphalan or doxorubicin in vivo. 
MATERIAL AND METHODS 
Chemicals 
Recombinant human TNF-a (TNF-a) was kindly provided by 
Boehringer Ingelheim GmbH, Ingelheim/Rhein, Gennany. TNF-a had a 
specific activity of 5.8 x 10' U/mg as determined in the murine L-M cell assay. 
Endotoxin levels were less than 1.25 endotoxin units/mg protein. Melphalan 
(Alkeran, 50 mg per vial) was purchased from Well come (Beckenham, UK). It 
was diluted in 10 mL diluent solvent and further dilutions were made in 0.9 % 
NaCI. Doxorubicin (Adriablastina, 2 mg/mL) was purchased from Farmitalia 
Carlo Erba (Brussels, Belgium). 
Tumor cell lines 
Colon carcinoma CC531: The dimethylhydrazine-induced, moderately 
differentiated, weakly immunogenic rat colon adenocarcinoma CC531 was 
used (Marquet et ai., 1984). CC531 tumor cells were maintained in vitro in 
RPMlmedium supplemented with 10% fetal calf serum. To all cell cultures 1 % 
penicillin (5000 U/mL), 1% streptomycin (5000 U/mL) and 1% L-glutamine 
(200 mM) was added. All media were obtained from Gibco (UK). 
Osteosarcoma ROS-1: The ROS-l rat osteosarcoma was used in the 
second series of experiments. This tumor originated spontaneously in the tibia 
of a rat (Barendsen and Janse, 1978). ROS-I tumor cells were maintained in 
modified Eagle's medium, supplemented with 10% fetal calf serum. 
Soft Tissue Sarcoma BN-175: The spontaneous rat soft tissue sarcoma 
BN-175 was used (Kart et ai., 1984). BN-175 is a rapidly growing and 
metastasizing tumor. BN-175 tumor cells were maintained in RPMI 
supplemented with 5% fetal calf serum. 
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Fibrosarcoma WEHI-164: The highly TNF-a sensitive WEHI-164 
murine tumor cell line was used and served as a positive control. WEHI- I 64 
tumor cells were maintained in RPM! medium supplemented with 10% fetal 
calf serum. 
Before usage the cells were trypsinized (5 min, 37°C), centrifuged (7 
min, 2000 rpm), resuspended in complete medium and counted. Viability was 
measured with trypan blue (0.3% in a 0.9% NaCI solution), and always 
exceeded 95%. All tumor cells were incubated overnight, maintained in a 
humidified atmosphere of 5% CO2 at 37°C. 
In vitro assessment of anti-tumor activity of doxorubicin or melphalan on 
tumor cell lines when co-incubated with TNF-a. 
Tumor cells were plated at I xl 04 cells per well in a flat bottomed 96-
wellmicrotiter plates (Costar, Cambridge, MA, USA) in a final volume of 0.1 
mL of medium per well. Cells were incubated at 37°C in 5% CO2 for 72 h in 
the presence of various concentrations of TNF-a, doxorubicin and melphalan. 
Concentrations ofTNF-a used were between 0 and 0.05 ]lg/mL for the WEHI-
164 cells and between 0 and 10 ]lg/mL for all other tumor cell lines. 
Concentrations of melphalan used were between 10'1_10' ]lg/mL and 
concentrations of doxorubicin used were between 10'2_102 ]lg/mL. 
Growth of tumor cells was measured using the Sulphorhodamine-B 
(SRB) assay according to the method of Skehan et al (1990) (Skehan et ai., 
1990). In short, cells were washed with phosphate buffered saline, incubated 
with 10% trichloric acetic acid (I h, 4°C) and washed again. Cells were then 
stained with SRB (15-30 min), washed with 1% acetic acid and were allowed 
to dry. Protein bound SRB was dissolved in TRIS (10 mM). Extinction was 
measured at 540 nm. Six replicate experiments were performed. Tumor growth 
was calculated using the formula: tumor growth = (test well/control) x 100 
percent. The drug concentration reducing the absorbance to 50 percent of 
control (IC50) was determined from the growth curves. 
In vitro assessment of the effect of pretreatment with TNF-a on the drug 
sensitivity of the tumor ceHlines. 
Cells were cultured in 96-well microtiter plates as described above for 
24 h. Cells were washed and exposed for 24 h to medium containing various 
concentrations of TNF-a, which were also used in the previous experiments. 
Subsequently, medium containing TNF-a was removed, cells were washed and 
exposed to doxorubicin or melphalan in various concentrations as described 
above for 72 h. Growth of tumor cells was measured using the SRB assay. 
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Effect ofTNF-a on cell cycle and apoptosis oftnmor cells. 
The various tumor cells were plated in 24 well plates in a concentration 
of 105 cells/mL. 0.4 mL/well, and incubated overnight in various 
concentrations TNF-a (between 0 and O.OS [lgimL for WEHI-164 and between 
o and 10 flg/mL for all other tumor cell lines), centrifuged (1 min, 1100 rpm), 
and washed with PBS. Thereafter, cells were trypsinized with trypsin-EDTA 
for 2 min, washed, and fixed in 1 mL ethanol (80%, Ih). Cells were centrifuged 
and washed again with PBS and I mL propidiumiodide buffer (0.12% triton-
XI00 and 0.12 mM EDTA), followed by incubation for 4S min with I mL 
Ribonuclease A (100 [lgimL). Nuclei were then stained with propidiumiodide 
solution and analyzed by flow cytometry in a FACScan (Beckton Dickinson 
using Cell Quest software on an Apple Mackintosh Computer). Positive control 
on cell cycle arrest was performed by incubation of the cells in minimal 
medium containing O.S% FCS. 
Statistical analysis 
The in vitro results were analysed using SPSS 8.0 and GraphPad Prism 
3.0 for windows. Data was evaluated for statistical significance using the 
Kruskal-Wallis statistic test and Mann-Whitney U 2-tailed significance test. 
Results were considered statistically significant for p<O.OS. 
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Figure 1. In vitro cytotoxicity of doxorubicin on (a) BN-175 soft tissue sarcoma or (b) 
ROS-1 osteosarcoma rat tumor cells after 72 h of co-incubation with TNF-a. The 
cytotoxicity is expressed as percentage growth compared to cells treated with medium 
alone as described in the materials and methods. Celis were exposed to 0 (0), 0.1 
~g/mL (411), 1.0 ~g/mL ('1") or 10 ~g/mL TNF-a (l1li). Mean values 016 to 8 bioassays are 
shown ± SEM. 
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RESULTS 
Effects of TNF -a combined with cytotoxic drugs on tumor cell in vitro. 
We investigated the effect of TNF -a on tumor cell sensitivity to either 
doxorubicin or melphalan on four tumor cell lines: the slowly growing 
adenocarcinoma CC5 31, the moderately growing osteosarcoma ROS I, and the 
fast growing soft tissue sarcoma BN-175. As a positive control the TNF-a 
sensitive cell line WEHI-I64 was used. To examine the effect of TNF-a on 
doxorubicin or melphalan, the cell lines were exposed to the drugs in vitro. 
In each of these cell lines a distinctive difference between the two 
chemotherapeutic agents was found. For all cell lines the IC50 of doxorubicin 
was significant lower as compared with melphalan (table I). Thus, the various 
cell lines proved to be more sensitive for the cell cycle specific drug 
doxorubicin. Addition of TNF -a to doxorubicin or melphalan had no or 
marginal effect on the growth inhibiting activity of these agents on CC531 and 
BN-175 tumor cells. In figure I the dose response curves for doxorubicin in 
combination with TNF-a on these cells is depicted. With melphalan 
comparable lack of activity ofTNF-a was observed (data not shown); the IC50 
of doxorubicin or melphalan were relatively unchanged in the presence of 
TNF-a (table 1, p>O.50 for both drugs and both cell lines comparing IC50 of 
cnlture with and without TNF-a). The osteosarcoma cell line ROS-I appeared 
Table 1. Drug sensitivity of various tumor cell lines in vitro to doxorubicin or melphalan 
in combination with TNF-a. 
Cell line 
CCS31 
BN 17S 
ROS I 
WEHII64 
ICSO I 
Doxorubicin 
TNF-a2 
no yes 
0.21 0.11 
O.IS 0.09 
139 0.17 
0.24 0.02 
Mel2halan 
TNF-cx 
no yes % dead3 TNF -cx(flg/ml) 
13.33 6.07 3 10 
2.87 2.03 0 10 
4.30 1.14 34 10 
6.19 1.18 20 0.001 
I) ICSO is expressed as concentration of cytotoxic drug in flglrnL. 
2) ICSO is shown, when TNF-cx is added to the cells, only at the TNF-a 
concentrations depicted in the last column. 
3) percentage of dead cells as scored in the bioassay with TNF-a alone. 
note: mean values 0/6 to 8 bioassays are shown, which were calculated from the dose 
response curves individually as described in materials and methods. 
to be modestly sensitive to treatment with TNF-a alone. A dose dependent 
growth reduction was observed when ROS-I was exposed to TNF-a at an 
ineffective concentration of doxorubicin with a maximum reduction of 38% at 
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10 Ilg/mL (fig. 2). Addition of TNF-o: to doxorubicin reduced the IC50 of the 
cells 7.5-fold as compared to doxorubicin alone (p<0.005), whereas the IC50 of 
melphalan was reduced 3.3-fold by TNF-o: (p<0.005). In spite of the 
diminished IC50 found for both drugs after combination with TNF-o: no 
objective cytotoxic synergy was found, as the maximnm and minimum growth 
inhibition of the cells were found at the same drug concentrations for all TNF-
0: levels tested (fig. 2). 
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Figure 2. In vitro cytotoxicity of (a) doxorubicin or (b) melphalan in combination with 
TNF-a on ROS-1 rat osteosarcoma tumor cells after 72 h of co-incubation. The 
cytotoxicity is expressed as percentage growth compared to cells treated with medium 
alone as described in the materials and methods. Cells were exposed to 0 (=), 0.1 
~g/mL (CI), 1.0 ~g/mL (") or 1 0 ~g/mL TNF-a (III). Mean values of 6 to 8 bioassays are 
shown ± SEM. 
As a control group the TNF-o: sensitive cell line WEHI-164 was used. 
As depicted in figure 3 growth reduction between 50 and 70% is reached 
already after the addition of 0.001 IlglmL TNF-o:. Without the addition of 
TNF-o: the IC50 for doxorubicin is reached with 0.24 Ilg/mL and for melphalan 
with 6.19 flg/mL (table 1). Co-incubation of the WEHI-164 tumor cells with 
TNF-o: and doxorubicin or melphalan resulted in strongly reduced IC50 for 
both drugs; respectively 0.02 (p<0.001) and 1.88 Ilg/mL (p<0.005 when culture 
with and without TNF-o: was compared). However, as was also found for 
ROS-l cells, the increased tumor cell killing resulted from additive effects 
between the drugs used rather than from synergy between TNF-o: and the 
cytotoxic agents. 
From the co-incubation studies we conclude that TNF-o: has no or only 
an additive anti-tumor effect in vitro on the tumor cells which depends on cell 
line used. However, in non of the cell lines tested a TNF-o: inflicted reduction 
of the- sensitivity towards the cytotoxic drugs could be found. On the other 
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hand, initiation of cell cycle arrest followed by diminished sensitivity towards 
doxorubicin might require pre-exposure to TNF-ct, 
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Figure 3. In vitro cytotoxicity of (a) doxorubicin or (b) melphalan in combination with 
TNF-a on WEHI-164 murine tumor celis after 72 h of co-incubation. The cytotoxicity is 
expressed as percentage growth compared to cells treated with medium alone as 
described in the materials and methods. Cells were exposed to 0 (0), 0.00001 ~g/mL 
(e), 0.0001 ~g/mL (T), 0.001 ~g/mL TNF-a (III) or 0.01 ~g/mL TNF-a (A). Mean 
values of 6 to 8 bioassays are shown ± SEM. 
Effects of 24 h pretreatment with TNF-a on tnmor cell sensitivity to 
cytotoxic drugs. 
According to the work of Prewitt et al (1994) TNF-a exposure shifts 
cells to the GO/G1 phase of the cell cycle (Prewitt et ai., 1994). As doxorubicin 
is a cell cycle dependent chemotherapeutic drug, an increase in survival might 
be expected when cells are pretreated with TNF-a before exposure to 
doxorubicin, an effect not to be expected with exposure to melphalan. The 
above mentioned tumor cell lines were exposed to TNF-a followed by 
incubation with doxorubicin or melphalan. Twenty-four hour pretreatment with 
TNF-a did not result in an attenuation of the sensitivity to doxorubicin (or 
melphalan) in CC531. ROS-l or WEHI tumor cell lines (table 2). A slight, but 
not significant increase in IC50 was seen when BN-175 were incubated with 
TNF-a prior to doxorubicin. Moreover, as was observed in the co-incubation 
study, pre-treatment of CC531 and BN-175 cells with TNF-a influenced had 
only a marginal effect on the sensitivity of the cells to the drugs, comparable to 
the co-incubation. Likewise, pre-treatment of the ROS-l cells with TNF-a 
resulted in a lower IC50 for both doxorubicin (p<O.05 when compared to 
culture without TNF-a) and melphalan (p<O.OI when compared to culture 
without TNF-a) comparable to the co-incubation study (table 2). Pre-treatment 
of WEHI with TNF-a resulted in strongly reduced IC50 for both drugs 
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(p<0.02 when compared to culture without TNF-a in combination with 
doxorubicin and p<O.OOI when compared to culture without TNF-a in 
combination with melphalan), and no attenuation of sensitivity of the cell line 
to the drugs was observed (table 2). 
Table 2. Drug sensitivity of various tumor cell lines in vitro to doxorubicin or melphalan 
after 24h pre-treatment with TNF-a. 
Cell line 
CC531 
BN 175 
ROSI 
WEHI164 
Doxorubicin 
TNF-a 
no yes 
0.14 0.07 
0.12 0.20 
5.85 0.32 
0.14 0.04 
MelEhalan 
TNF-a 
no yes % dead3 
12.52 9.91 8 
4.82 3.04 0 
5.73 1.71 27 
7.95 1.17 28 
1) IC50 is expressed as concentration of cytotoxic drug in JlglrnL. 
TNF-a(Jlglml) 
10 
10 
10 
0.001 
2) IC50 is shown, when TNF-a is added to the cells, only at the TNF-a 
concentrations depicted in the last column. 
3) percentage of dead cells as scored in the bioassay with TNF-a alone. 
note: IC50 of doxorubicin or melphalan alone is not the same as in the combination 
study (table I) which is due ta the expanded incubation time of the cells in the pre-
treatment experiment. 
Adean values of 6 to 8 bioassays are shown, which were calculated from the dose 
response curves individually as described in materials and methods. 
Effects of TNF-a on cell cycle kinetics and indnction of apoptosis of 
various tumor cell lines. 
As mentioned above, it is believed that TNF-a induces cell cycle arrest 
and by doing so influences the activity of cell cycle specific drugs. As we did 
not observe any counter-active effect of TNF-a pre-treatment or co-incubation 
on the cytotoxicity of doxorubicin towards the tumor cell lines tested we 
examined the effect ofTNF-a on the cell cycle of these cells. 
[n figure 4 typical cell distributions are depicted as measured by 
flowcytometry in which the region for apoptotic cells is shown, as well as the 
regions for cells in GO/I and G2 phase. No significant shift in GOIl :G2 ratio 
was observed after exposure of the BN-175 or CC531 cells to TNF~a 
(GOIl :G2 ratios at 0 JlglmL and maximum TNF-a concentration resp. BN-175: 
1.5±0.2 and 1.6±O.I, CC531: 2.0±O.5 and 1.9±OA). 
54 
Cell cycle and TNF 
, 
100 10' 10 2 10 3 10' 10° 10' 10' 10 3 10' 
Figure 4. Representation of the analysis of apoptotic cells and cell-cycle progression by 
flowcytometry using propidium iodide (PI) as described in materials and methods. 
Fluorescence is presented in this figure on a log scale and represents the amount of 
DNA bound PI. The regions for apoptotic cells (M1), cells in GO/1 phase (M2) and G2 
phase (M3) are indicated. Graphs are good representations of cell analysis as 
performed on TNF~a sensitive cell-lines when treated with (a) medium alone or (b) with 
TNF~a. 
Moreover, incubation of the TNF-a sensitive cell line WEHr 164 had no effect 
on progression of the cells through the cell cycle (GOIl :G2 ratios at 0 llg/mL 
and maximum TNF-a concentration resp. 1.5±0.2 and 1.3±0.2). Exposure of 
ROS-I cells to TNF-a exerted a significant effect on the GOII :G2 ratio of 
these cells. Strikingly, exposure to TNF-a shifted the cell cycle to a higher 
mitotic index after exposure to TNF-a, indicating an accelerated progression 
through the G I phase and a cell cycle arrest in G2 (fig. 5). Control 
experiments, in which the cells were depleted from vital nutrients by lowering 
the percentage of fetal calf serum to 0.5%, demonstrated an increased G 1/0:G2 
ratio in all cell lines as was expected (data not shown). Exposure of the ROS-1 
and WEI-IJ-164 cells to TNF-a resulted in an augmented percentage of 
apoptotic cells (fig. 6), whereas TNF-a failed to induce apoptosis in the BN-
175 or CC531 cells (data not shown). These observations correlate very well 
with the effect ofTNF-a on the growth rate of the cells in vitro. 
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Figure 5. Effect of TNF-a on the mitotic index of ROS-1 cells in vitro. The mitotic index 
was calculated by division of the percentage of cells in GO/1 phase (n1) by the 
percentage of cells in G2 phase (n2). The median value is presented (horizontal bar) 
with the 50% limits (box) and the minimum and maximum values (whiskers). A total of 6 
t011 independent tests were performed per TNF-a concentration. 
"r-------------~=-----------__. 
p<O.02 
.!!! 15 
1i 
~ 12 
~ , 
• • • i 
~ . 
(a) 
p<O.05 
. , , .• 
concentration of TNf-u in cell culture (i-Jg/mL) 
"~------;C~;:=;-I I(b) I p<0005 I 
0.0001 
concentration ofTNF-u in cell culture (l-lg/rnL) 
Figure 6. The effect of TNF-a on induction of apoptosis in (a) ROS-1 rat osteosarcoma 
cells or (b) WEHI-164 murine fibrosarcoma cells in vitro. The median value is presented 
(horizontal bar) with the 50% limits (box) and the minimum and maximum values 
(whiskers). A total of 6 to 11 independent tests were performed per TNF-a 
concentration. 
56 
Cell cycle and TNF 
DISCUSSION 
In this work we tried to answer the question whether the addition of 
TNF-a to doxorubicin results in attenuation of the anti-tumor activity of 
doxorubicin in the light of the claimed inhibitory effect ofTNF-a on cell cycle 
specitlc drugs (Prewitt et aI., 1994). Various chemotherapeutic drugs are used 
in local (e.g. ILP) or systemic therapy, and possible adverse interactions 
between TNF-a and these cytotoxic drugs would have implications for anti-
tumor therapy. 
For various cell lines TNF -a was reported to protect against the 
detrimental effects of cycle specific chemotherapeutic agents through cell cycle 
arrest in the Go/G j phase (Prewitt et al., 1994; Darzynkiewicz et ai., 1984; 
Vieira et al., 1996). We however, demonstrated in the presented study that 
addition of TNF-a had no inhibitory effect on the anti-tumor activity of the 
cell cycle specific drug doxorubicin in several tumor cell lines. Moreover, we 
found that TNF-a had no or only an additive effect on the cytotoxicity of 
doxorubicin or melphalan, whereas a direct effect of TNF-a on the cells was 
absent or only marginal. Only the TNF-a sensitive cell line WEHI-I64 
demonstrated high response to TNF -a, but also in this cell line no effect of 
TNF-a on cell cycle progression was found. 
In the literature conflicting data is presented concerning the combined 
activity of TNF-a and doxorubicin or other cytotoxic drugs in vitro on tumor 
cells. Comparable to our results synergism between TNF-a and topoisomerase 
II targeted drugs was absent on lung cancer cell lines or demonstrated only an 
additive effect (Giaccone et al., 1990; Soranzo et al., 1990). On the other hand 
synergistic enhancement of in vitro cytotoxicity of doxorubicin by TNF-a has 
been described by others (Alexander et ai., 1987; Safrit and Bonavida, 1992). 
However, also a reduced activity of doxorubicin has been reported when cells 
were pre-treated with TNF-a (Prewitt et al., 1994). A proposed mechanism of 
the enhanced cytotoxicity, when TNF-a is combined with doxorubicin, is the 
down-regulation of constitutive levels of mRNA for TNF-a and a concomitant 
reduced production of TNF-a protein (Safrit and Bonavida, 1992). A positive 
correlation was found between production of TNF-a mRNA and protein by 
tumor cells and resistance to TNF-a. Strikingly, others demonstrated that the 
relationship between sensitivity to TNF-a and to doxorubicin was proven to be 
inverse (Sleijfer et al., 1998). The close proximity oftopoisomerase-II gene and 
the gene encoding for c-erbB2 played a role in the enhanced sensitivity to 
TNF-a. Due to loss of c-erbB2 gene copies, doxorubicin resistant cell lines 
with decreased topoisomerase II gene copies can become sensitive to TNF-a. 
TNF-a can modify the topoisomerase activity, however the observed increase 
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was not required for the synergistic interaction between TNF-a and 
topoisomerase directed agents (Baloch et al., 1995). 
In comparison to our results TNF-a has generally a low cytotoxicity by 
itself (Haranaka et aI., 1984), although enhanced effect on vaJying cell lines is 
seen when TNF-a is combined with certain cytotoxic drugs. Several studies 
suggest that synergistic interaction between cytokines and cytotoxic drugs are 
sequence dependent (Kreuser et aI., 1995). In some studies synergism was 
reported to be achieved only when TNF-a was applied after or simultaneously 
with doxorubicin (Borsellino el al., 1994; Ehrke et al., 1998), whereas others 
found in vivo synergism in a chemosensitive melanoma when TNF-a 
application preceded doxorubicin (D'Alessandro and Borsellino, 1996). Here 
we demonstrate that the administration of TNF-a concomitantly with or 24 
hours before doxorubicin exposure did not influence the growth inhibiting 
effect of doxorubicin on various tumor cell lines. 
As stated above also an inhibiting effect of TNF-a on the cytotoxic 
activity of doxorubicin has been described. It is proposed that TNF-a alters the 
cell cycle of tumor cells, and by doing so affects the activity of the cell cycle 
dependent drug doxorubicin. We demonstrated only for one tumor cell line 
(ROS-l) a shift in the cell cycle, which however did not result in an attenuation 
of the cytotoxicity of doxorubicin. The other three cell lines did not experience 
a shift in the cell cycle when exposed to TNF-a. Also in the literature 
conflicting data is presented. TNF-a, among other cytokines, is known to exert 
radioprotective and chemoprotective effect on bone marrow precursor cells, 
which is believed to result from the cell cycle-specific effects of this cytokine 
(Dalmau el aI., 1997). It is already striking that TNF-a is able to exert both 
chemo- as well as radio-protection as it is suggested that cycling increases 
radioprotection, while arrest reduces chemical damage. 
In most studies an arrest of tumor cells in the GOIl phase has been 
shown (Prewitt et al., 1994; Vieira el aI., 1996; Puszlai el al., 1993; Belizario 
and Dinarello, 1991; Cheng et aI., 1994; Jeoung et al., 1995). For a breast 
cancer cell line, T470, it was repOlted that the cytostatic effect of TNF-a 
occurs at the G,/S phase transition of the cell cycle (Pusztai et aI., 1993). L929 
fibroblast cells, which are highly susceptible to TNF-a, cultured in the 
presence of TNF -a (and other cytokines like TGF -~, IL-l~, IL-6) show a 
growth arrest in G 1 phase of the cell cycle, making them less vulnerable 
against subsequent TNF-a cytotoxicity (Belizario and Dinarello, 1991). Vieira 
et al demonstrated a TNF-a-induced dramatic decrease in Cyclin A, Cyclin B 
and p34cdC2 , which are involved in control of cell progression through the cell 
cycle, in cells in which TNF-a exerts cell cycle arrest (Vieira et aI., 1996). 
Secondly, a correlation in accumulation of hypophosphorylated pRb and 
growth arrest of keratinocytes in the GOIl phase after exposure to TNF-a was 
found. The TNF-a inflicted cell cycle arrest was also shown to be dependent 
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on cell type, showing growth arrest (and concomitant cell progression blockage 
in the GOII phase) for neuroblastoma cells, whereas in glioma cells growth 
rates were increased and higher cell numbers where found in the G2 phase 
(Munoz-Fernandez el ai., 1991). Others again demonstrated that addition of 
TNF-a resulted in cytostasis in cultures of L-cells, manifested as cell arrest in 
the G2 phase (Darzynkiewicz et ai., 1984). In comparison to our study, in 
which we found no effect of TNF-a on cell cycle progression in most tumor 
cell lines tested, also exposure ofB-lymphoid cells to TNF-a had no effect on 
cell cycle distribution (Lama el aI., 1987). 
Direct interactions of TNF-a with tumor cells apparently playa minor 
role in the therapeutic outcome under in vivo conditions. The effect on the cell 
cycle of TNF-a seems therefore equivocal. Other mechanisms are likely to be 
responsible for the observed synergism between TNF-a and either doxorubicin 
or melphalan in vivo (Manusama el ai., 1996a; Manusama et aI., 1996b; de 
Will el aI., 1999; Eggermont et ai., 1996b; Eggermont el ai., 1996a). The major 
target organ of TNF-a remains the tumor vascular bed. In TNF-a based anti-
tumor therapy therefore the vascular effects are key and may lead to ischaemic 
necrosis, immediate permeability changes, hyperpermeability of the tumor 
vascular bed and a drop in interstitial pressure, which in itself leads to a better 
penetration of the drug (Renard et aI., 1995; Nooijen et aI., 1996; Kristensen et 
al., 1996; Folli el al., 1993; Yi and Ulich, 1992). We showed an increased 
accumulation of doxorubicin and melphalan in isolated perfusion setting with 
the addition ofTNF-a (van der Veen et ai., 2000, de Wi/t et aI., 2000). Next to 
that, a significant increase in accumulation of liposome-formulated doxorubicin 
(Stealth liposomal doxorubicin, DOXIL) was observed after systemic 
administration of DOXIL in combination with low dosages of TNF-a, 
resulting in improved tumor response in a rat soft tissue sacroma model (ten 
Hagen et aI., 1999)(len Hagen et ai, in press). This phenomenon could be 
confirmed in a mouse melanoma model showing identical improved drug 
accumulation and tumor response when DOXIL was combined with TNF-a 
(Takahashi et ai, submitted). These results indicate that TNF-a at low local 
dosages has no attenuating effect on doxorubicin but improves drug penetration 
and performance. FUlthermore, vasculotoxic effects of TNF-a lead to 
endothelial cell damage and suppression of adhesion receptor expressed by 
angiogenic endothelial cells (Ruegg et aI., 1998; Fajardo et ai., 1992). 
The effect of TNF -a on cytotoxicity of chemotherapeutic drugs 
appears more complicated than just a direct effect of the cytokine on the 
activity of cytotoxic drug. Although TNF-a appeared in our hands not or only 
marginally active towards tumor cells in vitro, and only an additive effect was 
shown when combined with doxorubicin or melphalan, in vivo (animal models 
or patients) strong synergy was observed. Isolated limb perfusion (ILP) or 
isolated perfusion of the liver (IHP) of tumor-bearing rats (BN-175 or ROS-I) 
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demonstrated strongly enhanced tumor response when TNF-a was added to 
doxorubicin or melphalan (Manusama et al., 1996a; Manusama et aI., 1996b; 
de Wilt et al., 1999)(1'an del' Veen et aI., 2000; van IJken et al. in press, J 
1mmunother.). Moreover, addition of high dose TNF-a to ILP with melphalan 
in patients with sarcoma or melanoma improved tumor response and limb 
salvage significantly (Eggermont et al., 1996b; Eggermont et al., 1996a; 
Lienard et al., 1992). As stated above also low dose systemic TNF-a increases 
tumor response when combined with stealth liposomal doxorubicin with no 
adverse effect on cytotoxicity of the drug. These results indicate that it is at 
least difficult, if not impossible, to predict outcome of combination anti-tumor 
therapy in vivo on in vitro data. In agreement with this are the observations by 
Ehrke et aI., who demonstrated that survival of mice from lymphoma was 
independent of the sensitivity of these tumor cells to TNF-a (Ehrke et aI., 
1998). 
To conclude, the major target of TNF-a is believed to be the 
neovascular bed, whereas cytotoxic drugs act primarily on the tumor cells itself 
explaining the synergy observed in vivo by this dual targeting. Direct 
interaction between TNF-a and cytotoxic drugs however does not seem to play 
a significant role as shown by us. A disadvantageous effect of TNF-a on the 
sensitivity of tumor cells to doxorubicin or melphalan could not be found. The 
results clearly demonstrate that TNF-a can be used in high dose isolated 
perfusion protocols in combination with doxorubicin and also warrant the 
exploration of the use of low dose TNF-a in systemic treatment with 
doxorubicin formulations. 
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ABSTRACT 
In this study blood residence half life and organ distribution of 
recombinant human TNF-a encapsulated in sterically stabilized liposomes was 
investigated in rats bearing a soft tissue sarcoma in the hind leg. We studied the 
decay in blood concentration of 'empty' liposomes using the aqueous marker 
'-Gallium-des/eral, as well as the blood concentration of soluble TNF-a and 
liposome encapsulated TNF-a using 125 J Encapsulation efficacy of TNF-a was 
24%. The pharmacokinetics of TNF-a were dramatically altered after 
encapsulation in liposomes, with a 33:fold increase in mean residence time of 
TNF-a in the blood, and a concomitant I4-fold increase in the area under the 
plasma concentration versus time curve for liposomal TNF-a Although the 
liposomes exhibit Stealth@ characteristics, uptake by mononuclear phagocyte 
rich organs (e.g. liver and ,Ipleen) was noticeable, especially at later time points. 
Encapsulation ofTNF-a in sterically stabilized liposomes resulted in a dramatic 
increase in localization of the cytokh1e in tumor measured as total uptake over 
time. However, peak TNF-a concentration levels in tumor were not significantly 
enhanced as compared-withjree TNF-a 
Besides the augmented localization of Tumor Necrosis Factor-a after 
encapsulation in sterically stabilized liposomes a diminished toxicity was 
observed. 
INTRODUCTION 
Tumor Necrosis Factor-a has impressive antitumor actIvIty in clinical 
and preclinical settings. Isolated limb perfusion (ILP) with high dose TNF-a, 
melphalan and mild hyperthermia proved to be velY successful in patients with in 
transit melanoma metastases or large nonresectable soft tissue sarcomas 
(Eggermont et aI., 1996a, 1996b). This was confirmed in our laboratory in a rat 
soft tissue sarcoma model (Manusama el aI., 1996). The high response rates 
reached with isolated limb perfusion prompted us and others to use TNF-a also 
in regional perfusion settings in treatment of solid tumors of organs such as liver, 
lung and kidney (reviewed by Eggermonl et aI., 1996b). Isolated perfusion of 
organs appeared feasible, but proved to be technically demanding. As metastatic 
disease is usually widespread, treatment requires systemic application. However, 
systemic treatment with TNF-a is complicated by its dose limiting toxicity at 
already relatively low concentrations (Tracey el al., 1986), as well as rapid 
plasma clearance and distribution to nonrelevant tissues (Kedar et aI., 1997). 
Thus, to obtain vasculo-toxic effects that require high concentrations of TNF-a 
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at the tumor site (Fajardo et 01., 1992), that are easily achieved in isolated 
perfusion systems, a TNF-cx targeting device is neceSSaIY to create potential 
efficacy after systemic administration. 
In our quest to expand the application of TNF-cx, we investigated the 
pharmacokinetic behavior and tumor localization of TNF-cx encapsulated in so 
called sterically stabilized, long circulating (Stealth®) liposomes as TNF-cx 
targeting device. 
Liposomes can be given systemically or regionally. A drawback of so 
called classical liposomes however, is the rapid uptake by cells of the 
mononuclear phagocytic system (MPS). MPS recognition can be diminished by 
incorporation of the hydrophilic polymer polyethylene glycol (PEG) in 
liposomes (Woodle et ai., 1994). It was shown that sterical stabilization of 
liposomes could increase blood residence time drastically (Woodle and Lasie, 
19920), resulting in enhanced tumor localization. These liposomes have been 
named Stealth® liposomes. Recent studies showed therapeutic advantages of 
encapsulation of drugs in sterically stabilized liposomes, and clinical trials with 
these liposomes have shown similar pharmacokinetic advantages as in pre-
clinical studies (Gabizol1 el ai., 1994). 
It was previously shown that encapsulation of TNF-cx in conventional 
liposomes reduced toxicity, allowed targeting to selected organs after intravenous 
administration, and immunomodulatOlY activity of TNF-cx was retained (Debs et 
a/., 1989; 1990). Encapsulation of TNF-cx in long circulating liposomes may 
augment the therapeutic index of the cytokine not only by lowering toxicity, but 
also by increasing concentration in tumor and lengthening of bioavailability. 
Equally important, liposomal encapsulation might diminish clearance of TNF-cx, 
which normally has a half-life in serum of minutes. 
In the present study a solid rat tumor model has been used to investigate 
toxicity, biodistribution and tumor localization of TNF-cx containing sterically 
stabilized liposomes after intravenous administration. We explored whether there 
is an alteration in blood circulation time, uptake of TNF-cx in tissues, and 
systemic toxicity after encapsulation in sterically stabilized liposomes. 
MA TERlALS AND METHODS 
Animals and tumor model 
Male inbred Brown Norway rats, weighing 250-300 g, obtained fi'om 
Harlan-CPB (Austerlitz, the Netherlands), were used. The spontaneous BN 175 
sarcoma (transplantable to Brown Norway rats) was used (Marquet et ai., 1983). 
The BN 175 is a rapidly growing and metastasizing soft tissue sarcoma, which is 
non-immunogenic as determined by the challenge method of Prehn and Main 
(Prehn & Main, 1957), and can be maintained in tissue culture. This well 
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vascularized solid tumor is maintained by serial passage in vivo. As previously 
described, viable fragments of the BN 175 sarcoma with a diameter of 2-3 mm 
were implanted subcutaneously in the right hind limb of the rat (Nfanusama et 
01.. 1996). Tumors were allowed to grow for approximately 10 days, when tumor 
diameter reached 10-15 mm, with a tumor weight between 500-1000 mg. 
Tumor Necrosis Factor-a 
Recombinant human Tumor Necrosis Factor-a (rHuTNF-a) was 
provided by Boehringer (Ingelheim, Germany) with a specific activity of 5.8 x 
10 7 units per mg as determined in the murine L-M cell assay. Endotoxin levels 
were less than 1.25 endotoxin un its (EU) per mg protein. 
Preparation of sterically stabilized long circnlating liposomes (SL) 
Materials 
The various chemicals were obtained as follows: Pmtially Hydrogenated 
Egg Phosphatidyl Choline (PHEPC) was kindly provided by Lipoid GMbH and 
Cholesterol (Cho!) was obtained from Sigma (St. Louis, USA). Oistem'oyl 
phosphatidylethanolamine (OSPE) is derivatized at its amino position with a 
MW 1900 segment of poly-( ethyleneglycol) (PEG). PEG-OSPE was kindly 
provided by Dr. P. Working (SEQUUS Pharmaceuticals Inc., Menlo Park, 
California, USA). Gallium" citrate was from Nordian (Montreal, Canada), 
10dide'25 from Amersham (Buckinghamshire, England), and deferoxamine 
mesylate (OF) was from ClBA-GEIGY (Basel, Switzerland). 
A mixture of PI-IEPC (242.5 mg), Cholesterol (64.5 mg) and PEG-OSPE 
(67.5 mg) in a molar ratio of 1.85 : 1 : 0.15, suspended in chloroform/methanol, 
was evaporated to dryness in a rotary evaporator. The dried lipid film was 
resuspended with HEPES buffer (10 mM HEPES, ISO mM NaCI, pH 7.4) as 
described previously (Gabizon and Papahadjopoulos, 1988a). The hydrated 
lipidfilm was vortexed and liposomes were brought to specific size by sonication 
during 10 to 15 minutes at amplitude 9 using an ultrasonic disintegrator supplied 
with an exponential microprobe (diameter 3.5111111) eSoniprep 150, Sanyo, UK). 
Thc liposomcs were sterilized through a 0.2 ~m filter. Liposome size was 
determined by dynamic light scattering (OLS, Malvern 4700 system, Malvern, 
UK). The liposomes were stored at 4°C until fUlther use after determination of 
total lipid concentration. 
Labeling of the liposomes with "Gallium 
For in vivo biodistribution studies, liposomes were labeled with 67Ga, 
using the high affinity 67Ga-OF complex (deferoxamine mesylate OF) as aqueous 
liposomal marker, as described by Gabizon et al (Gabizon et ai., 1 988b). "Ga-
labeled deferoxamine complex was entrapped in the aqueous interior of 
liposomes. This label proved to be an excellent tracer of intact liposomes because 
68 
Biodistribution of Stealth liposomal TNF-a 
of minimal translocation of label to plasma proteins and rapid renal clearance 
when label is released from liposomes. Unencapsulated 67Ga-DF, 67Ga-oxine and 
excess oxine sulfate were removed by gel filtratiou ou a Sephadex G-50 column 
eluted with HEPES buffer. 
Encapsulation ofTNF-a in sterically stabilized Iiposomcs 
TNF-a was incorporated into liposomes by addition of 2.5 ml TNF-a 
dissolved in HEPES buffer (400 /lg/ml) to the freeze-dried lipidfilm (1000 [tmol) 
for approximately 1 hour at 37°C and vortexed. Liposomes were prepared as 
described above. After sonication, the liposomes were washed twice with 
HEPES-buffer by ultra-centrifugation for 2 hr at 60.000 rpm after which 
supernatant was discarded, to remove the remaining free TNF-a. The amount of 
TNF-a associated with the liposomes was determined by using I"I-Iabeled TNF-
a. Before usage, the TNF-a liposomes were filtered through a 0.2 [un filter. Loss 
of activity of TNF-a was assessed using the TNF-a sensitive WEHI-I64 tumor 
cell line. Briefly, WEHI-164 cells were exposed to TNF-a in the presence of 
actinomycin D for 3 days after which cell death was determined usiug the MTT 
test. Samples were taken before aud after every step in the procedure. Using this 
procedure TNF-a is encapsulated in the aqueous phase, but also association with 
the liposolllallllelllbrane occurs, as at a very low TNF-a concentration (1 [tg/ml) 
60% of the TNF-a is encapsulated. 
Labeling ofTNF-a with 1251 
Fate offree or Iiposomal TNF-a in vivo was followed by labeling TNF-a 
with 1251. 1251 was coupled to TNF-a using the IODO-BEAD@ method (Pierce, 
Rockford, IL, USA). Briefly, TNF-a (400 [tg/ml), iodo-beads and 1251 (15 MBq) 
were diluted in iodination buffer. The reaction was allowed to proceed for 15 
minutes at room temperature. Hereafter the beads were discarded and free label 
removed by gel filtration. A trace amount of 125r_TNF_a was added to the TNF-a 
before injection or before encapsulation in liposomes. 
Pharmacokinetics of stcrically stabilized Iiposomes 
Rats (6 at each time point) were injected via the penile vein with 
liposome-encapsulated 67Ga. In a separate experiment, 125I-TNF-a (15 fig/kg) 
containing sterically stabilized liposomes (60 /lmol lipid/kg) were given. Rats 
were sacrificed at 0.08, 4, 12, 24, 48 and 72 hours after injection and tissues were 
excised, weighed, and counted in a Beckmann 8000 gamma counter. Tissues 
sampled included tumor, liver, spleen, kidneys, lungs, muscle, bone-marrow and 
synovia. Subcutaneous tumors could easily be separated from non-tumor tissue. 
Blood (0.5 ml) was taken from the heatt under anesthesia, before sacrifice. 
When free TNF-a labeled with 125r was injected (15 /lg/kg), rats were 
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sacrificed at 0, I, 4, and 8 hours after injection and same tissues as above were 
excised and counted for specific radioactivity as described above. 
To evaluate whether incorporation of TNF-a in Stealth® liposomes had 
any effect on the phannacokinetic behavior of the liposomes, double labeled 
liposomes were prepared. Liposomes were labeled with 67Ga liposomes and at 
the same time loaded with 125, labeled TNF-a. The short decay of "Ga (half-life 
72 hr) enabled detection of 67Ga and 1251 separately. "Gallium was detected 
directly after collection of the samples, whereas 1251 was detected 30 days later. 
Different energy windows were used; 15 LL - 60 UL for 1251 and 80 LL - 600 UL 
for 67Ga. 
Toxicity of free and IiposomaI TNF-a 
Free (60 !lglkg) and liposomal TNF-a (60 !lg/kg) was injected 
intravenously into Brown Norway rats bearing the BN 175 soft tissue sarcoma in 
the right hind leg (lF6). Rats were inspected for morbidity and weighed daily. 
Statistics 
The pharmacokinetics of the liposomes and free TNF-a were analyzed 
using a two phase exponential decay curve fitting by Prism (GraphPad Software, 
San Diego, USA; Table 1) 
RESULTS 
Preparation of TNF-a encapsnlated in sterically stabilized long circulating 
liposomes 
Liposomes (average diameter of 97 ± 5 nm, polydispersity <0.2; 
measured by dynamic light scattering) did not degrade or aggregate in HEPES 
buffer for a period of 8 weeks. 
Encapsulation of TNF-a at 400 !lg/ml, resulted in a 24 % encapsulation 
of the cytokine, determined by using '25I_labeled TNF-a. Free TNF-a was 
effectively removed from the encapsulated TNF-a by ultra-centrifugation. A 24 
% incorporation means that 15 ~lg of TNF-a is associated with 60 !lmol lipid. 
During the process of liposome production the activity of TNF-a was assessed 
using the TNF-a sensitive WEHI-164 cells. Significant loss of activity was not 
measured. It appeared that heating ofTNF-a to 37°e resulted in 132± 13 % of the 
initial activity, whereas sonication at 37°e for 20 minutes resulted in 104±27% 
ofthe initial activity. 
The total procedure (heating to 37°e, sonication, etc.) seemed to slightly 
increase the activity of TNF-a to 109±26% of the initial activity. These results 
are in close agreement with previous publications on TNF-a activity after 
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manipulation (Kedar el ai., 1997). 
Release of TNF-a from liposomes was examined in vitro. Incubation of 
TNF-a associated to Stealth liposomes in 90% serum at 37°C resulted in a 
release of 15.5 ± 1.5% in the first 12 h. Thereafter no detectable release ofTNF-
a from the liposomes into the serum could be measured. 
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FIGURE 1. Plasma clearance of placebo sterically stabilized liposomes (A) and liposome-
encapsulated Tumor Necrosis Factor-a (TNF-a) or free TNF'a (B). Rats were injected 
intravenously with 60 pmol/kg 67 Ga-Iabeled placebo liposomes (III), 1251_labeled TNF-a 
encapsulated in long circulating liposomes (+) and 1251-labeled free TNF-a (e). Activity in 
blood samples (6 rats at each time point) was determined by gamma radiation. Mean 
values ± SD are presented. TNF-a to lipid ratio at the given time points (C). Ratio in 
original preparation was 2.5. 
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Pharmacokinetics of Iiposome-encapsulated TNF-a 
Encapsulation ofTNF-a in sterically stabilized liposomes might increase 
blood residence time and by doing so promote uptake of liposomes in tumor. 
Therefore we examined the biodistribution of TNF-a encapsulated in these 
liposomes from time of injection up to 72 hours. 
TABLE 1. Pharmacokinetics of empty sterically stabilized lipasomes, and free or 
liposome-encapsulated Tumor Necrosis Factor-a (TNF-a) in rat plasma after intravenous 
administration. 
Treatment group 
Parameters Liposomes TNF-cx 
60 [lmol/kg liposomal free 
ty,ex l (h) 6.01 2.64 0.05 
t,",~ (h) 65.63 31.4 0.80 
MRT (h) 33.56 13.38 0.4 
AUC (U x h/ml) 102.5 17.7 1.27 
C1,,, (ml/h) 0.59 0.85 11.81 
V DSS(ml) 19.9 21.2 21.7 
I -L/,fX, distribution half-life; t y,0, elimination half-life; MRT, mean residence time (the time 
required for 63.2% of the administered dose to be eliminated); AUC, total area under the 
plasma concenh"ation versus time curve; elIot> clearance of Iiposomes from plasma; V DSS, 
volume of distribution at steady state. 
Note: AUC of liposomes and AUC afTNF-cx (fi'ee or encapsulated) can not be compared 
as the AUC is expressed in ~mol for liposomes and in ~g for TNF-cx. 
The values are the means of six experiments for each preparation. 
First, placebo "Ga-Iabeled liposomes (PHEPC:Chol:PEG-DSPE) were 
injected into the penile vein of rats bearing the BN 175 soft tissue sarcoma 
implanted subcutaneously in the right hind leg. Liposome blood circulation time 
is shown in Figure 1 and Table l. Typical Stealth® characteristics of the 
liposomes are shown by their clearance from the blood with a MRT (mean 
residence time in blood) of 33 h. The exponential decay of the liposomes in the 
blood is represented by the curve. The clearance of liposomes from the blood 
seems to be biphasic, with a rapid decay in the first hours (t,(F6.0 h) and a 
slower phase (t2J3~65.6 h) thereafter. Approximately 88 % of the injected dose 
was present in the blood after 4 h, whereas after 24 h almost 50 % was 
recovered. After 72 h 10-15 % of the injected dose was still circulating. This was 
not altered when the dose was changed from 60 to 240 flmollkg (data not 
shown). Injection of fluorescently labeled liposomes demonstrated comparable 
phannacokinetic behavior, indicating that decline in blood residence time was 
not due to release of 67Ga as the fluorescent label is integrated with high stability 
in the lipid bilayer (data not shown). 
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Incorporation of TNF-a within the long circulating liposomes did not 
influence circulation time of the liposomes themselves, in spite of the possible 
presence of TNF-a at the membrane surface, as was shown with double labeled 
iiposomes. 
Encapsulation of TNF-a results in a MRT of 13.38 h for TNF-a, 
whereas intravenously injected free TNF-a is cleared rapidly, with a MRT in 
blood of approximately 0.4 hr. As already stated, 'empty' liposomes circulated 
with a MRT of 33 h, indicating a rapid release of a fraction of TNF-a from the 
liposomes, which can also be determined from the drug to lipid ratio, as 
expressed in Figure I C. Calculated by comparing the AUCs of the different 
liposomal preparations, at 4 h 85 % of the TNF-a is still associated with the 
liposomes, whereas at 12 h 76 % is retained in the liposomes. Clearance ofTNF-
a from blood (Cit,,) is decreased 14-fold (0.85 mllh and 11.81 mllh for 
encapsulated and soluble TNF-a, respectively), when TNF-a is encapsulated in 
liposomes. The possible bioavailability ofTNF-a is thus increased considerably, 
as can be concluded from the calculated plasma AUC for TNF-a which is 14-
fold enhanced for encapsulated TNF-a when compared to soluble TNF-a: 17.7 
and 1.27 respectively. 
Tissue distribution ofTNF-a encapsulated in sterically stabilized Iiposomes 
Figure 2 shows the distribution of respectively 'empty' sterically 
stabilized liposomes, liposomes with encapsulated TNF-a and intravenously 
injected soluble TNF-a in various tissues. 
The tumor localized a considerable amount of the injected dose of 
liposomes. 24 h after injection 8 % of the injected dose localized in the tumor 
when 60 f.ltllol/kg was administered. Around 5 % of the injected dose was 
recovered after 12 h when the 240 f.lmollkg was used (data not shown). The 
percentage of injected dose recovered at later time points was lower, possibly 
expressing degradation of liposomes and rapid clearance of the marker. 
The pharmacokinetic profile of TNF-a was dramatically changed after 
encapsulation in long circulating liposomes (Table 2). The localization ofTNF-a 
in tumor was increased 13-fold (AUC in tumor 5.5 for free TNF-a and 69.9 after 
encapsulation). At 12 and 24 h after injection still a considerable amount of 
TNF-a could be measured in the tumor. Free TNF-a however was cleared 
rapidly by the kidney (peak at I h after injection), this in contradiction to TNF-a 
encapsulated in long circulating liposomes (Fig. 2E). 
Liposome uptake by the liver and spleen, organs with an active MPS, 
occurred to be prolonged, as they took up an increasing dose of liposomes in the 
time span used in these experiments. Still, a relatively low dose accumulated in 
these organs, almost equal amounts of liposomes localized in spleen and liver, 
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reaching 14% after 72 h. Per gram tissue on the other hand, the spleen was 
shown to be very active whereas the liver took up only small amounts of 
liposomes (data not shown). The uptake in organs as lung, kidney, bone-mmmw 
and skeletal muscle was low, or below detection level. 
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FIGURE 2. Tissue distribution of sterically stabilized liposomes and free or liposome-
encapsulated Tumor Necrosis Factor-a. Rats were injected intravenously with 67 Ga-
labeled placebo liposomes (V), 1251-labeled TNF-a encapsulated in sterically stabilized 
liposomes (A) and '''I-Iabeled free TNF-a (II). Biodistribution of preparations was 
assessed in tumor (A), liver (B), spleen (C). lung (D), kidney (E) and bone marrow (F). 
Activity in tissues (6 rats at each time point) is expressed as % of injected dose per tissue. 
Mean values + SD are presented. 
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TABLE 2. Pharmacokinetics of empty sterically stabilized liposomes,and free or liposome-
encapsulated Tumor Necrosis Factor-a (TNF-a) in rat tissues after intravenous 
administration. 
Treatment group 
Parameters Liposomes TNF-a 
60 ~unollkg liposomal ITee 
AUChepanc (U x h/m!)1 677.8 140A 20.98 
AUC,pleen 623.7 75.73 2.24 
AUCtllll101 267.7 69.85 5A8 
C[bepatic (mUh) 0.15 0.71 4.77 
CIsplccn (ml/h) 0.16 IJ2 44.72 
Clll!!llOrCml/h) 0.22 0.21 2.73 
ClIW ,\ 4.5 (~unol) 0.20 (Ilg) 0.22 (Ilg) 
Tmax (h) 12-24 12 1 
lAue, area under the concentration in tissue (liver) spleen, tumor) versus time curve; Cl, 
clearance in tissue (liver, spleen, tumor); Cma", maximum concentration at certain time 
point in tumor; Tma'l:' time point at which maximum concentration in tumor tissue is 
reached. 
Note: AUe of liposomes and Aue of TNF-a (rree or encapsulated) can not be compared 
as the AUC is expressed in MITIO[ for jiposomes and in ~g for TNF-a. 
The values are the means of six experiments for each preparation. 
Toxicity of free and stcrically stabilized Iiposomc-cncapsulated TNF-a 
Weight loss of rats upon injection of TNF-a is a sensitive parameter for 
systemic toxicity of this cytokine. After intravenous injection of 60 ~g/kg free 
TNF-a all rats showed diarrhea as well as a decrease in weight of 17% as 
compared to control rats (mean of 6 rats). The weight loss is totally abolished 
after encapsulation of TNF-a in sterically stabilized liposomes. No adverse 
etfects on clinical condition, nor mortality was observed. 
DISCUSSION 
Here we demonstrate that encapsulation of TNF-a in sterically 
stabilized, long circulating (Stealth®) Iiposomes results in a dramatic increase in 
blood circulation time and tumor localization of the cytokine. The area under the 
plasma concentration versus time curve for TNF-a increased 14-fold, suggesting 
a favorable pharmacokinetic profile. As toxicity is reduced, liposomal 
encapsulation may well be the means of systemic application of TNF-a and also 
allows multiple dosing. 
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The soluble cytokine TNF-ex is cleared rapidly from the circulation, and 
has serious side effects when administered systemically. Therapeutic tumor 
effects with TNF-ex were only seen when administered by means of intralesional 
injection or isolated perfusion (Eggermont et aI., 1996a). In studies performed in 
our laboratOlY with isolated perfusion of the extremity in an animal model, we 
showed that TNF-ex can be used successfully in the treatment of solid tumors, 
when applied regionally in high concentration combined with other modalities, 
such as ischemia and cytotoxic drugs (Manllsama et al.. 1994; 1996). To reach 
the same results in treating solid organ tumors and metastases, a sustained 
delivery system fe>!' TNF-ex such as liposomes, which could increase exposure 
time or peak concentration level, seems attractive when combined with liposomal 
encapsulated cytotoxic agents. 
In papers describing pharmacokinetics of long circulating liposomes a 
consistent finding is the prolonged residence time in blood (Gabizon and 
Papahadjopoulos., 19880; Woodle et 01., 1992b), which was confirmed in this 
study. Prolonged circulation is generally considered as the most essential 
requirement for therapeutic application. The in vivo behavior of liposome 
encapsulated TNF-ex is substantially different from intravenously injected free 
TNF-ex, which has a MRT of only 0.4 h. Liposomal encapsulated TNF-ex 
demonstrated a MRT of 13.4 h, resulting in a considerable enhanced 
pharmacokinetic profile as can be concluded from the increase of AUe in blood, 
and tumor uptake. This suggests an augmentation of the therapeutic index of 
TNF-ex after encapsulation. The placebo Ii po somes used in the present study 
circulated with a MRT of 33 h, whieh is considerably longer than the liposomal 
TNF-ex. The in vitro experiments demonstrated an initial release of TNF-ex from 
liposomes of 15.5% in the first 12 h. The shOlier plasma half-life of liposomal 
TNF-ex as compared to placebo liposomes could therefore patiially be explained 
by an initial release of liposome-associated TNF-ex, as demonstrated in vitro, 
which is also shown by the drug to lipid ratio curve. The fact that the curves of 
liposomes itself and liposomal TNF-ex are pat'allel in the second phase of the 
decline demonstrates that clearance of TNF-ex is at those time points dictated by 
the pharmacokinetic behavior of the liposomes. Also in vitro no significant 
additional release ofTNF-ex was measured after 12 h of incubation. Although the 
release of TNF-ex appeared to be more pronounced in vivo, we speculate that the 
rapid release observed in the first 12 h is responsible for most of the loss ofTNF-
ex. This fI'action might be associated on the outside of the liposome. 
The increased blood circulation time results in enhancement of 
localization of liposomes and thus of liposomal TNF-ex in tissue. In tumor an 
increased localization of TNF-ex encapsulated in sterically stabilized liposomes 
was observed. After encapsulation uptake of TNF-ex in tumor increased 12.7-fold 
as compared to the free cytokine. Free TNF-ex is rapidly cleared by the kidney, 
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already at 1 h a peak in localization is observed. The spleen as well as the liver 
are exposed to high levels of liposomes for extended periods of time, thus 
increasing the uptake of these liposomes by the MPS. Although hepatic uptake 
of Iiposomes expressed per organ is substantial, uptake per gram tissue is much 
lower. The spleen on the other hand shows a dramatic uptake of sterically 
stabilized liposomes when expressed per gram tissue, especially at later time 
points. Others (Gabizon et 01., 1997) did not find a splenic uptake of this 
magnitude in mice. A possible explanation could be that opsonins in rat plasma, 
like complement and fibronectin playa more active role in uptake of liposomes 
by the spleen in rats as compared to mice. It is also suggested that tumor-bearing 
animals, which were used by us, have an increased splenic clearance (Nfoghimi 
and Patel 1996). 
Increased permeability of tumor associated microvasculature, together 
with the longer circulation times of sterically stabilized liposomes, is considered 
responsible for improved accumulation of these liposomes in tumor tissues 
(Papahadjopoulos et 01., 1991, Wu ef al., 1993). The leakiness of tumor 
associated vessels (Jain el 01., 1994) allow extravasation of small diameter 
liposomes through the endothelial gaps (Huang el ai., 1992, Yuan et ai., 1994). 
The presence of intact Iiposomes in the tumor interstitium surrounding the blood 
vessels would provide a local depot for release of TNF-a for prolonged periods. 
We hypothesize that optimal anti-tumor activity with liposomal TNF-a will be 
reached when TNF-a is released after extravasation in tumor tissue. By using 
liposomes, which start to disintegrate after 12-24 h, the accumulation of TNF-a 
at the tumor site will be large, whereas toxicity is kept at a minimum. Moreover, 
liposomal delivered TNF-a is present in tumor tissue for an extended period. 
Thus, liposomes serve as a sustained delivery system. This may make the 
therapeutic application of systemic TNF-a again possible, not only as a single 
bolus injection, but multiple injections as well. 
The liposomaI preparations of TNF-a described until now (Debs el ai., 
1989; 1990; Nii el ai., 1991, Kedar el ai., 1997) were of the conventional type 
with diameters larger than 200 nm. Although reduction of toxicity of TNF-a 
has been demonstrated, these liposomes are not suitable for systemic disease, 
nor for the treatment of large solid tumors, as they are cleared relatively rapid 
and mainly target to MPS cells. The present study also shows decreased 
toxicity of TNF-a after incorporation in sterically stabilized liposomes. 
Therefore, incorporation of TNF-a in sterically stabilized liposomes seems to 
be promising, especially when combined with cytotoxic agents encapsulated 
within liposomes (len Hagen ef a/., 1997). 
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The results shown in this paper clearly demonstrate the usefulness of 
encapsulation of TNF-a in sterically stabilized liposomes. As TNF-a alone was 
shown to be inactive during isolated limb perfusion of sarcoma (Manusama et 
al.. 1996). but demonstrated a strong synergistic antitumor activity when 
combined with doxorubicin (own observations), studies are conducted to 
determine the effect of Stealth® liposomal TNF-a in combination with Stealth® 
liposomal doxorubicin (DOXIL ®). 
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ABSTRACT 
II has previously been demonstrated in the setting of an isolated limb 
pelfusion that application olhigh dose TNF-a in combination with chemotherapy 
(melphalan, doxorubicin), results in strong synergistic anti-tumor eflects in both 
the clinical and the preclinical setting. In this paper we demonstrate that systemic 
administration of low dose TNF-a augments the anti-tumor activity afa liposomal 
formulation of doxorubicin (DOXIL "). Addition ofTNF-a to a DOXIL" regimen, 
which by itse(( induced some tumor growth delay, resulted in massive necrosis and 
regression of tumors. Furthermore, we could demonstrate a significant increase 
of liposomol drug in Ihe fumor tissue vvhen TNF-a had been co-administered. 
Admh1isfration ofTNF-a augmented DOXfL I~ accumulation only afier repeated 
injections, whereas accumulation of Fee doxorubiein was not affected by TNF-a. 
Drug levels in the tumor interstitium appeared crucial as intracellular levels of 
Fee or liposome-associated doxorubicin were not increased by TNF-a. Therefore, 
we hypothesize that low dose TNF-a augments leakage of1iposomal-drug into the 
tumor interstitium, explaining the observed improved anti-tumor effects. Regarding 
the effects olsystemic administration of low doses ofTNF-a, thesefindings may 
be important fiJI' enhanced tumor targeting of various /iposomal drug 
formulations. 
INTRODUCTION 
It has previously becn shown that anti-tumor effects ofTNF-a require high 
concentrations of this agent to be effective (Asher et ai., 1987; Fajardo et ai., 
1992). Pre-clinical and clinical studies demonstrated impressive anti-tumor activity 
of mclphalan when combined with TNF-a in local regional treatment. Isolated 
perfusion oftbe limb with high dose TNF-a in combination with melphalan bas 
been repOited to result in high response rates in patients with ilTesectable sarcomas 
or melanoma in-transit metastases (Eggermont et ai., 1996a; Eggetmont et ai., 
1996b; Lienard et aI., 1992). Recently TNF-a has been approved and registered 
in Europe to be applied in the isolated limb perfusion setting for advanced soft 
tissue sarcomas. In syngeneic sarcoma rat models we have demonstrated that an 
isolated limb perfusion (ILP) with TNF-a in combination with melphalan or 
doxorubicin resulted in synergistic anti-tumor effects (Manusama et ai., 1996; van 
del' Veen et al. 2000). These observations clearly demonstrated synergy between 
TNF-a and the cytotoxic drugs used. A possible mechanism is that TNF-a 
increases accumulation of the cytotoxic drug in the tumor, which could be 
demonstrated by us in ILP with melphalan or doxorubicin combined with TNF-a 
(de Wilt, et aI., 2000; 1'011 del' Veen el al .. 2000). Unfortunately, the systemic 
application of high dosages of TNF-a is hampcred by severe toxicity, indicating 
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that only low dosages ofTNF-a can be applied (Feinberg et ai., 1988). TNF-a 
however could also possibly increase accumulation of drugs when applied 
systemically in a low dose which could be translated to the human setting. 
Although melphalan is the drug of choice in the majority of the isolated 
limb perfusions, especially for the treatment of melanoma and sarcoma, other 
agents might be useful too. Anthracyclines are among the most active agents 
against solid tumors and doxorubicin is the most widely used agent of this class. 
It is the agent of choice for the treatment of sarcoma. However, free doxorubicin 
is cardiotoxic, and induces bone marrow depletion and stomatitis (Herman et ai., 
1983) These side effects can be diminished by using a liposome-encapsulated 
formulation of doxorubicin, DOXIL" (Coukell and Spencer, 1997: Gahizon et ai., 
1986). In this preparation doxorubicin is encapsulated in high concentrations in so-
called Stealth or long circulating liposomes. Stealth liposomes exhibit 
characteristics which prolong blood residence time and result in increased tumor 
localization (Vaage et ai., 1997; Papahadjopoulos et ai., 1991). Treatment of 
refractory AIDS related Kaposi's sarcoma with DOXIL ® demonstrated favorable 
responses (Coukell and Spencer, 1997). This was accompanied by diminished 
toxicity in preclinical models (Vail et ai., 1997; Gabizon et ai., 1989). Based on 
our observation, concerning the effects ofTNF-a on the tumor vasculature and its 
permeability, we hypothesized that TNF-a could, by augmenting vascular leakage 
in the tumor, increase accumulation of liposomal-doxorubicin and so further 
potentiate the anti-tumor activity ofthis formulation, 
In this study we examined the effect of systemically applied low dose 
TNF-a on the anti-tumor activity of DOXIL ® in solid soft tissue sarcoma-bearing 
rats. 
MA TERIALS AND METHODS 
Chemicals, 
Human recombinant Tumor Necrosis Factor-a (specific activity 5xl07 
lUlmg) was kindly provided by Dr. G. Adolf (Bender Wien GmbH, Wien, Austria) 
and stored at a concentration of 2 mg/mL. Endotoxin levels (LAL) were below 
0.624 EUlmg. DOXIL ® was kindly provided by Dr p, Working (SEQUUS 
Pharmaceuticals, Inc. Menlo Park, CAl, Doxorubicin (Adriablastina@) was 
purchased from Farmitalia Carlo Erba (Brussels, Belgium). 
Animals and tUIIlOI' model. 
Male inbred BN rats, weighing 250 - 300 g (Harlan-CPB, Austerlitz, the 
Netherlands) were used. Small fragments (3 IIlm) of the syngeneic BN 175 soft 
tissue sarcoma were implanted subcutaneously in the right hind leg (Manusal71a et 
al., 1996). Tumor growth was recorded by calliper measurements and tumor 
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volume calculated usiug the formula O.4(A 'xB) (where B represeuts the largest 
diameter and A the diameter perpendicular to B). Rats were sacrificed if tumor 
diameter exceeded 25 mm or 4 weeks after treatment was started. All animal 
studies were done in accordance with protocols approved by the Animal Care 
Committee of the Erasmus University Rotterdam, the Netherlands. 
Treatment protocol. 
About 7-8 days after implantation tnmors reached an average diameter of 
8-12 mm when treatment was stalled. Rats were injected five times intravenously 
with an interval of 4 days between injections. First injection with DOXIL ® was 4.5 
mg/kg followed by four injections with Imglkg. Per injection 15 flg/kg TNF-a was 
administered to the rats in 0.2 mL volumes. When rats received both DOXIL ® and 
TNF-a these agents were injected separately. Coutrol rats were treated with 
equivalent amounts of placebo Iiposomes (i.e. drug free liposomes) or buffer. 
Histology. 
At 5 days (placebo or TNF-a treated rats) or 10 days (DOXIL ® or 
DOXIL ® + TNF -a treated rats) after stml of treatment, tumors were excised with a 
rim of skin and muscle from three rats per group. After removal, tumors were cut 
in two equal pmls, fixed in formalin and embedded in paraffin. The 4 flm sections 
were hematoxylin-eosin stained and assessed by conventional histological criteria. 
Video images of the slides were produced on a Leica microscope supplied with a 
Sony 3CCD DXC 950 video camera connected to a frame grabber. 
In vitro cytotoxicity assay. 
BN 175 soft tissue sarcoma cells were added in 100 fll aliquots to 96-well 
plates at a final concentration of 10" cells per well and allowed to grow as a 
monolayer in DMEM supplemented with 10% FCS. Free doxorubicin, liposomal 
doxarubicin (DOXIL®) or TNF-a were diluted in DMEM supplemented with 10% 
FCS, added to the wells and allowed for three days to incubate. The range of final 
drug in the wells was 0.005 - 100 flglmL far doxarubicin or DOXIL® and 0-10 
flg/mL for TNF-a. Growth of tumor cells was measured using the 
Sulphorhodamine-B (SRB) assay. In ShOll, cells were washed with phosphate 
buffered saline, incubated with 10% trichloric acetic acid (lh, 4°C) and washed 
again. Cells were then stained with SRB (15-30 min), washed with I % acetic acid 
and were allowed to dry. Protein bound SRB was dissolved in TRIS (10 mM). 
Extinction was measured at 540 nm. A total of 3 separate assays were performed 
in triplicate and the percentage of growth inhibition calculated according to the 
formula: percentage of tumor cell growth = (test well/control well)xl 00%. 
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In vitl'O assessment of doxornbicill uptake in tumor cells. 
To determine whether the in vitro observed toxicity correlated with cellular 
uptake of doxorubicin, the intracellular doxorubicin levels were determined by 
llowcytometry as previously described (Luk and Tannock, 1989). Briefly, BNl75 
soft tissue sarcoma cells or ROS-l osteosarcoma cells were added in 500 ~d 
aliquots to 24-well plates at a final concentration of 5xl04 cells per well and 
allowed to grow as a monolayer in DMEM supplemented with 10% FCS. 
Doxorubicin, DOXIL ® and TNF-a were diluted in DMEM supplemented with 
10% FCS and added to the wells, after which cells were incubated for 0, 10, 30, 
60, and 120 min. The final drug concentration in the wells was 0, 0.1,1.0 and 10 
~lg/mL for both doxorubicin or DOXIL ® and TNF-a. Thereafter mono layers were 
trcated with trypsin-EDT A for 2 min and the cell suspensions were washed two 
tillles in complete medium and resuspended in PBS. Cellular uptake was measured 
on a Becton Dickinson FACScan using Cell Quest software on Apple Macintosh 
computer. Excitation was set at 488 nm and emission at 530 nm. Fluorescence was 
corrected for cell size using the forward scatter (FSC) with the formula: corrected 
fluorescence (FLcor) = fluorescence at 530 nm (FL530) / FSC - FL530, / FSC, 
(FL530, and FSCc are fluorescence and forward scatter with no drug added to the 
cells). 
Assessment of doxorubicin uptake ill solid tumor alld tissue distribution. 
The effect ofTNF-a on DOXIL ® accumulation in tumors was examined. 
Since the tumor size of rats in the DOXIL® plus TNF-a group stmted to deviate 
significantly after three injections hom the tumor size of rats in the group treated 
with DOXIL ® alone, we decided to compare uptake not later than this time point. 
Rats received I or 3 injections of doxorubicin or DOXIL ® with or without TNF-a 
with an interval of 4 days betwecn injections as described in the treatment protocol. 
Tumor and muscle were excised 24 h after last injection, at which time maximal 
tumor localisation by Stealth liposomes was found (van der Veen et al.. 1998). 
Tissues were analysed for doxorubicin and its fluorescent metabolites as previously 
described (Mayer et al., 1989). Briefly, after incubation of tissue in acidified 
isopropanol (0.075 N HCI in 90% isopropanol) for 24 h at 4"C, the tumors were 
homogenized (PR0200 homogenizer with 10 mm generator, Pro Scientific, CT, 
USA), centrifilged for 30 min at 2500 rpm and supernatants harvested. Samples 
were measured in a Hitachi F4500 fluorescence spectrometer (excitation 472 nm 
and emission 590 nm) and compared with a standard curve prepared with known 
concentration of doxorubicin diluted in acidified isopropanol. Measurements were 
repeated after addition of an internal doxorubicin standard. The detection limit for 
doxorubicin in tissue was 0.1 Ilg per g tissue. 
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To investigate the effect ofTNF-a on tissue distribution ofDOXIL ® and 
free doxorubicin levels in lung, liver, hart, kidney and spleen, these organs were 
harvested at the time point described above. Doxorubicin extraction and 
measurements were performed according to tumor druglevel determinations. 
Statistical analysis. Results were evaluated for statistical significance with 
the Mann Whitney U test. P-values below 0.05 were considered statistically 
significant. 
RESULTS 
Effect of low dose TNF -a on anti-tumor activity of DOXIL ®. 
Intravenous administration of a total of 5 injections of DOXIL ® in 
combination with TNF-a (15 !lg/kg) with an interval of 4 days between injections 
resulted in significant tumor response of the soft tissue sarcoma (figure 1). 
Responses lasted for more than three weeks. In contrast, treatment of the tumor-
bearing rats with doxorubicin or DOXIL ® alone did not induce a significant tumor 
regression, only a slight delay in growth was observed. Administration ofTNF-a 
in the free form alone, also had no significant anti-tumor effect. 
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FtGURE 1. Anti-tumor activity of Stealth® liposome-encapsulated doxorubicin (DOXIL"') in 
combination with low dose TNF-a on soft tissue sarcoma in rats. Rats were injected five 
times with DOXIL® alone (4.5 mg/kg first dose and 1.0 mg/kg for consecutive doses) (A), 
TNF-a (15Ilg/kg per injection) plus DOXIL® (same dosages) (+), or placebo liposomes (III) 
or five times with TNF-a alone (0), free doxorubicin alone (same dosages as DOXIL ",)(Y), 
or free doxorubicin plus TNF-a (e), after which tumor growth was recorded. Mean tumor 
volume of 6 to 14 rats +/- SEM is expressed. 
Combining low dose TNF-a with f1'ee doxorubicin slightly enhanced tumor growth 
delay, however, no tumor regression was observed. Administration of higher 
dosages ofTNF-a (e.g. 200 rlg/kg) resulted in an anti-tumor response comparable 
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with 15 )lglkg TNF-a, which was however accompanied by severe systemic 
toxicity such as extreme weight loss and high mortality. Treatment with low dose 
TNF-a combined with DOXIL ® had no significant toxic effect on the rats as 
measured by body weight changes (table 1), diarrhea and behavior ofthe animals. 
Table 1 Body wei~ht changes in tumor-bearing rats treated with multiple administration 
of OOXIL or free doxorubicin in combination with low dose TNF-ex. 
TN F -ex (flg/kg) 
Drug Day 0 5 10 15 
DXR 8 94.7 (2.7)' 93.6 (9.5) 95.4 (2.1) 91.1 (2.7) 
16 
DOXIL® 8 94.6 (3.1) 98.2 (2.9) 94.8 (1.8) 105.8 (3.3) 
16 110.8 (1.1) 111.6 (5.1) 109.0 (4.2) 
PL 8 99.1 (2.0) 104.5 (0.3) 107.6 (5.6) 92.3 (7.6) 
16 
I Values are weight changes 8 and l6 days after begin of treatment with free doxorubicin 
(DXR), Stealth liposomal doxorubicin (DOXIL ®) or placebo liposomes (PL) with or 
without TNF-cx, and expressed as percentage of initial body weight. 
2 Rats were sacrificed before this time point because of excessive tumor growth. 
Note. Untreated rats with no tumor implanted normally gain around 5-10% in a period 
to' 6000 
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FIGURE 2. Anti-tumor activity of Stealth® liposome-encapsulated doxorubicin (OOXIL ®) 
in combination with decreasing concentrations ofTNF-a on soft tissue sarcoma in rats. 
Rats were injected five times with OOXIL ® (4.5 mg/kg first dose and 1.0 mg/kg for 
consecutive doses) combined with 15 ~lg/kg (+), 10 ~g/kg (T), 5 ~g/kg (A.) or 0 ~lg/kg 
TNF-ex (III). Mean tumor volume of 6 to 14 rats +1- SEM is expressed. 
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A clear dose response curve was observed when declining dosages ofTNF-a were 
combined with DOX1L® (figure 2). Whereas a dose of 10 j.lg/kg TNF-a to the 
DOXLL ® treatment still resulted in significant enhancement of the tumor response, 
a dose of 5 ~Lg/kg had no effect anymore on DOXIL ® activity. Although not 
significant, a slight increased growth rate was observed when 5 j.lg/kg TNF-a was 
administered ill combination with DOXIL ® when compared to DOXIL ® alone. This 
might be explained by the growth stimulating activity of TNF-a at very low 
concen trations. 
Histologic examination of anti-tumor activity of DOXIL ® combined with 
TNF-a. 
Treatment of the rats with the combination of DOX1L ® and TNF-a 
resulted in severe necrosis of the tumor (figure 3). Massive coagulative necrosis of 
at least 60% of the area and extensive cell death was seen , accompanied by 
inliltrates and irregular hyperaemia. Percentage of (central) necrosis as observed 
in cross section of rats trcated with placebo liposomes, TNF-a, or DOXIL ® alone 
was at most 30%, occasionally accompanied by infiltrates. 
A 
, 
., 
• 
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FIGURE 3. Paraffin sections of rat BN175 soft tissue sarcoma from systemically treated 
rats, haematoxylin-eosin stained. Overview of tumor after five fold treatment with (a) 
placebo liposomes, (b) free TNF-a (15 pg/kg), (c) DOXIL ® (4.5 mg/kg first dose and 1 
mg/kg dose 2 to 5) or (d) TNF-a combined with DOXIL ®. Original magnification 2.5X. 
88 
Systemic low dose TNF-a plus Doxil 
In vitro activity of DOXIL ® combined with TNF-a on BN175 tnmor cells. 
To evaluate whether the observed synergistic anti-tumor activity of 
DOXIL Jj) and TNF-a in vivo was due to a direct effect on the cytotoxicity of 
DOXIL 00, an in vitro bio-assay was conducted. 
Figure 4 shows that exposure of BN 175 tumor cells to doxorubicin resulted in a 
dose dependent cell growth inhibition, with an IC50 of 0.1 J.lg/mL. DOXIL 00 
however appeared in vitro much less active (IC50 2,5 J.lg/mL), Incubation of the 
tumor cells with TNF-a alone had no effect on cell growth, Moreover, addition of 
TNF-a to doxorubicin or DOXIL ® had no effect on the cytotoxicity of the anti-
tumor agents, Comparable IC50 values were found with or without the addition of 
TNF-a, 
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FIGURE 4, In vitro growth of the BN175 tumor cells as function of the added amount of 
DOXIL ® (dotted line) and doxorubicin (continuous line) in combination with 0 ~9 (e), 0,1 
,t9 (V), 1 ,0 ~9 (A) or 10 ~9 TNF-a per mL (Ill). The mean of 5 individual experiments 
performed of 16 days.in triplo is shown ± SEM, 
In vitro uptake of DOXIL ® or doxorubicin in tumor cells. 
We examined if TNF-a augmented the intracellular accumulation of 
DOXIL@, which could explain the improved tumor responses, We observed that 
the addition ofTNF-a, up to 10 J.lg/mL, had no effect on intracellular doxorubicin 
levels of DOXIL aD TNF-a also had no effect on uptake of free doxorubicin in vitro 
(data not shown), 
89 
Chopter 6 
DOXIL ® and doxorubicin accnmulation in solid tumor and tissue 
distribution. 
To investigate whether the observed beneficial effect ofTNF-a in vivo could be 
explained by an increased extravasation of DOXIL ® into the tumor interstitium, 
concentrations of doxorubicin in tumor and surrounding tissue were determined. 
Figure SA shows measurable amounts of doxorubicin in the tumors after single 
intravenous administration of free doxorubicin. Moreover, doxorubicin levels in 
tumors increased 3 to 3.5-fold when doxorubicin encapsulated in stealth liposomes 
was injected (p < 0.02 when compared to free doxorubicin). Addition ofTNF-a 
induced no further accumulation of DOXIL ® at this time point. However, when 
three injections of DOXIL ® were given, addition of TNF-a augmented tissue 
concentrations of stealth liposome-encapsulated doxorubicin 3-fold when 
compared to three administrations of DOXIL ® alone (p ~ 0.02)(figure 5B). A 
significant decline in tumor accumulation of DOXIL ® was observed after the third 
injection as compared to a single injection with the liposomal formulation when no 
TNF-a was added. When three injections of free doxorubicin were given tissue 
levels remained comparable to levels after a single injection. 
5 
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FIGURE 5. Concentrations of doxorubicin in soft tissue sarcoma BN175 after systemic 
administration of doxorubicin (DXR) or stealth liposome-encapsulated doxorubicin 
(DOXIL') with or without TNF-a. Tumors were excised 24 h after end of treatment and total 
doxorubicin content was determined as described in materials and methods. Treatment 
consisted of (A) a single injection of free doxorubicin or DOXIL ® with or without TNF-a or 
(B) three injections of free doxorubicin or DOXIL ® with or without TNF-a as described in 
materials and methods. The mean of 4 to 6 rats are shown ± SEM. 
Accumulation of free doxorubicin or DOXIL® in healthy muscle after 
single or multiple injections remained below 1.0 flg/mL (data not shown). Also in 
heart accumulation of doxorubicin remained below 1.0 flg/mL and was not 
signiticantly affected by addition ofTNF-a (figure 6). In lung, liver and kidney a 
slight increase of doxorubicin was observed after multiple treatments for both free 
and liposomal doxorubicin. The liposomal formulation however, accumulated 
significantly better in spleen than free doxorubicin. In all organs no improved 
uptake of doxorubicin was observed when TNF-a was added to the treatment. 
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FIGURE 6. Concentrations of doxorubicin is organs of BN rats after administration of 
doxorubicin (OXR) or stealth liposome-encapsulated doxorubicin (OOXIL"'l with or without 
TNF-a. Tumors were excised 24 h after end of treatment and total doxorubicin content was 
determined as described in materials and methods. Treatment consisted of a single 
injection (1x) or three injections (3x) of free doxorubicin or OOXIL ® with or without TNF-a 
as described in materials and methods. The mean of 3 rats are shown ± SEM. 
DISCUSSION 
Anti-tumor activity in animals and in man has been obtained with TNF-a 
when used in an isolated perfusion setting combined with melphalan (Eggermont 
e/ al., 1996b; Lienard et 01., 1992). Previously we repOlted on the anti-tumor 
activity of melphalan plus TNF-a in soft tissue sarcoma-bearing rats, which were 
in close agreement with the clinical findings (Manusama et 01., 1996). A consistent 
finding in these in vivo studies is the strong synergy between melphalan and TNF-
a, which was also demonstrated in an ILP model in rats and in humans with 
doxorubicin (Di Filippo et 01., 1998)(van del' Veen et 01., 2000). Here we 
demonstrate that TNF-a also augments the anti-tumor activity of liposomal 
formulated doxorubicin (DOXIL ®) when administered systemically. Secondly, 
repeated injection of DOXIL ® combined with TNF-a results in augmented 
accumulation ofthe doxorubicin which could explain the observed synergistic anti-
tumor effect. 
A major draw back in the application of TNF-a is the severe toxicity 
which accompanies its systemic use. Application of this drug in isolated perfusion 
is likely to reduce toxic side effects. It has been shown that isolated limb perfusion 
results in very low systemic exposure levels due to extreme low leakage during 
perfusion and an effective wash out procedure thereafter (Barker e! 01.. 1995). 
Therefore, in ILP dosages can be used which are up to 50 times the MTD resulting 
in strong anti-tumor effects. Systemic treatment with TNF-a however is only 
possible at very low dosages. Undesirable side effects are also noted when 
doxorubicin is used in the free form. Therefore a liposomal formulation has been 
developed which lowers toxicity. Moreover, with the application of the Stealth 
technology the efficacy of the preparation, ie DOXIL ®, is increased when 
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compared to fi'ee doxorubicin (Gabizol1, 1992; Vaage et 01., 1997). The application 
of Stealth liposomes, relatively smallliposomes which are coated with polyethylene 
glycol, rcsults in prolonged circulation time of the encapsulated drug with 
enhanced accumulation in solid tumors (Papahadjopoulos et 01.,1991; Yuan et 01., 
1994, Gabizon et aI., 1989; Gabizon, 1992) This mechanism is believed to be 
responsible for the improved tumor responses of the liposomal formulation 
DOXIL@ when compared with hee doxorubicin. DOXIL@ is effective in the 
treatment of AIDS-related Kaposi's sarcoma, and in some studies appears to be 
better than standard doxorubicin, bleomycin and vincristine (ABV) combination 
therapy (Coukell and Spencer, 1997). 
Although doxorubicin is the drug of choice for the treatment of sarcoma, 
in ILP mostly melphalan is used, We and others demonstrated that strong anti-
tumor effects can be obtained when doxorubicin is used in this setting when 
combined with high dose TNF-a (Di Filippo et aI., 1998., van der Veen et ai., 
2000). These results indicate that the synergistic activity ofTNF-a is independent 
of the chemotherapeutic drug used, In the present study, it is shown that systemic 
treatment with fi'ee doxorubicin or DOXlL ® resulted in delay of rumor growth, with 
better results when DOXIL ® is used. In vitro on the other hand free doxorubicin 
appeared much more potent than DOXIL@ The improved anti-tumor activity of 
DOXIL ® in vivo is explained by an augmented accumulation of the drug in the 
tumor as shown here by us and previously by others (Gabizon et ai., 1989; 
Gabizol1, 1992; Vaage et ai., 1994; Papahadjopoulos et ai., 1991; Vaage et 01., 
1997). However, addition of TNF-a to a single injection of DOXIL® did not 
further improve accumulation, which is in discrepancy with findings by others 
(Suzuki ef ai., 1990). They observed an increased accumulation of liposome-
encapsulated doxorubicin when combined with TNF-a after one single injection, 
In this study doxorubicin was encapsulated in liposomes which were not very well 
defined and probably have a large size distribution, The large liposomes not only 
contain a relatively large quantity of the drug, but also do not pass the endothelial 
lining in the tumor, as the gaps exhibit a cut off of 400 and 600 nm (Yuan et 01., 
1995). TNF-a increases the leakiness of the vasculature by increasing the gaps 
between the endothelial cells possibly explaining the augmented accumulation after 
extravazation of the large liposomes (Brett et 01., 1989; Smyth et ai" 1988). In 
another study the addition ofTNF-a was shown to increase the anti-tumor activity 
of doxorubicin encapsulated in large liposomes (with sizes varying in the [lm 
range), which was however not accompanied by a significant increase in tumor 
acculllulation ofthe drug (ManlO et 01., 1992). Stealth liposomes on the other hand 
already extravazate relatively easily as they are small (with a very small size 
distribution) and experience little resistance due to the lubricating activity of PEG 
(Yuan et aI., 1994). This most likely explains the high accumulation after a single 
injection. We speculate that any additive effect of TNF-a at this stage is 
superseded by the observed initial high localization ofDOXIL ®, We could however 
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demonstrate an improved accumulation of DOXIL ® in tumor tissue after three 
injections when combined with TNF-a. This is in line with the efficacy results, as 
significant anti-tumor effect is observed after three injections when the DOXIL 00 
and DOXIL® plus TNF-a groups stmi to deviate from each other. Before that, the 
tumor growth curves of the DOXIL ® plus TNF-a treated rats are comparable to 
tumor growth curves from rats treated with DOXIL ® alone. Clearly a continuation 
of doxorubicin accumulation has to take place to induce a significant anti-tumor 
response, which does not take place in the rats treated with DOXIL 00 alone. No 
significant effect ofTNF-a on drug accumulation however could be observed in 
all organs tested independent of drug formulation used, indicating a more or less 
tumor vasculature specific activity ofTNF-a. 
To explain this discrepancy, an important observation is the decline in 
DOXIL ® accumulation after three administrations. For a tumor to grow new vessels 
have to be formed. As the neo-vascularization is characterized by leaky vessels, 
especially in this region extravazation of liposomes is expected (WU et aI., 1993). 
Due to administration of DOXIL 00 a growth inhibition is observed, which is most 
likely accompanied by an diminished demand for new vessels, resulting in a 
diminished accumulation ofDOXIL"'. We speculate that administration ofTNF-a 
apparently compensates for this phenomenon: it increases the leakiness of the 
endothel ial lining, irrespective of maturation state and thus inducing an ongoing 
accumulation ofDOXIL@ 
In conclusion, we demonstrate that administration of DOXIL ® results in 
improved drug accumulation in soft tissue sarcoma when compared to fi-ee 
doxorubicin. However, in all ofthese rats co-administration ofTNF-a results in a 
dramatic enhancement oftumor reponse, which is shown to be due to an ongoing 
improved accumulation of DOXIL 00. In rats receiving DOXIL ® alone a decline in 
tumor accumulation of doxorubicin is observed. These findings therefore also 
indicate that multiple administrations are mandatory to receive a good tumor 
response. 
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ABSTRACT 
Tumor Necrosis Factor-a is a multifunctional cytokine which use has 
been extensively investigated in the treatment of cancer. Initial enthusiasm 
was tempered -when systemic treatment with TNF-a 1vas found to cause severe 
toxic side effects in phase 1111 studies. Other modalities for treatment were 
sought and a revival olthe drug was the application of high dose TNF-a in 
combination with the cytotoxic drug melphalan in isolated limb perfusion 
(ILP). This review covers the preclinical and clinical studies which led to the 
slIccess h1 treatment of patients -with irresectable extremity soft tissue sarcoma 
and multiple melanoma in-transit metastases confined to the limb. TNF-a is 
now approved jar registration in Europe for ILP in combination with 
melphalan/or locally advanced extremity sarcoma. This achievement may lead 
to Ihe development olnew applications of TNF-a in isolated organ pelji/sion 
sellings. An extension of the use of TNF-a may be jound in the application of 
the cy/okinc in sferically stabilized lipo.somes, which are also considered here. 
The review concludes with the possible application of low dose TNF-a, which 
can be given systemically to enhance the anti-tumor potency of solid tumor 
targeting formulations, e.g. doxorubicin encapsulated in sterically stabilized 
liposomes jar treatment of cancer. TNF-a remains a highly interesting 
vasculotoxic anticancer drug with a number of settings for its application to be 
explored. 
iNTRODUCTION 
Since the observation of spontaneous regression of cancer in patients 
with concurrent bacterial infection (Coley, 1896) many years have passed. It 
was not until 1975 that a factor causing hemorrhagic necrosis in experimental 
tumors, later named Tumor Necrosis Factor-a (TNF-a), was discovered 
(Carswell, 75, Ole!, 85). 
The common structure of humau TNF-a protein is a homotrimeric 
complex of 52 kD that is biologically active (Pennica, 84). TNF-a is produced 
by many cell types, but is mainly secreted by activated 
monocytes/macrophages (Matthews, 81, Aggarwal, 85, Sidhu, 93). Its 
expression and regulation is affected by a variety of other cytokines, as 
interferon-y (IFN-y), interleukines (IL-l, lL-2, IL-12), GM-CSF, Platelet 
Aggregating Factor (PAF) as well as TNF-a itself (Sidhu, 93). 
TNF-a has pleiotropic effects, which may depend on its concentration. 
It has been shown to have vasculotoxic effects at high concentrations (Fajardo, 
98 
Discussion 
92), while at low concentrations it may promote DNA synthesis and 
angiogenesis (Beyer, 90, Fajardo, 92). High concentrations of TNF-a have 
anti-tumor activity in murine tumor models (Nawroth, 86). 
The effects of TNF-a are exerted by binding to two types of receptor, 
with molecular weights of 55 kDa (TNF-RI) and 75 kDa (TNF-R2) 
respectively (Brockhaus, 90, Tartaglia, 92), which are present on nearly all 
mammalian cells (Agganval, 85). Apart from these two distinct types of 
receptors, also soluble' forms consisting of the extracellular domain of the 
receptors have been described (Engelmann, 90). The number of receptors on 
the cell does not predict the magnitude of response to TNF (Creasey, 87), but 
upregulation (IFN-y) and downregulation (IL-I) of TNF receptors have been 
reported (Hieber, 94). 
It was not until the purification of Tumor Necrosis Factor-a (TNF-a), 
using recombinant DNA techniques (Pennica, 84), that clinical application 
became feasiblc. 
The introduction of TNF-a in clinical trials commenced with systemic 
administration. These phase 1111 trials proved to be disappointing, mainly 
caused by the deleterious side effects of TNF-a (Chapman, 87, Sherman, 88 
Spriggs, 88). Locoregional administration of TNF-a seemed the only option 
for successful application of TNF-a. Intralesional (Bartsch, 89, Kahn, 89) and 
intraperitoneal (Raeth, 91) administration were repOlted to increase response 
rates somewhat but proved no essential improvement of the effective use of 
TNF-a. This all changed when TNF-based isolated extremity perfilsion in 
melanoma (Lienard, 92) and in soft tissue sarcoma (Eggermont 93, 96a, 96b) 
were reported to yield impressive response rates. 
This led to the exploration of its use in the isolated organ perfusion 
setting. It was attempted in lungs (Weksler, 94, Pass 96), livers (Fraker 94, 
Borel Rinkes 97), and in kidneys (van del' Veen, 99). In general, the isolation 
procedures proved to be technically difficult and organ toxicity limited the 
dose of TNF-a that could be used. Moreover, disseminated disease still 
remained an untreatable entity. Therefore, ways to find a reappraisal of 
systemic treatment with TNF-a were sought. For instance less toxic mutants of 
TNF-a (Soma, 88, Kuroda, 95) bave been developed and tbeir lise has been 
explored (Lodato, 95, Van Oslade, 93, Miyata, 92, Shikama, 95, De Wilt, 
submitted). 
Yet another possibility for systemic application is the incorporation of 
TNF-a in liposomes. Drug-delivery systems, like conventional Iiposomes, 
were used to incorporate TNF-a with some success (Debs, 89,90, Diizgiines, 
89). The main drawback of these multi lamellar vesicles however, is the rapid 
recognition and uptake by the mononuclear phagocyte system (MPS). We 
therefore tried to incorporate TNF-a in new generation (long circulating) 
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liposomes as will be described below (van der Veen, 98). 
In this review we will discuss the role of TNF-a in anti-tumor therapy, 
from preclinical studies to a reappraisal of systemic therapy with low dose 
TNF-a. 
PRECLINICAL STUDIES WITH TNF-a 
In vitro studies 
For a small minority of cancer cell lines TNF-a is directly cytostatic or 
cytotoxic (Haranaka, 81). On other cell types TNF-a shows a growth 
inhibitory or even a growth stimulatory effect (reviewed by Sidhu, 93, Hieber, 
94). The mechanism by which TNF-a exerts its cytotoxic effects are not yet 
fully understood. The number of receptors on the tumor cell are probably of 
less importance than the role of oxygen free radicals in TNF-a cytotoxicity, 
and activation of lysosomal enzymes (Fiers, 95, Sidhu, 93). 
In vitro, synergism between TNF-a and a number of cytotoxic agents 
may be present. In our laboratory we investigated several cell lines on 
susceptibility to TNF-a and certain cytotoxic drugs, like the alkylating agent 
melphalan or the topoisomerase-II inhibitor doxorubicin. In contrast to what 
was expected, in two sarcoma nor in an adenocarcinoma cell line thus far 
investigated, no direct cytotoxic effects of TNF-a, nor synergism with 
melphalan or doxorubicin in vitro could be observed (Manusama, 96a, b, van 
del' Veen, 2000). Additive anti-tumor effects however were noted. 
Furthermore, cytotoxic effects ofTNF-a can be enhanced by a number 
of other biological response modifiers like IFN-y (Salmon, 87, Schiller, 87, 
Dea/try, 87) or IL-I (Ruggiero, 87), hyperthermia (Watanabe, 88a) and 
irradiation (Matsunaga, 92). 
In vivo studies 
Many animal studies have demonstrated the anti-tumor effect of TNF-
a in vivo. In fact Carswell, in her original work on describing tumor necrosis 
factor, studied the Meth A sarcoma in mice (Carswell, 75). This tumor showed 
the classical hemorrhagic necrosis after application of TNF-a, but eventually 
recurred. 
Making use of the rapidly growing, spontaneously metastasizing, non-
immunogenic, grade III fibrosarcoma (BN 175), which originated spontaneously 
in the Brown Norway rat (Kart, 84), we developed an isolated limb perfusion 
model in our laboratory (Manusama, 96a). Moreover, in a wi star-derived WAG 
rat strain a similar tumor model (Manusama, 96b) with an osteosarcoma ROS-I, 
which originated spontaneously in the tibia of a WAG rat, was developed 
(Barendsen, 78). In these non-immunogenic and syngeneic tumor systems both 
tumors grow in fully immunocompetent rats, and the models resemble the 
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clinical situation closely. In both tumor systems highly synergistic anti-tumor 
effects are observed when TNF-a is combined with melphalan, resulting in a 
complete remission rate of 70-80% (Manusama, 96a,b, De Wilt, 99). 
Histopathologically extensive haemorrhagic necrosis is observed after ILP with 
the combination and not after ILP with melphalan alone (Nooijen, 96). Early 
endothelial damage and platelet aggregation in the tumor vessels are observed 
after ILP with TNF-a and melphalan and this is believed to lead to ischemic 
(coagulative) necrosis, which is in line with observations in patients (Renard, 95, 
Nooijen, 96, Fraker, 96, Manusama, 98). We also performed isolated limb 
perfusions with TNF-a and doxorubicin in solid tumor bearing rats with 
comparable outcome (van der Veen, 2000). Both solid tumor models showed 
progressive disease after perfusion with doxorubicin alone. Addition of 50 fig of 
TNF-a however resulted in a 54% response (paJtial aJld complete) in the soft 
tissue sarcoma and a 100% response in the osteosarcoma. An increased 
accumulation of doxorubicin was found in tumor tissue after ILP with a 
combination of doxorubicin and TNF-a in comparison with an ILP with 
doxorubicin alone. Synergistic anti-tumor response in vivo could be explained by 
this enhancement of local drug concentration. In vitro TNF-a fails to augment 
drug uptake in tumor cells or to increase cytotoxicity of the drug. These findings 
make it unlikely that TNF-a directly modulates the activity of doxorubicin in 
VIVO. 
A1echanism of action on tumor associated vascular bed 
Data obtained in experimental animal studies as well as in human 
studies strongly indicate that TNF-a targets the vascular bed of the tumor. The 
tumor vasculature consists of pre-existent vessels in normal tissues in which 
the tumor has invaded as well as microvessels as a result of angiogenesis, 
resulting in neovascularization (Skinner, 90, Brown, 98). These vessels are 
characterized by an inherent high permeability caused by incomplete 
endothelial linings and basement membranes, and the vasculature is not well 
organized. The vessels run a tOltuouS and convoluted path, with venous lakes, 
regurgitant flow and stasis (Dvorak, 88, Dewhirst, 89). Blood flow through the 
neovasculature is therefore irregular and sluggish. In addition, tumor stroma is 
characterized by absence of lymphatics, increased permeability of endothelial 
cells and high interstitial pressure. Drug delivery to solid tumor therefore is 
influenced by the microvasculature and tumor stroma (reviewed by Jain, 96b). 
The majority of TNF-a anti-tumor effects are believed to be indirectly 
mediated through damage of the tumor associated vasculature (TAV). Thus, 
activation of procoagulant activity in vascular endothelium appeared to be 
responsible for hemorrhagic necrosis (Bevilacqua, 86, Watanabe, 88b), also 
thrombus formation and negative influence on tumor blood flow seemed to 
playa pivotal role (Nawroth, 88, Shimomura, 88, Kallinowski, 89, Renard, 95, 
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Nooijen, 96). Vasculotoxic effects lead to anoxic necrosis. It is suggested that 
TNF-a induces endothelial cell damage, leading to congestion, hemorrhage 
and edema as representatives of an impaired blood Ilow (Renard, 95 Nooij'en, 
96, JvJanusal11a, 96, Fraker, 95, Dvorak, 88, Denekal11p, 83). Furthermore, anti-
vascular effects lead to immediate permeability changes (Vargas, 96, 
Krislensen, 96). Endothelial damage, proven by a change in distribution of von 
Willebrand factor, occurred already three hours after onset of TNF-a based 
pcrfusion during ILP (Renard, 95). However, also a delayed type of 
hyperpermeability may be present, explaining the fact that complete tumor 
regression frequently requires longer periods after TNF-a based isolated 
perfusion (Nooijen, 98). Vasculotoxic effects of TNF-a lead to a significant 
drop in tumor interstitial pressure and permeability changes (Kristensen, 96) 
which leads to better penetration of cytotoxic drugs into tumor tissue (Suzuki, 
9()). We showed an augmented accumulation of doxorubicin as well as 
melphalan in tumor tissue when TNF-a was added to the perfusate (Van Der 
Veen, 2000, De Will, 2000). Moreover, vasculotoxic effects lead to endothelial 
cell activation, upregulation of adhesion molecules and infiltrate formation 
through inOux of polymorphonuclears, more specifically granulocytes. 
Subsequently injury to the endothelial cells may be the beginning of a cascade 
of events (Yi, 92, Renard 94, Manusal11a, 98). 
Recently, more insight in the mechanism of disruption of tumor 
associated vasculature was obtained (Ruegg, 98). Suppression of integrin 
aVp3, an adhesion receptor expressed by angiogenic endothelial cells and that 
binds to provisional extracellular matrix components, is the putative 
mechanism by which TNF-a and interferon-y causes disruption of the 
vasculature. Synergistic or additive anti-tumor effect between TNF-a and IFN-
y were observed earlier (Brouckaert, 86, Balkwill, 87, Marquet, 87), probably 
based on receptor upregulation, which is also shown in vitro. However, 
conOicting results have been repOlied (JvJanusal11a, 99), with IFN-y slightly 
enhancing anti-tumor efficacy of TNF-a in combination with melphalan, 
whereas toxicity was considerably increased. Moreover, we recently 
demonstrated that an increase in drug accumulation due to the addition of 
TNF-a could very well explain the improved tumor response by itself (van del' 
Veen, 20()O). 
Synergism with other cytokines like IL-l (Okhura, 90), 11-2 
(Nishimura, 87, Winkelhake, 87, Mcintosh, 88) and il-6 (Mule, 90) have also 
been described. 
In vivo, synergism of TNF-a with drugs like alkylating agents 
(melphalan) is the crucial element that determines the success of isolated limb 
perfusion (Manusama, 96a,b), whereas also synergism with topoisomerase II 
inhibitors (doxorubicin) (Hieber, 94, Fiers, 95, van der Veen, 2000), or 
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temperature (Yamaguchi, 92) have been reported. Prerequisites for effective 
isolated limb perfusion with TNF-a and melphalan have been described by 
our group. A 30 min perfusion under mild hyperthermic conditions (38-39'C) 
proved to be optimal to achieve a synergistic effect (de Wilt et al 1999). 
Synergism between TNF-a and melphalan in high dose perfusion setting may 
be explained by dual targeting, where TNF-a (and IFN-y) is suggested to be 
responsible for disruption of the neovasculature, while melphalan causes a 
non-specific necrosis of cancer cells in vivo (Lejeune, 95). Also, for another 
chemotherapeutic drug, 5-fluorouracil (5-FU), it was observed that the in vivo 
anti-tumor effects ofthe combined treatment of 5-FU and TNF-a depend upon 
the development of capillaries in tumors (]VIanda, 90) 
Moreover, immune factors are seemingly important in determining the 
anti-tumor effect of TNF-a. Immunogenic tumors showed more regression 
than non-immunogenic tumors (Asher, 87), and the viable rim of tumor left 
after administration ofTNF-a disappeared only in immune competent hosts. 
To lower systemic toxicity of native TNF-a, it was proposed to couple 
TNF-a to polyethylene glycol (PEG), thereby increasing their molecular size 
and steric hindrance, resulting in augmented plasma half lives, increased 
bioavailability and stability (TsutsUl71i, 95, 96). In vitro, a reduction in 
bioactivity was noted, in vivo however, PEGylated TNF-a showed markedly 
higher percentages of hemorrhagic necrosis in solid tumor (S-180 sarcoma) 
than native TNF-a as well as an abrogation of its toxic side effects. 
The success of isolated limb perfusion and the indication that the 
common denominator of the anti-tumor effect is the tumor vascular bed led to 
expansion of the field of isolated perfusion with TNF-a to isolated organ 
perfusions as lung (VVeksler, 94, Pogrebniak, 94), kidney (van del' Veen, 99) 
and liver (Fraker, 94, Borel Rinkes, 97, de Vries, 98, van IJken, 98). In each of 
these organs isolated perfusion with TNF-a was feasible, with marked 
differences in systemic toxicity, which probably accounts for the repOIted 
variance in tumor responses. 
CLINICAL STUDIES WITH TNF-a 
Systemic application 
Systemic application of TNF-a, whether as a bolus or continuous 
intravenous (i.v.) injection, proved to be deleterious to the organism and 
clinical phase IIII studies yielded disappointing results with severe toxicity. 
The maximal tolerated dose (MTO) varied between 200 and 400 flg/m', 
depending on treatment schedule (Brouckaert. 86, Feinberg, 88, Spriggs & 
Yates, 92). A variety of side effects was noted after i.v. injection of TNF-a 
(Hieber, 94, Fiers, 95), hypotension being the dose-limiting toxicity (Feinberg, 
88, Spriggs, 88). In patients systemic toxicity prevents the administration of 
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adequate doses of TNF as only 1/50 of the effective dose in mnrine tumor 
models could be given in humans. Due to these low concentrations of TNF-a 
when given systemically, only low response rates were achieved. Phase II 
studies revealed a meager 1-20/0 complete remission rate after intravenous 
administration of TNF-a as a single agent (Figlin, 88, Kemeny, 90, Feldman, 
92) or combination therapy with chemotherapeutic drugs (Jones, 92). The 
addition of IFN-y or IL-2 did not enhance anti-tumor efficacy appreciably 
(Fiedler, 91, Negrier, 92), but it did fmiher increase toxicity. 
Locoregional application 
Intralul110ral injection 
Since the MTD of TNF-a in clinical trials was 50 fold lower than the 
TNF-a levels necessary to obtain responses in animal models (Asher, 87), 
other routes of injection were explored to achieve a high local concentration of 
TNF-a in tumor tissue. Intratumoral injection revealed only slightly better 
responses than intravenous injection with similar side effects at the same MTD 
(Bartsch, 89, Kahn, 89, Ijzel'mans, 91). Hepatic artery infusion (Mavligit, 92) 
and intraperitoneal (Raeth, 91) administration of TNF-a revealed only modest 
results. 
Isolated limb peljilsion (1LP) 
The first consistent anti-tumor results with TNF-a were obtained after 
isolated perfusion of the limbs (ILP). In this setting TNF-a is combined with 
melphalan and interferon-y to treat high grade melanoma and irresectable 
sarcoma (Lienard, 92, Eggel'l11ont, 93). A major advantage of ILP is the 
achievement of high local concentrations: 15-20 times higher than those 
reached after systemic administration (Benckhuijsen, 88). 
Isolated perfusion of the extremities was developed by Creech over 40 
years ago (Creech, 58). Isolation of the blood circuit of a limb is achieved by 
clamping the atiery and vein, by ligating collateral vessels and by applying a 
tourniquet around the base of the limb to compress the remaining minor 
vessels. After cannulation of the vessels, the isolated extremity is connected to 
an oxygenated extracorporeal circuit, into which the cytostatic agent is 
injected. After perfusion a thorough rinsing procednre to wash out the drugs is 
performed, after which the cannulas are removed and the circulation is 
restored. 
In combination with hyperthermia, isolated limb perfusion with 
mclphalan, an alkylating agent, yielded a 54% complete response rate for 
patients with melanoma in transit metastases confined to the limb (Eggermont, 
96d). In the late eighties ILP with melphalan, high dose Tumor Necrosis 
Factor-a and interferon-y was undertaken for multiple melanoma in transit 
metastases and irresectable high grade soft tissue sarcomas of the Limb 
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(Denard, 92, Lejeune, 94, Eggermont, 93, 96a, b). The rationale for this 
strategy was dose escalation of a cytotoxic agent with virtually absent systemic 
toxicity while determining the superior effect of addition of TNF-cx. The 
choice for melphalan as the cytotoxic drug in isolated limb perfusions was the 
result of the vast experience with this drug in the standard isolated perfusion 
for melanoma. For irresectable soft tissue sarcomas confined to the limb, ILP 
was applied as induction treatment to render these sarcomas resectable. It 
became clear that high complete response rates were feasible, with a 82% limb 
salvage rate (Eggermon/, 96b,c, 97). 
As previously mentioned in animal studies, also in clinical setting the 
tumor vascular bed appears to be the selective target for TNF-cx. The effects on 
the tumor associated vasculature after ILP with TNF-cx were described as early 
endothelium activation, upregulation of adhesion molecules and invasion of 
polymorphonuclear cells, leading to coagulative necrosis with or without 
hemorrhagic necrosis (Renard, 94,95). However, examination of melanomas 
and sarcomas of patients treated with the triple regimen in ILP did not show 
diffcrcnccs in expression of adhesion molecules as ICAM-l, E-selectin 
(ECAM-I), VCAM-I or PECAM-l in tumors compared with healthy tissue 
(Nooi/en, 96). Recently, in patients treated with isolated limb perfusion with 
TNF-cx, IFN-y and melphalan, detachment and apoptosis of the integrin cxvJ33 
positive endothel ial cells was demonstrated in vivo in melanoma metastases 
(Ruegg, 98), again pointing to the importance of selective disruption of tumor 
associated blood vessels. This was further indicated by angiography studies 
which clearly showed the disappearance of tumor associated vessels after 
TNF-based lLP (Eggermont, 94, Olieman, 97). 
Anthracyclines are among the most active agents against solid tumors 
and doxorubicin is the most widely used agent of this class (Bielack, 96, 
Bramwell, 88, Budd, 95). Moreover, doxorubicin is the agent of choice for the 
treatment of sarcoma, and has shown good anti-tumor activity in clinical and 
experimental perfusion settings for the treatment of lung metastases (Weksler, 
94, Abolhoda, 97, Wang, 95). Therefore, doxorubicin has also been used in 
isolated perfusion of the extremity (Rossi, 94). However, in most series results 
were inferior to melphalan. When comparable results were obtained this was 
often at the cost of increased regional toxicity (Thompson, 92, Krementz, 94). 
l\"Ola/ed organ peljilsion 
The indications that the tumor vascular bed is the common 
denominator for success of isolated perfusions with TNF-cx, opened gates to 
the application ofTNF-cx in other settings, as isolated organ perfusion. Various 
organs which are amenable to isolated perfusion have been described in which 
the applicability and anti-tumor efficacy of TNF-cx was evaluated. Isolated 
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lung perfusion proved to be relatively safe (Pass, 96), phase I studies for 
isolated renal perfusion are underway (Walther, 96) and recent reports 
dcscribed the efficacy of isolated liver perfusion with TNF-a (Fraker, 94, 
Oldhafer, 98, Alexander, 98). 
Our own experiences in pigs showed that drug levels comparable to 
those achieved in isolated limb perfusion can be obtained in a leakage free 
isolated hepatic perfusion setting (Borel Rinkes, 97). In a phase I study in 
patients with irresectable colorectal cancer liver metastases isolated hepatic 
perfusion with TNF-a in patients with irresectable colorectal metastases in the 
liver are summarized here. One histologically confirmed complete remission 
(CR) and 4 partial remissions (PR) were found in 6 evaluable patients. Two 
patients died due to acute coagulation disorders after substantial blood loss, 
and protracted hepatic toxicity related dysfunction was observed (De Vries, 
98). Toxicity was less dramatic in the series repOlied by Alexander et aJ. 
(Alexander, 98). In our patients the liver was perfused via the portal vein and 
the hepatic artery simultaneously. This may in part account for the unexpected 
high toxicity, as it has been shown that infusion via the pOlial vein is more 
toxic than when given systemically (Khaky, 90). Anti-tumor effects may be due 
to activation of inflammatory and coagulation cascades, resulting in induction 
of secondary cytokines and a prolonged period of high levels TNF-a. 
However, TNF-a does not preferentially accumulate in tumor tissue (Kuppel?, 
97) 
NEW STRATEGIES FOR SYSTEMIC APPLICATION OF TUMOR 
NECROSIS FACTOR-a 
Mutants of Tumor Necrosis Factor-a 
Because of the systemic toxicity associated with TNF-a, less toxic but 
equally effective recombinant TNF-a molecules were sought. In one of these 
mutants of conventional TNF-a the N-terminal amino acid sequences were 
altered to achieve higher basicity (TNF-SAM)' Various types of TNF-SAM, 
differing in amino acid species and position in the N-terminus were described 
(Soma, 88) Toxic side effects seemed to be lower with these molecules, 
whereas TNF-S"MI and TNF-SAM2 revealed a stronger cytocidal activity than 
conventional TNF-a on various murine tumors (Gatanaga, 89). Isolated limb 
perfusion with TNF-S"M2 and either melphalan or doxorubicin resulted in a 
synergistic anti-tumor response in BNI75 soft tissue sarcoma in rats (de Wilt, 
submitted). Other mllteins, in which amino acids were changed (F4236, F4168, 
F4614), showed less lethal toxicity and increased anti-tumor activity (Miyata, 
92, Miyala, 95, Kuroda, 95). Low inducibility of lIitric oxide and prostaglandin 
E, correlated with a reduced hypotensive effect, consequently an increased 
therapeutically effective dose compared to native TNF-a could be given 
(Shikama, 95). New TNF-a analogues as LK 801 and LK 805 confirmed that 
106 
Discussion 
modification of the parental molecule leads to lower systemic toxicity and 
comparable anti-tumor effect (Novakovic, 97). These novel muteins were 
thought to have greater potential for clinical application. 
Liposomes 
Convenfionalliposomes 
Liposomes were originally described some 30 years ago by Bangham 
rBangham, 65). He described a concentric arrangement of lipids, which were 
called liposomes for the first time in 1968 (Bangham, 65, Sessa and 
Weissmann, 68). These Iiposomes were composed of several layers of 
phospholipids, which enclosed an aqueous center. 
These multilamellar vesicles were first used in pharmaceutical 
experiments by Gregoriadis and Ryman (Gregoriadis And Ryman, 72). They 
concluded that liposomes are captured by the liver macrophages (Kupffer 
cells), and are degraded in lysosomes. Later, investigators discovered that by 
encapsulating drugs in liposomes the pharmacokinetics were altered, which 
could mean a broadening of the therapeutic window (Forssen And Tokes, 79, 
81). Hence, it was foreseen that potentially toxic drugs could be used in 
cancer therapy (Gabizon, 97). 
In the early eighties it became clear that liposomes were not the 
magic bullet they once were thought to be. Unexpected problems in large 
scale production and long-term stability arose, and major drawbacks with the 
use of conventional liposomal formulations were the retention of the drug 
while in circulation, the inability to extravasate in tumor tissue, as well as the 
problem of rapid clearance by the mononuclear phagocyte system (MPS), 
formerly called the reticulo-endothelial system (RES). Consequently, other 
approaches were tried. Temperature-sensitive liposomes were manufactured 
as well as pH-sensitive liposomes (Yatvin, 78, 80), but these liposomes were 
also not the answer to the major problem in human cancer: the metastatic 
lesion. 
Thus, new strategies were sought to make liposomes more resistant to 
factors responsible for clearance. Initially, incorporation in the lipid bilayer 
of small amounts of natural glycolipids, primarily monosialoganglioside GM1 
and hydrogenated phosphatidylinositol (HPI), enhanced circulation time of 
liposomes (Woodle, 95). 
Sterically stabilized liposomes 
In the late eighties, a new kind of liposome surface modification was 
introduced (Allen, 87, Klibanov, 90), These liposomes are coated with a 
polyethyleneglycol (PEG) of 1900 to 5000 daltons linked to the 
distearoylphospatidylethanolamine (OSPE) (Gabizon 88, Papahadjopoulos, 
91, Woodle and Lasic, 92), which increases hydrophilicity of the Iiposomal 
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surface, thereby reducing adherence of plasma proteins and opsonins, and 
prolonging blood circulation. Unlike conventional liposomes, the new 
generation of sterically stabilized liposomes provide a means to avoid rapid 
uptake by the MPS and to alter drug kiuetics and tissue distribution for 
therapeutic advantage (Gabizol1, 92, 97, Lasic, 95). 
Classical Liposomes VS Stealth® Liposomes 
Figure 1. Schematic representation of conventional liposomes and Stealth® 
liposomes (courtesy of dr. T.L.M. ten Hagen) 
The optimum level of PEG in the bilayer appears to be between 3 and 10 
mol % (Allen, 94a). It was also proved to be possible to insert polyethylene 
glycol derivatized phospholipid into pre-formed liposomes, which showed the 
same pharmacokinetic advantages as sterically stabilized liposomes (Uster, 
96). The longer circulation times were largely dose independent (Allen, 91, 
Lasic, 91), and the longer life plasma half-life of these sterically stabilized 
(Stealth') liposomes in circulation allow accumnlation in the tumor tissue 
(Gabizon, 92). This is thought to facilitate passive targeting, whereas active 
targeting by coupling antibodies to these liposomes also proved to be feasible 
(Allen, 94b, Hansen, 95). 
Stability and clearance of liposoll1es 
One important factor to consider when using liposomes is their 
stability in circulation. Because liposomes are injected intravenously, plasma 
proteins playa major role in liposomal clearance. The stability of the vesicle in 
plasma depends on size, lipid composition, lameilarity and temperature (.Jones, 
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91, Scherphof, 84, Lasic, 91). Several groups have elaborated on the 
importance of opsonization and subsequent elimination of liposomes (Patel, 
92, Chonn 92, Harashima, 93). Here, attention will be focused upon the 
sterically stabilized liposomes. 
The presence of the hydrophilic, flexible polymer poly-ethylene glycol 
(PEG), extending from the liposomal membrane for a distance of 5-6-nm 
(Needham, 92), alters the interaction between plasma proteins and the 
liposomcs by steric hindrance (Senior, 91, Allen, 94). PEG-coated liposomes 
still accumulate in the MPS, mainly comprised of Kupffer cells in the liver and 
fixed macro phages in the spleen, although uptake also takes place in bone 
marrow and lymph nodes (Allen, 97), but the exact mechanism of elimination of 
sterically stabilized liposomes is not clear. It is suggested that the removal from 
circulation of PEG-liposomes occurs by the same mechanism as the removal of 
conventional liposomes, as a result of the gradual removal of the PEG from the 
liposomalmembrane and their subsequent opsonization (Allen, 94). Complement 
is likely to play an important role in liposomal clearance, influenced by 
cholesterol (Ishida, 97), animal species (Liu, 95, Harashima, 96) and liposome 
size (Litzinger, 94, Devine, 94). Larger (ie diameter> 300 nm) liposomes show an 
increascd accumulation into spleen, whereas PEG-liposomes of smaller diameter 
(below 90 nm) are preferentially taken up by the liver (Allen, 94). Enhancement 
of uptake of pegylated liposomes by the spleen was noted before (Gabizon, 92, 
Woodle, 94), probably resulting from high blood concentration. In our sarcoma 
model we found an equal amount of sterically stabilized liposomes in liver and 
spleen, however per gralll tissue the spleen was shown to be very active (van der 
Veen, 98). Non-immunogenic opsonins in rat plasma, like fibronectin, may also 
playa role in the uptake of liposomes by the spleen (Aramaki, 95), furthermore, 
it is suggested that tUlllor-bearing animals have an increased splenic clearance, 
possibly related to an altered opsonic activity of serum in thesc animals 
(Moghimi, 96) 
Application of Ii po somes in anticancer therapy 
The advantages of liposomes as an effective delivery system are most 
obvious in anticancer therapy. Cytotoxic drugs are characterized by their low 
therapeutic index (TI) due to (i) inability to achieve therapeutic concentrations 
at the sitc of the tumor, (ii) nonspecific cytotoxicity to normal tissues or (iii) 
problems arising with the formulation of the drug (Sharma, 97). 
In general, the purpose of encapsulation of cytotoxic drugs will be a 
reduction of toxicity, while at the same time enhancement of therapeutic 
efficacy (e.d. reversal of multidrug resistance mechanisms, slow release 
system) and selective delivery of the encapsulated drug to tumor tissue is 
pursued (Ranson, 96). 
For cytotoxic drugs to reach their target site it is mandatory that the 
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carrier system leaves the circulation. Solid tumors show a disorganized 
microvasculature, with increased capillary permeability due to wider 
endothelial gaps and depleted endothelial layers and basal lamina (Dvorak, 
88). In addition, physiological parameters as the increased interstitial fluid 
pressure and the absence of an adequate lymphatic barrier playa role in the 
deposition of liposomes in the tumor (Jain, 87, 94). 
Tumor-structure: Barriers to StealthtE LIPOISOme!S 
Figure 2. Schematic representation of tumor tissue vs normal healthy tissue 
(courtesy of dr. T.L.M. ten Hagen) 
Sterically stabilized liposomes, with their extended circulatiou times, 
have a high probability of extravasation in the tumor interstitial space (Jain. 
960, Gabizon, 97). and with light and electron microscopy in vivo distribution 
was studied (Huang, 92a). It appeared that the PEG-liposomes were located 
around blood vessels in the tumor (Litzinger, 94) and in areas with 
angiogenesis. The perivascular distribution of intact liposomes was 
heterogeneous (Brown, 98). The difference between intravascular hydrostatic 
and interstitial pressure serves as a driving force for liposomes to leave the 
bloodstream (yuan, 94. Kristensen, 96), and with fluorescence studies it was 
proven that sterically stabilized liposomes, which show a higher vascular 
permeability than conventional liposomes (Yuan, 95), preferentially are taken 
up in tumor tissue as opposed to non-tumor tissue with relative impermeable 
capillaries (F17u, 93, Dewhirst, 95, Wu, 97). 
The encapsulation of anthracyclines, especially doxorubicin, 
epirubicin and daunorubicin, in liposomes has been recently reviewed 
(Gabizon, 94, 97, Ranson, 96). In this review we will discuss the preclinical 
and clinical studies with anticancer drugs in sterically stabilized liposomes, 
focussed on encapsulated doxorubicin. 
The pharmacokinetics of anticancer drugs in pegylated liposomes are 
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characterized by a prolonged blood residence time, slow plasma clearance and 
a small volume of distribution, as well as a reduced leakage rate of the 
encapsulated drug. The altered pharmacokinetics and efficacy of 
anthracyclines encapsulated in sterically stabilized liposomes have been 
described for a variety of animal tumor models (Papahadjopoulos, 91, Huang, 
92b, Mayhew, 92, Gahizon, 92, 93, Siegal, 95, Vaage, 92,93). All showed an 
increased accumulation of the encapsulated drug versus the non-encapsulated 
drug, with peak levels in tumor tissue reached at a later timepoint. In a 
xenografted human pancreatic carcinoma, drug levels remained high for a 
prolonged period of time (Vaage, 97). The longevity in circulation, 
characteristic of steric stabilization, with resultant selective extravasation at 
the tumor site, was suggested to be responsible for improvement of therapeutic 
efficacy in an ascitic tumor model in mice (.1-6456) as well as a solid mouse 
lung carcinoma (M-I 09) (Gabizon, 96). 
Not only for solid tumors, also in a liver metastasis model the 
deposition of doxorubicin loaded sterically stabilized Iiposomes (Doxil®) was 
followed (Cay, 97). Intravital fluorescence microscopy of the liver revealed 
homogeneous distribution of the liposomes to metastatic liver tumors after 
intraarterial and intrap0l1al administration, where a sustained release of 
encapsulated cytotoxic drug was observed (Unezaki, 96). Electron microscopy 
confirmed intracytoplasmic, perinuclear uptake of liposomes in tumor cells. 
Intravenous injection of the liposomes did not seem as effective as 
locoregional administration, therefore this last study opens new perspectives in 
the field of sterically stabilized liposomal anticancer drugs. 
In human studies the alteration of pharmacokinetics of doxorubicin 
after encapsulation in sterically stabilized liposomes was confirmed (Gabizon, 
94). The plasma elimination of Doxil® was even slower than in animal studies 
(Gabizon, 93), following a biexponential curve with median values of2 and 45 
h. Doxil®, tested at two dose levels, 25 and 50 mg/m2, showed a slow clearance 
and small volume of distribution (V d). When the V d is decreased as opposed to 
free drug, the drug concentration in normal tissues will be reduced, Therefore 
the toxicity profile of the free drug is altered, sometimes at the cost of new 
toxicities. In a subsequent phase I study, patients with a variety of malignant 
tumors were treated with escalating doses between 25 and 60 mg/m2 every 3 to 
4 weeks (Gabizon, 94, Gordon, 95). The efficacy of PEG-Iiposomal 
doxorubicin is most obvious in the management of AIDS-related Kaposi's 
sarcoma, where augmented tumor site concentration of doxorubicin was 
measured (North/elt, 96) and overall response rates were impressive (Coukell, 
97). Higher response rates were achieved with pegylated liposomal 
doxorubicin (20 mg/m2) than with the standard regimen containing 
doxorubicin, bleomycine and vincristine given systemically (North/elt, 98). 
The drug formulation is generally well tolerated. In a minority of patients dose 
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limiting skin tOXICity (hand-foot syndrome; palmar-plantar 
erythrodysaesthesia) occurred, which is characterized by skin eruptions on the 
palms and soles, with pain and inflammation Other, major, toxicities are 
myelosuppression, neutropenia in particular, nausea, vomiting and alopecia 
(Alberts, 97). 
These studies led to the approval of doxorubicin (Doxil®, Caelyx®) for 
clinical use. Several hundreds of patients with mV-related refractory Kaposi 
sarcoma have been treated up to now, At present mUltiple phase III! and III 
studies are being performed for a variety of tumors, like (metastatic or 
recurrent) breast cancer, refractory ovarian cancer and prostate cancer as well 
as non-small cell lung cancer and soft tissue sarcomas (Lasic 97, Sharma, 97, 
Muggia, 97). 
Application of TNF-a in liposomes 
Typically, cytokines exhibit short plasma half-lives, biodistribution to 
non-relevant tissues, and high toxicity, which hampers clinical applicability, 
Delivery of cytokines via liposomes may extend the therapeutic index of the 
encapsulated agent. Indeed, improvement of pharmacokinetics and biologic 
ability of a wide spectrum of cytokines after encapsulation in liposomes has 
been recently reviewed (Kedar, 97b), 
To address the main adverse effect of Tumor Necrosis Factor-a, being 
its severe toxicity, liposomal encapSUlation was proposed. Preparation ofTNF-
a in conventional, multi lamellar liposomes (MLV) has been described by 
several authors (Debs, 89, 90, Diizglines, 89, Nii, 91, Utsumi, 91, Weber, 94, 
Lodato, 95, Kedar, 97). 
Encapsulated TNF-a retained immunomodulatory and anti-tumor 
activity in vivo, at the same time reducing toxicity compared to free TNF-a in 
rats (Debs, 90). For alteration of the biological activity of TNF-a, stable 
association on or within the liposomalmembrane appears mandatory, This was 
further proven by the fact that liposomal TNF-a retains bioactivity in vitro in 
the presence of anti-'fNF-a antibodies (Debs, 89), Sensitive target cells, like 
the human melanoma A375 and the murine fibroblasts L929, were effectively 
lysed by TNF-a entrapped in liposomes (Nil~ 91), Others found that liposomes 
loaded with TNF-a had a growth inhibitory effect on human glioma cells, a 
cell line which is resistant to free TNF-a (Weber, 94). 
It was soon recognized that encapsulation of TNF-a in liposomes was 
hampered by the low hydrophobicity of the cytokine. The preparation of a 
more lipophilic variety of the native TNF-a was therefore attempted. 
Incorporation of TNF-a coupled to long chain fatty acids proved to be 
successful (Utsumi, 91, Klostergaard, 92) in small unilamellar vesicles. The 
biological activity however, was negatively influenced by modification of the 
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amino residues in TNF-a, thought to be essential for its cytolytic effect. 
Nevertheless, the binding efficiency was markedly improved (>50%), and a 
possible usage was foreseen in treating tumors. 
Encapsulation of TNF-a in liposomes was also enhanced by varying the 
calcium concentration in the membrane (Saito, 95). Supposedly, negatively 
influencing the stability of the phospholipid membrane played a role in the 
process. 
Sterically stabilized liposomes 
It is likely that incorporation of celiain biologic response modifiers in 
sterically stabilized liposomes opens possibilities for a wider range of anti-
tumor therapy. The prolonged circulation time, extravasation and accumulation 
in tUlllor tissue and decreased toxicity of newer generation liposomes caused 
attention to become focused on encapsulation of cytokines in these long 
circulating liposomes. Especially the problem of disseminated disease seems to 
be rcndered manageable. 
Incorporation of lL-2 in sterically stabilized liposomes (SSL) enhanced 
immunomodulatory activity (Kedar. 94a). and SSL-IL-2 were demonstrated to 
have superior therapeutic efficacy in mice with advanced metastatic tumors, 
either alone or in combination with cyclophosphamide pretreatment (Kedar. 
94b). 
Our laboratory demonstrated that Tumor Necrosis Factor-a could be 
incorporated in sterically stabilized liposomes of 95 nm diameter with an 
encapsulation efficiency of 24%, meaning that 15 fig TNF-a is associated with 
60 fllllol lipid (val1 der Veel1. 98). No significant loss of activity was measured 
using thc TNF-a sensitive cell-line WEHl 164. 
These liposomes were therefore used to determine biodistribution and 
tumor localization in a soft tissue sarcoma bearing rat model. Earlier, we have 
shown that the blood circulation ofTNF-a encapsulated in sterically stabilized 
liposomes (TNF-a-SSL) was comparable to the circulation times mentioned in 
the literature for other long circulating liposome formulations (Gabizol1. 94. 
Harashima. 96). With incorporation in the aqueous compariment of 67Gallium_ 
desferal, a mean residence time in blood of approximately 33 hours was 
demonstrated. TNF-a encapsulated in liposomes had a shorter residence half-
life, probably caused by in vivo release of TNF-a from the liposomes (Ten 
Hagen. 97). Initial release of entrapped drugs from the circulating liposomes is 
more rapid than the aqueous labels, producing a faster rate of clearance, 
followed by a slower release from the liposomes making the liposome 
clearance rate dominate at the latter time (Woodle, 93). This phenomena is also 
known for IL-2 in sterically stabilized liposomes (Kedar. 94a). Still, the 
possible bioavailability of TNF-a was increased considerably. The liposomes 
used showed a localization in a soft tissue sarcoma in the leg, a tUlllor model 
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also used in isolated limb perfusion studies, of almost 8% of the injected dose, 
24 hours after injection. The localization of TNF-a in tumor was increased by 
13-fold, but also uptake by the MPS appeared prolonged (van der Veen, 98). 
Comparable to the results shown with TNF-a entrapped in 
conventional liposomes, toxicity with TNF-a sterically stabilized liposomes 
was markedly reduced. No loss in body weight and no alteration in blood cell 
count was recorded. 
Subsequently, in soft tissue sarcoma bearing rats we tested the anti-
tumor efficacy of different combinations of TNF-a-SSL and doxorubicin 
encapsulated in Stealth® liposomes (Doxil®, kindly provided by Dr. Working, 
SEQUUS Pharmaceuticals, Menlo Park, CA, USA). With the combination of 
TNF-a-SSL (15 f!g/kg per injection) and Doxil® (1" dose 4.5 mg/kg, followed 
by 4 dosages of I mg/kg), injected five times over a 20 day period, we 
observed a tumor response which is improved compared with Doxil® alone 
(val7 der Veen, 96). All the tumors showed at least a stable disease for a 
prolonged period of time. In a number of cases the tumor, but also the 
overlying skin, became necrotic, as is also observed in the isolated perfusion 
setting using TNF-a and melphalan. In histopathologic studies this region of 
necrosis was marked, albeit not a 100%. A viable rim was seen around the 
necrotic region (Ten Hagen, 97). 
Low dose TNF-a h1 combination yvith /iposomal anti-tumor formulations 
From the studies with liposomal encapsulated TNF-a it seems 
probable that to improve an anti-tumor response by augmenting homing of 
drug formulations only low local concentrations of TNF-a are needed. 
Although in vivo activity of TNF-a is preserved after encapsulation in 
liposomes, we therefore explored the possibility of combining low dose TNF-
a, systemically injected in combination with Doxil® (Tel7 Hagen, in press). In 
two solid tumor models (a soft tissue sarcoma and an osteosarcoma) addition 
of low dose (15 ~lg/kg) TNF-a to Doxil® (same regimen as above) resulted in 
an increased anti-tumor response, potentiating the activity of DoxiI® alone. 
Whereas administration of doxorubicin liposomes alone had only a marginal 
effect, co-administration of TNF-a resulted in a strong tumor response and 
long duration of tumor control. It appeared that addition of TNF-a enhanced 
accumulation of doxorubicin in the tumor interstitium after repeated injections 
of the liposomal drug in combination with TNF-a. Similarly, augmented 
accumulation of less well defined liposomes by TNF-a has been shown before, 
however with minimal etfect on tumor response (Suzuki, 90). Drug levels in 
the tumor interstitium appeared to be crucial as intracellular levels of free or 
liposome encapsulated doxorubicin were not increased. 
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5. CONCLUSIONS 
After the initial disappointing results of systemic application of Tumor 
Necrosis Factor-a in clinical trials. the demonstration of anti-tumor efficacy of 
TNF-a and melphalan in isolated perfusion of the extremities caused a revival 
in enthusiasm. Strong and consistent anti-tumor effects have been reported for 
TNF-a in animal and human studies. This led to the registration of TNF-a as 
an anticancer drug in Europe in the setting of isolated limb perfusion in 
combination with melphalan for advanced extremity sarcomas. The primary 
target for TNf-a seems to be the disorganized tumor vasculature, and 
especially the vascular endothelium. The interaction with cytostatic agents has 
been proven to be of paramount impOliance in the treatment of cancer. 
New strategies have been sought to extend the therapeutic use ofTNF-
a. Pegylation of TNF-a to extend its circulation half-life, muteins of the 
parental cytokine to diminish its toxic side effects and increase the therapeutic 
indcx proved to be of value. Other regional treatment protocols with TNF-a, 
like organ perfusions and stop-flow infusion techniques are currently under 
investigation. These developments in the application ofTNF-a have led to new 
perspectives in systemic application, namely encapsulation of TNF-a in 
sterically stabilized liposomes or treatment with low-dose TNF-a in 
combination with (Iiposomal) formulated drugs, in order to improve homing, 
resulting in increased tUlllor respOl1S. 
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SUMMARY 
Effective treatment of solid tumors is complicated by factors due to the 
nature of the tumor and by possible side effects which accompany treatment. 
The penetration of solid tumors and the heterogeneity with which this takes 
place is very much influenced by the vascularization of the tumor. It is known 
that in well vascularized tissue higher drug levels can be reached than in poorly 
perfused regions. Furthermore, in tumors the interstitial pressure tends to be 
higher, which may act as an extra barrier to penetration of a suitable drug and 
especially of formulated drugs, such as liposomes. 
Solid tumors however also exhibit characteristics which favor the 
passage of drugs to and in the tumor tissue. Especially, the tumor associated 
vasculature (TA V) has characteristics differing from normal vasculature. These 
vessels are characterized by an inherent high permeability caused by 
incomplete endothelial linings and basement membranes, and the vasculature is 
not well organized. Blood flow through the neovasculature is irregular and 
sluggish. In addition, tumor stroma is characterized by absence of lymphatics. 
Drug delivery to solid tUinOI' therefore is influenced by the microvasculature 
and tumor stroma. 
The majority of Tumor Necrosis Factor-a (TNF-a) anti-tumor effects 
arc believed to be indirectly mediated through damage of the tumor associated 
vasculature (TA V). It has been shown to have vasculotoxic effects at high 
concentrations, while at low concentrations it promotes DNA synthesis and 
angiogenesis. Systemic administration of TNF-a however resulted in serious 
side effects, hypotension being the dose-limiting toxicity. The maximal 
tolerated dose was reported to be 200 - 400 ~lg!m2, which is only 1I50th of the 
doses that causes tumor regression in animal tumor models. Locoregional 
administration seemed the only option for successful clinical application of 
TNF-a. TNF-a-based isolated extremity perfusion (ILP) in combination with 
cytotoxic agents revived the clinical use of the cytokine. It was proposed that 
the application of TNF-a in isolated perfusion of organs would also be 
possible. FUl1hennore, an experimental program was started to make systemic 
administration of TNF-a again possible, avoiding the severe toxic side effects. 
Chapter Ol1e describes the previous work with TNF-a and the 
applicability of isolation perfusion. Furthermore previous work with liposomes 
is described. The aim of the present study was the development of isolated 
organ perfusion models and the development of protocols to resurrect the 
systemic administration of TNF-a, thereby exploring possibilities to treat 
disseminated disease. 
In chapter two we describe the development of an isolated organ 
perfusion model. For technical reasons the kidney was chosen. At first, the 
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technique of isolated kidney perfusion (IKP) is described, subsequently the 
feasibility of a perfusion with TNF-a is studied and the anti-tumor effects of 
IKP with TNF-a and melphalan is assessed. The maximal tolerated dose 
(MTD) of TNF-a proved to be I iJ.g. Higher doses induced renal failure and 
fatal respiratory disease, a septic shock like syndrome allegedly caused by a 
secondary cytokine release. In vitro and in vivo experiments with TNF-a and 
melphalan failed to show the synergistic anti tumor response so 
characteristically for the combination in isolated limb perfusion (ILP). 
Apparently, the minimal threshold concentration of TNF-a to exeli its anti-
tumor cffects was not reached, therefore the outlook for clinical applicability of 
isolated kidney perfusion with TNF-a seems low. 
In chapter three the combination of high dose TNF-a and doxorubicin 
in ILP was explored to extend the preclinical-clinical anti-tumor program 
currently performed in Rotterdam with TNF-a and melphalan. Doxorubicin is 
one of the more potent drugs in the treatment of soft tissue sarcoma and 
therefore it was warranted that the efficacy of doxorubicin and TNF-a was 
explored in the preclinical model of ILP in two different rat sarcoma tumor 
models. It is shown that the anti-tumor effects of the combination are 
comparable to the synergistic response of TNF-a and melphalan in earlier 
studies. The addition of high dose TNF-a to doxorubicin results in regression 
of the tumor in 54% of the BN I 75-fibrosarcomas and in 100% of the ROS-l 
osteosarcomas. The combination is shown to be mandatory for optimal tumor 
response. Secondly, it was demonstrated that TNF-a enhances intratumoral 
accumulation of doxorubicin: 3.1-fold in the BNl75 and 1.8-fold in the ROS-l 
sarcoma after ILP with doxorubicin combined with TNF-a in comparison with 
an lLP with doxorubicin alone. In vitro however, TNF-a fails to augment drug 
uptake in tumor cells or to increase cytotoxicity of the drug. Enhancement of 
intratumoral drug concentration is explained by increasing the leakiness of the 
tumor associated vasculature as well as a reduction in interstitial pressure by 
TNF-a. It is suggested from this study that TNF-a does not directly modulates 
the activity of doxorubicin in vivo. As TNF-a by itself has no or only minimal 
effect on tumor growth, an increase in local concentrations of 
chemotherapeutic drugs might well be the main mechanism for the synergistic 
anti-tumor effects. 
In chapter four we explored whether TNF-a could playa regulatory 
role in the cell cycle. Doxorubicin is a well known cell cycle dependent drug, 
and TNF-a is claimed to have inhibitory effects on doxorubicin. This is not in 
agreemenl with our findings in ILP, where a clear synergism between the two 
drugs was proven in vivo. Cells were tested in vitro where no attenuating effect 
of TNF-a on doxorubicin cytotoxicity could be demonstrated in either of the 
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three cell lines tested. Also, preincubation of the cells with TNF-a, prior to 
incubation with doxorubicin or melphalan, did not induce a significant effect 
on cytotoxicity. To evaluate whether TNF-a has indeed effect on cell cycle 
kinetics, flow cytometry was used to determine the DNA content of nuclei 
isolated from cells exposed to TNF-a. It was demonstrated that TNF-a slightly 
increases the amount of cells in G, phase only in the osteosarcoma cell line, 
however this did not result in an attenuation of the cytotoxicity of doxorubicin 
towards these cells. In the other tumor cell lines tested no or marginal effect on 
cell cycle progression was found. 
In chapter five the applicability of TNF-a in long circulating liposomes 
was explored. Liposomal encapsulation has several advantages: prolonged half-
life time of encapsulated drugs, reduced toxicity, smaller volume of distribution 
and the possibility of reaching high concentrations at specific sites, more in 
particular in tumor tissue. Newer generation liposomes, sterically stabilized or 
Stealth® liposomes, tend to have longer circulation times in circulation and are 
therefore of special interest in anti-tumor therapy. Long circulating liposomes 
can be manufactured by various methods, however different methods can have 
more or less detrimental effects on the bioavailability of TNF-a. With these 
liposomes the blood residence half-life and organ distribution of TNF-a 
encapsulated in sterically stabilized liposomes were investigated in tumor-
bearing rats. Pharmacokinetic profile of TNF-a was markedly different after 
encapsulation: 33-fold increase in blood residence time with a concomitant 14-
fold increase in the area under the curve. Total uptake in tumor tissue ofTNF-a 
after encapsulation also was enhanced, peak TNF-a concentration however, 
was not increased in tumor tissue as compared to free TNF-a. The toxicity of 
the product was diminished. We concluded that encapsulation of TNF-a was 
promising, the encapsulation efficacy however, was not as high as expected. 
In chapter six the option of systemic administration of low dose TNF-a 
in combination with chemotherapeutics was explored. Again, the synergy 
betwecn TNF-a and cytotoxic drugs found in isolated limb perfusions with 
high dose TNF-a can be explained by the enhanced accumulation of the 
cytotoxic drug in the tumor. It was therefore interesting to examine the effect of 
systemic administration of low dose TNF-a on the distribution of cytotoxic 
drugs. Doxorubicin however, has also toxic side effects, mainly on cardiac 
muscle. The combination of systemic low dose TNF-a and liposome 
encapsulated doxorubicin (Doxil®) seemed especially attractive. We 
demonstrated that not only TNF-a enhances the anti-tumor activity of 
liposomal doxorubicin, also three or more injections of Doxil® combined with 
TNF-a results in augmented accumulation of the cytotoxic drug in tumor tissue 
when compared to either the free drug or Doxil® alone. Therefore, the ongoing 
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accumulation of doxorubicin at the site of the tumor after co-administration of 
low dose TNF-a results in a synergistic response probably due to a permissive 
effect of TNF-a on the neo vascularization of the tumor. This effect is 
translated in positive anti-tumor responses after multiple administrations of 
Doxil® and low dose Tumor Necrosis Factor-a. Moreover, this enhanced tumor 
targeting of liposomal drug after systemic low dose TNF-a may also be seen 
with other liposomal formulations. 
In chapter 7 the above mentioned results are discussed in the light of 
the present knowledge about the applicability of TNF-a. With the registration 
ofTNF-a in Europe for combination therapy of advanced extremity sarcoma in 
isolation limb perfusion, further exploration of the usefulness of TNF-a in 
combination with cytotoxic drug for the treatment of solid tumors is warranted. 
CONCLUSIONS 
Application of high dose TNF-a in anti-tumor therapy in conjunction with 
cytotoxic drugs results in high response rates in isolated limb perfusion. This 
led to the approval and registration of Tumor Necrosis Factor-a in Europe 
(Beromun®) for clinical use in patients with locally advanced extremity 
sarcomas treated by ILP with TNF-a and melphalan. 
In this thesis other modalities to achieve the same impressive results are 
explored. We gained insight in the mechanism by which TNF-a exerts its 
effects and by means of a revival of systemic application of low dose TNF-a in 
combination with chemotherapeutics, paved the path for treatment of multiple 
forms of cancer as well as metastatic disease. More research is needed to 
extend the positive results of pre-clinical experiments with low dose TNF-a to 
the cl inic, where successful anti-tumor therapy and duration of remission is all 
the more important. Conclusions made on the basis of the studies are: 
I. IKP model: technically feasible, but not a suitable model to test efficacy of 
TNF-a due to high toxicity. 
2. Synergistic anti-tumor response in high dose TNF-based isolated limb 
perfusion with doxorubicin in vivo. 
3. Enhanced levels of doxorubicin in tumor tissue in high dose TNF-based 
ILP. 
4. TNF-a has no measurable effect on cell cycle. 
5. TNF-a can be encapsulated in long circulating liposomes with acceptable 
efficiency. 
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6. Pharmacokinetic profile of TNF-a IS positively influenced after 
encapsulation. 
7. Systemic application of low dose TNF-a in combination with liposome 
encapsulated Doxorubicin (Doxil®) results in enhanced accumulation of the 
cytotoxic drug in tumor tissue and results in long lasting anti-tumor effects. 
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SAMENV ATTING 
Effectieve bchandeling van solide tumoren wordt bemoeilijkt door de 
eigenschappen van de tumor en bijwerkingen, welke de behandeling kunnen 
compliceren, De penetratie van geneesmiddelen in tumorweefsel en de 
heterogeniteit waarmee dit samengaat worden voor een belangrijk deel bepaald 
door de vascularisatie van de tumoL Het is bekend dat in goed gevasculariseerd 
weefsel een hogere spiegel van cytostatische geneesmiddelen wordt gevonden, 
dan in slecht geperfundeerde gebieden, Bovendien is de interstiele druk in het 
tumorweefsel hoger, wat een extra barriere vormt in de penetratie van 
genecsmiddelen of carriers hiervan, zoals bijvoorbeeld liposomen. 
Solide tumoren hebben echter ook kenmerken die de passage van 
geneesmiddelen naar en in het tumorweefsel vergemakkelijken. Met name 
wijken de eigenschappen van de in de tumor aanwezige vaten af van nonnaal. 
De capillairen in het tumorweefsel worden gekarakteriseerd door een hoge 
permeabiliteitsfactor, veroorzaakt door de onderbroken endotheelcellaag van de 
tutnorvaten en cell afwezige basaalmembraan. Bovendien is de organisatie van 
het tumorvaatbed wanordel ijk. De bloedstroom in het tumorvaatbed is traag en 
irregulair. Het tumorweefsel wordt voorts gekenmerkt door de afwezigheid van 
lymfebanen. De depositie van geneesmiddelen wordt derhalve voor een 
belangrijk deel bepaald door de microvasculatuur van de tumor en de 
eigenschappen van het tumorweefsel. 
De anti-tumoreffecten van Tumor Necrose Factor-a worden voor een 
belangrijk deel veroorzaakt door directe beschadiging van het tumorvaatbed. 
Het is aangetoond dat TNF-a een vasculotoxische werking heef! indien 
toegediend in hoge doseringen, doch in lage doseringen DNA synthese en 
angiogenese kan bevorderen. 
Systemische toediening van TNF-a bij patienten resulteerde m 
ernstige bijwerkingen, waarbij met name het optreden van hypotensie de 
dosering beperkte. De maximaal getolereerde dosis (MTD) was 200 - 400 
flg/m', wat maar 1/50' is van de dosis, die tumor regressie veroorzaakt in 
diermodellen. Locoregionale toepassing van TNF-a leek de enige optie voor 
klinische toepassing. Door de veel effectievere combinatie van TNF-a met 
cytostatica onstond een hernieuwde klinische belangstelling voor de toepassing 
van gei'so[eerde extremiteitsperfusie. Gezien het succes hiervan bij patienten 
met melanoom en sarCOOI11, werd gedacht dat de toepassing van TNF-a en 
cytostatica ook mogelijk 1110est zijn in de vorm van gelsoleerde perfusie van 
organen. Daarnaast werd een experimenteel programma opgestart om na te 
gaan of zelfs systemisehe toepassing van TNF-a nu mogelijk was zonder 
ernstige toxische bijwerkingen. 
Hoofdstuk 1 beschrijf! eerder onderzoek met TNF-a en de 
toepasbaarheid in gelsoleerde perfusie. Bovendien zijn de resultaten met 
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liposomen als carrier vermeld. Het doe I van de m dit proefschrift bewerkte 
studies wordt beschreven. 
In hoofds/uk 2 beschrijven we de ontwikkeling van een model voor 
orgaanperfusie. Hiervoor werd de nier gekozen. De techniek van gelsoleerde 
nierperfusie (lKP) met TNF-a aileen en in combinatie met melphalan wordt 
beschreven. De anti-tumoreffecten van deze combinatie werden onderzocht. 
De maximaal getolereerde dosis (MTD) van TNF-a in deze setting bleek maar 
I Ilg te zijn. Hogere doses veroorzaakten nierfalen en fatale respiratoire 
complicaties, zoals voorkomend bij septische shock, mogelijk veroorzaakt door 
in overmaat circulerende cytokines. Mede hierdoor kon het synergisme tussen 
TNF-a en melphalan, wat bij ge"isoleerde extremiteitsperfusie wordt gevonden, 
bij gelsoleerde nierperfusie niet worden aangetoond. Door de slechte tolerantie 
werd de drempel voor het bereiken van anti-tumoreffecten middels TNF-a niet 
bereikt. Klinische toepassing van gelsoleerde nierperfusie van de combinatie 
TNF-a en melphalan lijkt dan ook nog niet tot de mogelijldleden te bellOren. 
Hoofds/uk 3. In het kader van het preklinisch-klinisch anti-tumor 
programma in Rotterdam betreffende de toe passing van TNF-a werd de 
combinatie van TNF-a en doxorubicine onderzocht. De resultaten van 
gei·soleerde extremiteitsperfusie met doxorubicine en TNF-a worden 
bcschreven. Doxorubicine is werkzaam gebleken bij de behandeling van het 
weke delen sarcoom en het was daarom nuttig om de effectiviteit van de 
combinatie in twee verschillende sarcoma modellen in de rat te onderzoeken. 
Een zelfde synergistische werking werd gevonden als bij de toepassing van 
melphalan. Het fibrosarcoom BN 175 liet een tumorrespons zien van 54%, het 
osteosarcoom ROS-I zelfs van 100%. Aangetoond werd dat voor een optimale 
tumorrespons TNF en doxorubicine inderdaad gecombineerd moeten worden. 
Ten eerste werd aangetoond dat TNF-a de concentratie van doxorubicine in het 
tumorweefsel verhoogde, 3, I-voudig bij het weke delen sarcoom en 1,8-voudig 
bij het osteosarcoom. 111 vitro echter werd geen toename van de concentratie 
doxorubicine in de tumorcellen zelf gevonden, evenmin werd de cytotoxische 
werking van doxorubicine gestimuleerd. De toename van de intratumorale 
concentratie van doxorubicine werd verklaard door een toename van het 
capillaire lek in de tumorvaten, alsmede door een verlaging van de interstiele 
druk in het tumorweefsel door TNF-a. Het is waarschijnlijk dat TNF-a il1 vivo 
de anti-tumoractiviteit van doxorubicine indirect belnvloedt. Omdat TNF-a 
geen of maar een minimaal effect heef! op tumorgroei, is de toename van de 
concentratie van cytostatica in de tumor door TNF-a waarschijnlijk het 
belangrijkste mechanisme dat de synergistische anti-tumorrespol1s 
bewerksteIIigt. 
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Hoofdsluk 4 behandelt de vraag ofTNF-a een regulerende functie heeft 
III de eelcyclus. De fase van de celeyclus speelt een rol in de cytotoxische 
werking van doxorubieine. TNf-a zou de voortgang van de celcyclus 
afremmen in de Go/G, fase en zodoende de werking van doxorubicine 
verminderen. Onze bevindingen in gei"soleerde extremiteitsperfusie tonen 
synergisme aan tussen TNF-a en doxorubicine. In goon van de drie geteste 
cellijnen, werd een remmende werking van TNF-a op doxorubicine 
aangctoond. Ook voorbehandeling met TNF-a had geen significant effect op 
de cytotoxiciteit van melphalan of doxorubicine. Door middel van 
Ilowcytometrie werd de hoeveelheid DNA in de nuclei" van aan TNF-a 
blootgestelde cellen bepaald. Er bleek een liehte toename te zijn van 
osteosarcoomcellen in de G2 fase, hetgeen echter niet resulteerde in een afname 
van de cytotoxisehe werking van doxorubicine op deze cellen. In de andere 
getesle cellijnen werd goon of slechts een marginaal effect op de celcyelus 
gevonden. 
In hooji.l\-ruk 5 wordt onderzoek beschreven naar systemische 
toepasbaarheid van TNF-a. Hiertoe werd TNF-a ge"incorporeerd in liposomen. 
Liposomale inkapseling biedt een aantal voordelen: langere halfwaarde tijd van 
ingekapselde geneesmiddelen, afname van de toxiciteit, kleiner 
distributievolume en mogelijk het bereiken van hogere weefselspiegels in 
tumorweefse!' De nieuwe generatie Stealth® liposomen circuleren langer in de 
bloedbaan en zijn daarom interessant in het kader van anti-tumortherapie. 
Stealth" liposomen kunnen op verschillende manieren worden gemaakt, 
hetgeen hun biologische beschikbaarheid be"invloedt. De halfwaardetijd in de 
circulatie alsmede de orgaandistributie, van in lang circulerende liposomen 
ge"ineorporeerd TNF-a, werden onderzocht in tumordragende ratten. Het 
farmacokinetische profiel van TNF-a veranderde evident: de verblijfsduur in 
de eireulatie nam 33-voudig toe, gepaard gaande met een 14-voudige toename 
van de area onder the curve. Tumorweefsel toonde ook een hogere opname van 
TNF-a na inkapseling, hoewel de piekconeentratie van TNF-a in tumorweefsel 
in vergelijking met vrij TNF-a niet toenam. De toxieiteit van TNF-a was 
minimaa!. Wij eoneludeerden dat inkapseling van TNF-a veelbelovend was, 
hoewel het percentage ingekapseld TNF-a niet zo hoog was als verwacht. 
Hoofdsluk 6 besehrijft de systemische toepassing van [age doses TNF-
a in combinatie met cytostatica. Zoals eerder gezegd wordt de synergie tussen 
hoge doses TNF-a en cytostatica in ge"isoleerde extremiteitsperfusie verklaard 
door een toename in de concentratie van het cytostaticum in het tumorweefsel. 
Het effect van systemisch toegediende lage dosis TNF-a op de distributie van 
cytostatica was tot 1111 toe onduidelijk en dam'om interessant om te 
onderzoeken: Een bijwerking van systemisch toegediend doxorubicine, in 
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werkzame doses, is cardiale toxiciteit. Dam'om werd de combinatie van 
systeillisch loegepast TNF-a in lage dosering en liposomaal ingekapseld 
doxorubicin (Ooxil®) bestudeerd. Wij toonden aan dat TNF-a niet aIleen de 
anti-tumoractiviteit van liposomaal doxorubicine verhoogde, maar dat, na drie 
of meer injecties van Ooxi[® en TNF-a, de concentratie van doxorubicine in het 
tUlllorweefse[ toenam in verge[ijking met hetzij de vrije vorm van doxorubicine 
a[s Ooxi[® aIleen. De gevonden toename van doxorubicine in het tumorweefsel 
bij ge[ijktijdige toediening van TNF-a resulteer! in een synergistische respons, 
waarschijnlijk veroorzaakt door de effecten van lage dosis TNF-a op het 
tumorvaatbed. Oit Iaat zich vertalen in een positief anti-tumoreffect na 
Illu[tipele toedieningen van Ooxil® en lage doses TNF-a. Bovendien zou deze 
toegenomen tumor targeting ook kunnen gelden voor andere I iposomaal 
ingekapse[de medicijnen. 
In hODfclstuk 7 tens[otte worden de hierboven genoemde resultaten 
besproken in het licht van de huidige stand van zaken omtrent de toepassing 
van TNF-a. Met de registratie van TNF-a in Europa voor combinatietherapie 
van sarcomen in geYsoleerde extremiteitsperfusie, is verder ondel'zoek naal' de 
bruikbaarheid van TNF-a in combinatie met chemotherapeutica in de 
behande[ing van solide tumoren nuttig. 
CONCLUSIES 
Toepassing van hoge dosis TNF-a in anti-tumortherapie gecombineerd 
met cytostatica geeft een synergistische respons in gelsoleerde extremiteits-
perfusie. Oit heeft ge[eid tot de registratie van Tumor Necrose Factor-a in 
Europa (Beromun@) voor toepassing in gelsoleerde extremiteitsperfusie in 
combinatie met melphalan bij patienten met locaal irresectabele sarcomen. 
In dit proefschrift worden andere modaliteiten onderzocht, die zouden 
kunnen leiden tot dezelfde indrukwekkende resultaten als bereikt in gelsoleerde 
perfusie van [edematen. Er werd inzicht verkregen in het werkingsmechanisme 
van TNF-a. Systemische toediening van lage doses TNF-a is mogelijk, 
waardoor in combinatie met al dan niet liposomaal ingekapselde cytostatica, 
verscheidene tumorsoorten en mogelijk ook metastasen behandelbaar worden. 
Verder onderzoek is echter noodzakelijk 0111 de positieve resu[ta!en van de 
toepassing van [age doses TNF-a in deze combinaties te velialen naar de 
k[iniek, waarin een hoge tU111orespons en re111issieduur van groot be[ang zijn. 
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Concilisies naar aanleiding van dit proefschrift: 
I. Ge·isoleerde nierperfllsie is technisch mogelijk, doch gezien de hoge locale 
toxiciteit van TNF-a niet geschikt als tllmormodel. 
2. Hoge doses TNF-a in combinatie met doxorllbicine in vivo geeft een 
synergistische anti-tumorrespons in gelsoleerde extremiteitsperfusie. 
3. Bij toepassing van hoge doses TNF-a in g6soleerde extremiteitsperfusie 
worden hogere concentraties doxorubicine gevonden in tumorweefsel. 
4. Het effect van TNF-a op de celcyclus is verwaarloosbaar. 
5. TNF-a kan met een acceptabele effectiviteit worden gelncorporeerd in lang 
circulerende iiposomen. 
6. Liposomale inkapseling van TNF-a leidt tot een verbeterd 
pharmacokinetisch profiel. 
7. Systemische toepassing van lage doses TNF-a in combinatie met 
liposomaal doxorubicine (Doxil®) resulteert in een toegenomen 
accul11ulatie van het cytostaticul11 in tUl110rweefseI en veroorzaakt een 
langdurig anti-tul11oreffect. 
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Ais slot past altijd een clankzegging aan diegenen die hebben bijgedragen aan 
de totstandkoming van het proefschrift. lk maak hierop geen uitzondering. De 
afgelopcn zes jaar hebben veer mensen een inspanning geleverd die ik niet licht 
zal vergeten. Voor mij was het een geweldige ervaring. 
Als allerecrste wil ik mijn onders bedanken. De prima opvoeding die jullie mij 
en mijn drie zussen hebben gegeven was voorwaar geen gemaldcelijke opgave. 
Daal'naast de hulp bij de juiste sehoolkeuze, en aIle vrijheid om te gaan 
studeren. De altijd aanwezigc steun en de continue stimulatie hielpen mij om 
mijn dromen waar te maken. Ik zal mijn best blijven doen. 
Niet het minst hebben oak mijn schoonouders een continue belangstelling 
weten op te brengen voor mijn wetenschappelijke vorderingen. Dolf, dank voor 
het kritisch doorlezen van wat nog niet eens een manuscript was op het 
moment dat ik clonkere wolken zag verschijnen. 
Dan past het am Prof. dr. A.M.M. Eggermont te bedanken. Beste Lex, ik weet 
nag dat we samen naar een Europees kampioensehap voetbal zaten te kijken (iij 
deed nag dienst in het Zuiderziekenhuis) toen ik je vroeg of er geen 
wetenschappelijk onderwerp was om te bewerken. lk kon toen nag niet 
bevroeden, dat dit zou leiden tot dit proefschrift. Jouw onnavolgbare werklust 
en creativiteit hebben een onuitwisbare indruk achtergelaten. Dank voo!' de niet 
ailatende steun in al cliejaren die achter ons liggen. 
Dr. T.L.M. ten Hagen, beste Timo, waar zou ik zijn zonder de stimulerende 
samenwerking met jou. Jij was clegene die mij regelmatig van een dood spoor 
haalde, die mij aanmoedigde om nou toch eindelijk eens met dat artikel aan te 
komen, en die het lab opbouwde tot wat het I1lI is. Jouw kritische houding was 
onmisbaar en heeft voor een belangrijk dee I bijgedragen tot het tot stand komen 
van dit boekje. 
Prof. dr. J. Verweij, Prof. dr. G. Storm en Prof. dr. E.A. de Bruijn, ik clank u 
allen hartelijk voor de snelle beoordeling van het manuscript. 
Aan het begin van het promotiepad stond tevens Dr. R.L. Marquet. Richard, 
wat keek ik op van de fax uit Nederland toen ik weer eens in het mooie Zuid-
Afrika was. Of ik geen trek had in een onderzoeksjaar voor arts-assistenten 
gefinancierd door het Koningin Wilhelmina FondslNederiandse Kanker-
bestrijding. Maar ik moest wei snel beslissen. lk had niet vee I tijd nodig. De 
eerste stappen in de wereld van het onderzoek werden door jou begeleid en 
altijd weer stond jij open voor goede gesprekken, ook toen de betrokkenheid 
met het onderwerp wat minder werd. Veel dank daarvoor. 
Eric Manusama en Grard Nieuwenhuijzen, paranimfen. Eric, vanaf het eerste 
llur samen op een kal1lelije achter de microscoop) weer een experiment op een 
rat. Jij was altijd vrolijk, chaotisch maar toch opgeruimd, en steeds weer bereid 
tot hulp. Zelfs nn nog weet je me prikkelende vragen te stellen, ik weet er 
echter nu, meestal, een antwoord op. Grard, samen als nieuwkomers in de 
maatschap, samen op weg naar de fusie. De laatste weken hebben geleid tot een 
goede samenwerking. Het feest kan beginnen. 
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Hans de Wilt heeft een niet onaanzienlijk aandeel geleverd aan de 
pootperfusies met doxorubicine. Hans, je hebt me dan weliswaar rechts 
ingehaald, maar je eigen promotie heeft de mijne in elk geval dichterbij 
gebracht. 
Marc van IJken en Mark de Vries, TNF-mannen, bedankt voor de plezierige 
discussies en vele e-mails. Het bracht af en toe weer de broodnodige afleiding. 
Ga zo door. 
Sandra van Tiel en Ann Seynhaeve, vanaf het moment dat de Iiposomen in 
beeld kwamen en het labje een volwaardig lab werd hebben jullie als analisten 
ongelooflijk veel werk voor mij verricht. De celkweken, perfusies, Facs-
metingen en het inzetlen van tumoren had ik onmogelijk aileen kunnen doen en 
waarschijnlijk was de promotiedatum zander jullie nag vee I verder weg 
geweest. Veel dank voor jullie hull" 
Peet Nooijen, bedankt voor de histologische analyses voor de verschillende 
hoofdstukken. 
Dank ook aan de verschillende afdelingen waarmee ons lab heeft 
salllengewerkt: de afdeling microbiologie van Dr. Bakker-Woudenberg, de 
afdeling pathologie van Prof. dr. Ruiter van het Academisch Ziekenhuis 
Nijlllegen, de afdeling experimentele oncologie van Prof. dr. De Bruijn in 
Leuven en het Utrecht Institute for Pharmaceutical Sciences, Prof. dr. Storm. 
Niet onvermeld mogcn blijven de medewerkers van het 'oude EDC' en het 
'nieuwe ECO'. De verzorging van de proefdieren was altijd optimaal, de sfeer 
was altijd goed en de koftie stond altijd klaar. Gelukkig hebben we nu een 
koffiemachine. 
Guy van Dael wil ik bedanken voor de vormgeving van dit proefschrift en het 
begeleiden van het drukken. 
Dan wil ik toch even stilstaan bij mijn opleiders chirurgie. Dr. G.A.A. Olthuis, 
u heeft Illij altijd gestimuleerd om onderzoek te doen en u deed me gel oven dat 
ik daar zelfs geschikt voor was. Ik betreur het dan oak zeer dat u deze dag niet 
meer heeft mogen meemaken. Dr. M.K.M. Salu en Dr. KJ. Brouwer hebben 
mij verder een goede perifere opleiding gegeven. Prof. dr. H.A. Bruining, beste 
Kieje, dank voor de gelegenheid die jij mij hebt geboden om mijn academische 
opleiding een jaar te onderbreken. Het is allemaal tach niet voor niets geweest. 
Een zelfde dank gaat uit naar Prof. dr. J. leekel, die steeds voldoende 
vertrouwen in Illij bleef houden. Beste Hans, dank voor de positie in de klilliek 
die je mij aanbood op een moment dat het onderzoek niet zo voortvarend liep. 
Chirurgcn cn assistenten van het Dijkzigt ziekenhuis, dank voor de bereidheid 
om een aantal taken over te nemen op het moment dat ik onderzoek doen 
belangrijker vond dan de kliniek. 
Maatschapgenoten en assistenten uit het Catharina ziekenhuis in Eindhoven. 
Veel dank ben ik jullie verschuldigd. De afgelopen maanden ben ik meer dan 
mij lief was weg geweest am dit promotieonderzoek tot een goed einde te 
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brengen. Nooit haarde ik een onve,1ogen woord als ik een OK afzegde of weer 
bezig was om met Marga een aantal polidata te blokkeren. 
En tens lotte. Marjan en de kinderen. Marjan. liefste. zonder jouw stimulerende 
kracht en niet aflatende druk om weer achter de computer de gaan zitten was ik 
nooit en te nimmer gepromoveerd. De liefde die je mij hebt gegeven heeft elke 
keer weer gezorgd voor een stukje ontwikkeling, niet aileen van dit boekje. 
maar zeker ook van mijzeJf. Ik hoop oprecht dat ik nu tijd aanjou, Floris, Daan 
en Lotte kan besteden, zonder aan het eind van het weekend weer een 
schuldgevoel te hebben dat ik enerzijds jullie en anderszins het proefschrift 
tekOJ1 had gedaan. Er wachten ons mooie tijden! 
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CURRICULUM VITAE 
Alexander van der Veen werd 21 juni 1959 geboren te Warnsveld. Na 
verscheidene omzwervingen werd Delft als domicilie gekozen, waar het 
ongedeeld VWO aan het Christelijk Lyceum Delft in 1977 werd afgesloten. 
Dankzij uitlotingen kon in Amsterdam studie-ervaring worden opgedaan aan de 
Vrije Universiteit. Nadat via de hardheidsclausule een opleidingsplaats was 
veroverd, werd in 1980 begonnen met de studie medicijnen aan de Erasmus 
Univcrsiteit Rotterdam, waar in 1987 het a.isexamen werd behaald. Tijdens 
zijn studie werd onderzoek gedaan in Gainesville, Florida op het laboratorium 
van Prof. Fulton Crews, en werd in Rotterdam onderzoek gedaan bij patienten 
met cen Barrett oesophagus onder begeleiding van de gastro-enterologen M. 
van Blankenstein en J. Dees. 
In 1988 werd begonnen met het AGNIO-schap chirurgie in het 
Zuiderziekenhuis te Rotterdam, alwaar in januari 1990 ook de opleiding tot 
chirurg werd gestart (opleider: Dr. G.A.A. Olthuis, na diens pensionering: Dr. 
M.K.M. Salu en Dr. K.1. Brouwer). In januari 1993 werd de opleiding 
vOOligezet in het Acadcmisch Ziekenhuis Dijkzigt te Rotterdam (opleider: Prof 
dr. !-I.A. Bruining). In mami 1994 werd de opleiding onderbroken voor een 
onderzoeksjaar voor mis-assistenten gefinancierd door het KWFINKB, alwaar 
de basis voor dit proefschrift werd gelegd. In april en mei 1995 werkte hij in 
het Ikazia ziekenhuis (opleider Dr. H.F. Veen). Op 1 juli 1996 volgde 
inschrijving in het specialisten register als chirurg. 
Van I juli 1996 tot 31 december 1998 was hij fellow traumatologie op de 
afdeling heelkunde van het Academisch Ziekenhuis Dijkzigt te Rotterdam. 
Sinds I januari 1999 werkt hij met vee I plezier als maat in de maatschap 
chirurgie van het Catharina ziekenhuis te Eindhoven. 
Schrijver dezes is getrouwd en heef! drie kinderen. 
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